Peptide sequences and compositions

专利摘要:
Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or 5 comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP 10 SEQ ID 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID 3 DLIFLARSALILRGSVAHKSC SEQ ID 4 PGIADIEDLTLLARSMVVVRP SEQ ID 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID 6 IIGILHLILWILDRLFFKCIYRLF wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete influenza virus protein. 3745052_1 (GHMatters) P78534.AU.1
公开号:AU2013201008A1
申请号:U2013201008
申请日:2013-02-22
公开日:2013-03-14
发明作者:Wilson Romero Caparros-Wanderley；Gregory Alan Stoloff
申请人:Peptcell Ltd；
IPC主号:C07K14-11

专利说明:
PEPTIDE SEQUENCES AND COMPOSITIONS The entire disclosure in the complete specification of our Australian Patent Application No. 2007213562 is by this cross-reference incorporated into the present specification. 5 The invention concerns peptide sequences, compositions comprising the peptide sequences, and in particular influenza vaccines comprising the sequences and the compositions, and uses of the sequences. The present invention is especially concerned with vaccines that are protective against a plurality of influenza virus strains, including existing viruses across 10 different species (e.g. protective against both human and avian influenza) as well as future viruses that have mutated from existing viruses (such as a future mutated form of avian flu that is readily transmissible from human to human, which could potentially give rise to an influenza pandemic). 15 The defence against disease is critical for the survival of all animals, and the defence mechanism employed for this purpose is the animal immune system. Understanding the immune system is therefore a key to understanding the development of new and more sophisticated treatments for humans and animals alike. 20 The mechanism of operation of the immune system has been under investigation for many years. The system is composed of a number of cell types and a variety of molecules, making it extremely complex. Even after many years of study, the full extent of the immune system components, and their interaction with each other, is imperfectly understood. 25 Many years ago it was recognised that a person who recovers from a particular disease may acquire some protection in future against that disease, but not against a disease which that person has not yet contracted. This fundamental aspect of the immune system was interpreted at that time by considering that the immune system acquired a kind of 'memory' against certain pathogens once exposure to such pathogens had taken place, that memory 30 being specific to a certain disease. Gradually, it became known that exposure to less harmful variants of a pathogen could induce protection against more harmful variants (e.g. exposure to cowpox to protect against 2 3745052_1 (GHMatters) P78534.AU.1 smallpox, or exposure to an inactivated anthrax to protect against live anthrax). Thus, the idea of vaccination against a disease arose. It is now known that the immune system has at least two divisions: innate immunity and 5 adaptive immunity. The innate system is fully functional before a pathogen enters the system, whilst the adaptive system is switched on after the pathogen enters the system. It then develops an attack specific to the pathogen. The innate system comprises a number of components, including phagocytes such as macrophages, which (as the name suggests) 'eat' or engulf foreign bodies such as pathogens. 10 Typically, but not exclusively, the present invention is concerned with the adaptive immune system, and unless specifically indicated otherwise, 'immune system' in the present context refers to the adaptive immune system. 15 In order to understand more fully how the immune system functions, the role of its individual components must be carefully considered. In respect of the adaptive immune system, it is well known that immunity against pathogens is provided by the action of lymphocytes, which constitute the most common cell type in the immune system. There are two types of lymphocyte: the B lymphocyte and the T lymphocyte. These are generally termed B cells 20 and T cells respectively. B cells have the ability to develop into plasma cells, which manufacture antibodies. Antibodies are very important components of the animal immune system. They are produced in response to some signature portion of the invading pathogen (an antigen of the pathogen 25 antigens here being defined as any foreign substance recognised by the immune system) and are usually specific to that pathogen. However, if two pathogens are very similar, or at least contain the same antigen, then antibodies produced against one can nevertheless be effective against the other (they may 'cross-react'). This explains why inoculation with cowpox may protect against smallpox. It is important to realise that the antibodies 'recognise' only a small 30 portion of the antigenic molecule of the pathogen rather than the pathogen as a whole. These portions are termed epitopes. 3 3745052_1 (GHMatters) P78534.AU.1 T cells do not possess or produce antibodies. Instead, they recognise fragments (i.e. epitopes) of the foreign antigen complexed with major histocompatibility complex (MHC) (or in the case of humans, human leucocyte antigen (HLA)) via a specialised receptor known as TCR (T cell receptor). T cells are themselves divisible into subsets which can have either a 5 regulatory function or an effector function. The effector cells are involved with 'effecting' the removal of foreign substances. For example, cytotoxic T cells (CTL) are effector cells that are able to kill infected cells, as well as other unwanted species such as tumour cells. Regulatory T cells, on the other hand, play a role in helping effector T and B cells to become more effective. Due to this function, these regulatory T cells are often termed 'helper' T 10 cells. Other regulatory T cells, termed 'suppressor' T cells, are thought to inhibit immune responses, but these are less well understood. Regulatory T cells may also interact with components of the innate immune system to boost their activity. In a normal healthy individual, the lymphocytes in the immune system remain in an inactive 15 'resting' state until an immune response is triggered. When an immune response is required, the lymphocytes become activated, proliferate and begin to carry out their designated functions. For example, any resting T cell displaying on its surface a TCR that recognises an epitope of the invading pathogen complexed with a MHC molecule is activated, proliferates (this being termed clonal expansion) and the resulting offspring start to actively carry out 20 their predetermined effector functions required to combat the invading organisms. When the immune response is completed, (i.e. the pathogens and/or infected cells have been eliminated) the lymphocytes revert to a resting state once again. This resting state is not, however, equivalent to the initial inactive resting state. Activated, but resting lymphocytes, 25 can be rapidly recruited and induced to proliferate in response to an infection by the same, or closely related, pathogen at a later time. This ability of activated resting lymphocytes, to deliver a faster and more powerful response following a second encounter with an invading pathogen, effectively provides the immune 30 system with 'memory'. The exploitation of the immune system's memory is the basis for all long-term immunoprophylactic drugs (e.g. vaccines) and remains the goal of much long-term immunotherapeutic drug development. 4 3745052_1 (GHMatters) P78534.AU.1 In order for cells to perform their functions within the complex systems of an animal, the cells need to have 'receptors' on their surfaces. These receptors are capable of 'recognising' specific substances that control various essential processes such as activation, proliferation and adherence to other cells or substrates. For example, in the case of the immune system, the 5 receptors on T and B cells allow them not only to recognise antigen but also to interact with each other and thus regulate their activities. Without these receptors, the cells would lack an essential means of communication and would be unable to act effectively in the concerted way that is essential for the immune system of a multicellular organism. 10 In order to be able to specifically recognise and deal with the wide range of pathogens present in the environment, the immune system has developed two types of highly variable antigen receptor on lymphocytes: antibodies in B cells and T cell receptors, or TCRs, in T cells. 15 There are a great many different possible antigen receptors present in the body, to enable the immune system to recognise a wide variety of invading pathogens. In fact there are approximately 1012 different B cells and T cell receptors in an individual. Each individual B cell has only one type of receptor, and so to deal with a particular pathogen, a B cell having the 'best fitting' receptor for an antigen of that pathogen must be selected. This process is 20 termed 'clonal selection'. In theory, only a single clone may respond (a monoclonal response) or several (an oligoclonal response) or many (a polyclonal response) depending on the number of antigens/epitopes exhibited by the pathogen, and the specificity of the various selected B cells to these antigen/epitopes. 25 There is a major difference between the types of antigen that can be recognised by B cells and T cells. As far as it is known, only the receptors on the surface of B lymphocytes (i.e. antibodies) are capable of directly recognising antigens such as proteins on viruses and bacteria, or foreign molecules dissolved in body fluid. Antibodies can also be produced in a soluble form by the B cells when they are activated and develop into plasma cells. The 30 antibodies are also termed immunoglobulins (abbreviated to Ig). T cell receptors, on the other hand, recognise only short peptides, also known as T cell epitopes, on the surface of cells of the body. These T-cell epitopes are produced by degradation of larger proteins that are either self (i.e. naturally occurring body proteins) or non-self (i.e. derived from foreign 5 3745052_1 (GHMatters) P78534.AU.1 organisms infecting the body). Only those derived from foreign proteins, i.e. antigens, are normally capable of inducing an immune response in the body. Once produced, these epitopes are bound to a special type of molecule, the MHC (major histocompatibility complex) and the resulting complex is then presented on the cell surface for binding the T 5 cell receptor. It should be clear that due to the destructive nature of the immune response, the response has to act only against foreign pathogens, not against the body's own cells or proteins. Thus, the immune system needs to distinguish between 'self and 'non-self'. It has been proposed that 10 although clones of lymphocytes reacting against self are produced, they are deleted before any reaction can occur. This process is termed 'clonal deletion'. It has also been proposed that any self-reacting lymphocytes could be retained but only in a 'switched-off state. This mechanism is termed 'clonal anergy'. Whatever the process considered, it remains unclear what is the exact underlying mechanism allowing lymphoid tissues, such as the thymus, to 15 identify individual T cell clones reacting against self from the pool of T lymphocytes reacting only against non-self. The present inventors have now investigated more fully the mechanism of self/non-self discrimination, which has led to the development of the present invention. The inventors have now established a method of predicting the immunogenicity of a substance such as a peptide, which has enabled quicker identification of immunogenic 20 peptide sequences within large proteins. It has been known for many years that the major histocompatibility complex (MHC) plays a key role in the immune system of animals. The MHC molecules enable T cells to recognise antigens, as has already been discussed above. There are three general types of MHC 25 molecule, class I, class II and class III. Class I and class II MHC molecules are glycoproteins that are present on the surface of the cell, whilst class III are usually soluble molecules present inside the cell. There are a large number of different types of MHC molecule. For example in humans (where MHC is termed HLA, human leukocyte antigen) there are several hundreds of different alleles of the genes coding for MHC molecules, meaning that in the 30 human population there are many different types of HLA. The MHC of different species is typically named according to different conventions, thus MHC for mouse is termed H-2, for rat RT 1 and for rabbit RLA. The different gene regions coding for different MHC molecules in an individual are usually individually named, such as HLA-A, HLA-C etc. in humans. 6 3745052_1 (GHMatters) P78534.AU.1 The MHC molecule is a critical immune system molecule, since it is this molecule that presents the epitopes of the antigens to the immune system. For example, if a T cell is to respond to a particular pathogen, the pathogen must have a least one antigen (such as a 5 protein) that has at least one epitope (such as a peptide portion of the protein) that can bind to an MHC molecule on the surface of a cell and thus interact with a T cell which binds to the MHC-peptide complex. Thus, the immune response is dependent on the ability of the MHC to bind to an epitope. If there is no epitope that the MHC will bind to, or if there is no T cell which will bind to the MHC-peptide complex, then no immune response will occur. 10 In respect of 'self' proteins, however, one of several epitopes may be able to bind to the MHC molecule and hence potentially induce an immune response. On these occasions a specific "signal" must be provided for the self-reacting lymphocyte clones to be deleted or "switched off'. 15 Since, as indicated above, both self and foreign (i.e. non-self) peptides can bind to MHC molecules, the binding of various peptides to MHC molecules has received particular scrutiny in the immunology field. Many investigations have sought to calculate or predict the strength of binding between certain MHC (particularly HLA and H-2) types and peptide 20 sequences, to try to account for immune responses, or the lack of them (i.e. the "signal" required for discrimination between self and foreign). Examples of these include the following: Altuvia Y, Schueler 0, Margalit H. 1995. "Ranking potential binding peptides to MHC 25 molecules by a computational threading approach". J. Mol. Biol., 249:244-250. Altuvia Y, Sette A, Sidney J, Southwood S, Margalit H. 1997. "A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets". Hum. Immunol. 58:1-11. 30 G.E. Meister, C.G.P. Roberts, J.A. Berzofsky, A.S. De Groot, "Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published 7 3745052_1 (GHMatters) P78534.AU.1 epitopes from Mycobacterium tuberculosis and HIV protein sequences" Vaccine, 13:581-591, (1995). Gulukota K, Sidney J, Sette A, DeLisi C. 1997. "Two complementary methods for predicting 5 peptides binding major histocompatibility complex molecules". J. Mol. Biol. 267:1258-1267. Pamer EG, Harty JT, Bevan MJ. "Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes". Nature 1991; 353: 852 -855. 10 Parker KC, Bednarek MA, Coligan JE. 1994. "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains". J. Immunol. 152:163-175. Rammensee HG, Friede T, Stevanoviic S. 1995. "MHC ligands and peptide motifs: First 15 listing". Immunogenetics 41:178-228. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. 1993. "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules". Cell 74:929-937. 20 Schueler-Furman 0, Elber R, Margalit H. 1998. "Knowledge-based structure prediction of MHC class I bound peptides: A study of 23 complexes". Fold Des. 3:549-564. Sette A, Buus S, Appella E, Smith JA, Chesnut R, Miles C, Colon SM, Grey HM. 1989. "Prediction of major histocompatibility complex binding regions of protein antigens by 25 sequence pattern analysis". Proc. Natl. Acad. Sci. USA 86:3296-3300. Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, Grey HM, Kubo RT. 1994a. "Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays". Mol. Immunol. 31:813-822. 30 Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, Melief CJM, Oseroff C, Yuan L, Ruppert J, et al. 1994b. "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes". J. Immunol. 153:5586-5592. 8 3745052_1 (GHMatters) P78534.AU.1 Stefan Stevanovic (2002): "Structural basis of immunogenicity", Transplant Immunology 10 133-136 5 Stumiolo T, Bono E, Ding J, Raddrizzani L, Tuereci 0, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J. 1999. "Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices". Nat. Biotechnol. 17:555-561. 10 T. Sudo, N. Kamikawaji, A. Kimura, Y. Date, C.J. Savoie, H. Nakashima, E. Furuichi, S. Kuhara, and T. Sasazuki, "Differences in MHC Class I self peptide repertoires among HLA-A2 subtypes." J. Immunol.: 155: 4749-4756, (1995). T. Tana, N. Kamikawaji, C.J.Savoie, T. Sudo, Y. Kinoshita, T. Sasazuki, "A HLA binding 15 motif-aided peptide epitope library: A novel library design for the screening of HLA-DR4 restricted antigenic peptides recognized by CD4+ T cells." J. Human Genet., 43:14-21 (1998). K. Falk, et al. "Allele-specific motifs revealed by sequencing of self-peptides eluted from 20 MHC molecules", Nature, Vol. 351, 290-297 (1991). T Elliott et al. "Peptide-induced conformational change of the class I heavy chain", Nature, Vol. 351, 402-407, (1991). 25 P. Parham, "Deconstructing the MHC", Nature, Vol. 360, 300-301, (1992). Hwai-Chen Guo et al., "Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle", Nature, Vol. 360, 364-367, (1992). 30 Y. Chen et al. "Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations", J. Immunol., 152, 2874-2881, (1994). 9 3745052_1 (GHMatters) P78534.AU.1 D. F. Hunt et al. "Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry", Science, Vol. 255, 1261-1263, (1992). Generally, the prior art attempts to predict the immunogenicity of particular peptides by 5 calculating the strength of binding between that peptide and the known binding environment of a particular MHC molecule. The binding environment involves a 'pocket' in the MHC molecule that is adapted to accept a peptide of a certain length (such as 7-15 amino acids). The structure of the pocket may already be known from previous X-ray crystallographic studies. This strength may be calculated mathematically using appropriate algorithms for 10 atomic and molecular interaction. Alternatively, the prior art may attempt to 'score' the binding strength of a peptide based upon motifs existing in the peptide, such as particular amino acids being present at particular positions in a peptide of a certain length, e.g. a proline present at position 3 in an 8-amino acid peptide binding to a particular known HLA molecule. Generally these approaches have met with limited success. 15 The present inventors believe that they have improved upon the above theories from a better understanding of how T cells reacting against self-substances such as self-proteins are identified prior to their elimination (clonal deletion) or silencing (clonal anergy). Accordingly, the inventors have been able to identify specific immunogenic peptide 20 sequences that may provide protection against specific pathogens, and have developed vaccines to these pathogens, using the identified sequences. In the case of the present invention, the inventors have developed peptides useful in influenza vaccines eliciting a T cell response. 25 Previously, influenza vaccines have been developed by identifying an existing influenza virus strain and then producing a vaccine specific to that virus. Generally, the vaccines have been based upon a B cell (antibody) response, the antibody being reactive with the surface antigens (i.e. Hemagglutinin and Neuraminidase) of the specific influenza virus strain against which it has been developed. Typically, the surface proteins comprising the antigens are 30 variable from one influenza virus strain to the next, since mutation of the virus to produce a new virus tends to occur in the surface proteins. The consequence of this is that conventional influenza vaccines generally protect only against one specific virus strain, and will not protect against a new strain that results from a mutation. Thus, a new vaccine is required for 10 3745052_1 (GHMatters) P78534.AU.1 protection against an emerging strain. The clear problem with this approach is that there is a period of time between emergence of the new virus strain, and development of the vaccine, during which there is no protection available against the virus. If the virus is particularly harmful, this can lead to many millions of deaths, as occurred in the major influenza 5 pandemics of the last century. It has been known for some time that cytotoxic T lymphocytes may provide an immune response to influenza virus strains. Recent studies have shown that a CTL response in humans may be directed towards multiple epitopes. It has been suggested that there is a 10 dominant response to the HLA-A2 restricted M-1 58-66 epitope. Such studies include A.C. Boon et al, J. Virol, Jan. 2002, 582-90; S. Tamura et al Jpn. J. Infect. Dis., Dec. 2004, 236-47; G. Deliyannis et al J. Virol., May 2002, 4212-21; C. Gianfrani et al Hum. Immunol., May 2000, 438-52; and J. Jameson et al J. Immunol., Jun. 1999, 7578-83. 15 There has recently also been investigation into specific immunogenic peptides that might be useful in developing an influenza vaccine eliciting a T cell response. Typically, such work has involved investigation of CTL response to test influenza peptides, e.g. in transgenic mice. The tested peptides tend to be short sequences that might be reactive to one MHC (or HLA) type, and are taken from a specific test influenza strain. For example, in Vaccine, 2005, 20 5231-44, N. Hu et al disclose testing wild type M1 58-66 peptide in HLA Tg mice expressing HLA-A2, -B7 or -B27. The results show that the peptide is an influenza epitope recognised by transgenic mice expressing HLA-A2. In Clin. Exp. Immunol., October 2005, 45-52, A.C. Boon et al disclose M1 58-66 and NP 44-52 influenza A peptides as epitopes recognised in HLA-A*0101 and HLA-A*0201 individuals. In Cell Immunol., April 2005, 110-123, E. 25 Cheuk et al disclose NP 383-391 influenza A peptide as an epitope recognised in HLA-B27/H2 class I-deficient mice. Using epitope prediction programs, the authors identified three more B27 restricted influenza A epitopes, BP-2 702-710, PB-i 571-579 and PB-2 368-376. In J. Immunol., Feb 2004, 2453-60, A.C. Boon et al disclose human CTL clones specific for natural variants of the HLA-B*3501-restricted epitope in NP 418-426. In 30 J. Immunother., Jan-Feb 2003, 41-6, A. Trojan et al disclose the HLA-A3-restricted 9-mer RLEDVFAGK which is capable of inducing specific CTL reactivity. HLA-A2 restricted influenza A virus matrix peptide GILGFVFTL is also disclosed. In J. Gen. Virol., July 2001, 1749-55, S. Tourdot et al identify a murine D(k) restricted epitope derived from the influenza 11 3745052_1 (GHMatters) P78534.AU.1 virus strain A/PR/8/34 polymerase protein PB-1, corresponding to amino acid residues 349-357 (ARLGKGYMF). In J. Immunol., April 2001, 4627-33, G.T. Belz et al identify an immunogenic peptide (SSYRRPVGI) from influenza polymerase protein PB-1, corresponding to amino acid residues 703-711 and a mimotope (ISPLMVAYM) from PB-2 5 polymerase. PCT/US2005/002954 discloses CTL epitopes comprising NP 265-273, having the sequence ILRGSVAHK, and also epitopes comprising NP 305-313. Finally, US 6,740325 discloses two CTL epitopes: NP 335-350, and NP 380-393. Further studies have shown that data from transgenic mice provide a reliable model for the 10 investigation of CTL responses in humans. In Int. Immunol., Apr. 1995, 597-605, S. Man et al have shown that the dominant influenza A epitope recognised by HLA-A2.1-restricted cytotoxic T lymphocytes from HLA-A2.1 transgenic mice was the matrix protein 1 (M-1) peptide epitope that is immunodominant in human CTL responses. Further studies in this area have been conducted by E.J. Bernhard et al (J. Exp. Med., Sep 1998, 1157-62) and E. 15 Cheuk et al (J. Immunol., Nov 2002, 5571-80). However, although known epitopes have been studied extensively, none has yet been satisfactory for forming the basis of an influenza vaccine that is capable of protecting against more than a single strain of influenza virus. Moreover, vaccines based upon these single 20 epitopes, even if they were to provide some protection, would likely be specific for a particular HLA, making them ineffective in a large proportion of the human population. Thus, a significant problem with known vaccines, whether relying on a B-cell or T-cell response is that they only protect against an existing virus strain, and do not provide 25 protection against possible future strains that might develop. With the emergence of the highly dangerous H5N1 strain in the avian population, the need for a vaccine in advance of a human pandemic based upon a subsequent mutation of the H5N1 strain has become more acute. Moreover, vaccines based upon known peptides eliciting T-cell responses may not be effective in large sections of the population. 30 Accordingly, it is an aim of the present invention to solve the problems associated with the known prior art as set out above. It is a further aim of the present invention to provide a polypeptide that is capable of eliciting a CTL immune response in vertebrates against a 12 3745052_1 (GHMatters) P78534.AU.1 plurality of influenza strains and/or in a plurality of individuals expressing differing MHCs (HLAs). It is a further aim of the present invention to provide an influenza vaccine using the polypeptide of the invention. Preferably the vaccine is capable of protection against a plurality of influenza strains and/or is effective in a plurality of individuals expressing 5 differing MHCs (HLAs). It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. 10 Accordingly, the present invention provides a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that 15 has the same length as the epitope: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID 3 DLIFLARSALILRGSVAHKSC 20 SEQ ID 4 PGIADIEDLTLLARSMVVVRP SEQ ID 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID 6 IIGILHLILWILDRLFFKCIYRLF wherein, the polypeptide is immunogenic in a vertebrate expressing a major 25 histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete influenza virus protein. Thus, the polypeptide is one that may comprise the whole of (or may comprise at least two 7 or more residue parts of) any of the above sequences, but cannot have more than 100 amino 30 acid residues in total. The polypeptide must also be immunogenic in a vertebrate expressing an MHC (HLA in humans) allele. An immunogenic polypeptide is understood in the present context to mean a polypeptide that elicits an immune response in a vertebrate, such as by binding to a vertebrate MHC and causing it to react with a cytotoxic T cell lymphocyte. One 13 3745052_1 (GHMatters) P78534.AU.1 method for determining whether a polypeptide possesses immunogenicity is set out in Experiment 1 below. However, the present invention is not limited to such methods, and the skilled person may select any known method for determining immunogenicity, as desired. 5 As mentioned above, the polypeptide may be one comprising two 7 or more residue epitopes that react with one or more MHCs and so elicit a broad CTL response. The response may be in a single individual or may be in at least two different individuals (and the individuals may be of the same species or different species). Thus, the polypeptide may comprise at least two different 7 or more residue epitopes, each of which individually provides a response to a 10 different subject. An epitope in the context of the present invention is a part of a polypeptide which is capable of binding to a vertebrate MHC in a vertebrate, preferably eliciting an immune response, such as by causing the MHC-epitope complex to react with a CTL. One method for determining whether a polypeptide is or contains an epitope is set out in Experiment 1 below. However, the present invention is not limited to such methods, and the 15 skilled person may select any known method for determining whether a polypeptide is or contains an epitope, as desired. The present inventors have found that the above sequences comprise a plurality of CTL epitopes, which may afford protection against influenza for a wide variety of vertebrates in a 20 population. In addition, the inventors have analysed all known influenza virus strain sequences across all species, and have found that the specified sequences are remarkably conserved across all known influenza virus strains. As such, these sequences are very unlikely to be significantly altered in new strains resulting from mutation of existing strains. Accordingly, the epitopes within these sequences that provide protection are highly likely to 25 be present in unchanged form in new strains, since mutation does not normally occur in these regions. Consequently, these epitopes provide excellent opportunity not only for providing protection against existing influenza strains (such as the H5N1 strain of 'bird flu'), but also protecting against as yet unknown strains (such as a mutated form of H5N1 that could pass easily from human to human and form the basis of a pandemic). 30 As discussed above, the sequences have been identified after analysis of all known influenza virus strain sequences across all species. The sequences are thus consensus sequences developed from the above analysis. Despite being consensus sequences, the sequences in 14 3745052_1 (GHMatters) P78534.AU.1 some cases correspond exactly to natural sequences in some of the known influenza virus strains. Due to the remarkable conservation in the sequences across all viruses in all species, the consensus sequences, even when differing from actual sequences, only differ in a small number of residues, and thus contain many smaller epitopes (8-mers, 9-mers, 10-mers etc.) 5 for which there are no differences from natural sequences. The above consensus sequences as a whole thus contain many effective epitopes that are the same as the natural epitopes, as well as effective epitopes that differ only slightly from natural epitopes. It will be apparent to the skilled person that the invention extends not only to the consensus sequences and their epitopes, but also to the corresponding actual sequences in any influenza virus strains. Thus, 10 sequences with some homology to the consensus sequences are also within the scope of the invention. Such homology allows substitution of, for example, up to 3 amino acids in an 8-mer epitope (62.5% homology) or in a 9-mer, 10-mer, or 11-mer epitope. It is preferred that no more than 10 such substitutions are identifiable in a sequence of the invention corresponding to the full sequences of SEQ ID 1-6 (66.6% homology for a 30-mer). Such 15 substitutions are preferably conservative substitutions in line with known substitution schemes. Having in mind that the invention extends from the consensus sequence to the corresponding natural sequences, then the invention also provides a polypeptide having no more than 100 20 amino acids, which polypeptide comprises one or more sequences defined by the following amino acid residues of an influenza virus protein, or comprises two or more epitopes having 7 amino acids or more from a sequence defined by the following amino acid residues of an influenza virus protein: 25 residues 36-75 of an M1 protein (preferably from an influenza A strain) residues 124-158 of an M1 protein (preferably from an influenza B strain) residues 255-275 of an NP protein (preferably from an influenza A strain) residues 306-326 of an NP protein (preferably from an influenza B strain) residues 395-428 of a PB1 protein 30 residues 32-55 of an M2 protein 15 3745052_1 (GHMatters) P78534.AU.1 wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete influenza virus protein. 5 The sequence numbering referred to in the present invention is defined according to well-recognised principles. Thus, the numbering begins at 1 from the recognised translation initiation codon (ATG). This corresponds to a Methionine (M), for the segment of the Influenza genome coding for the protein of interest. In other words, it begins at 1 in respect of the Methionine shown as the first amino acid in the protein sequence of interest as used 10 and defined by the databases in which the sequences have been set forth (i.e. GenBank, SwissProt, etc.). The present invention will be described in more detail by way of example only with reference to the following Figures, in which: 15 Figure 1A to IF show IFN-y production by primary splenocyte cultures of FLU-v and NRP vaccinated mice stimulated with Con A (10 pg/ml), soluble Lysozyme (5 pg/ml), purified soluble polypeptides (P1 (Figure 1A), P2 (Figure 1B), P3 (Figure IC), P4 (Figure ID), P5 (Figure 1E) and P6 (Figure IF); 5 pg/ml) and HLA-matched TI (TI) and mismatched 20 JURKAT (Ju) human cells transfected with either Lysozyme, P1, P2, P3, P4, P5 or P6 according to the protocol described in Example 1 below (splenocyte to transfected cell ratio is 10:1). IFN-y production is represented as the differential between the level of production in response to the antigen considered minus the IFN-y produced in response to either soluble Lysozyme or the corresponding cell transfected with Lysozyme. Background levels of 25 Lysozyme mediated production of IFN-y were for soluble antigen 25 ± 10 pg/ml, for antigen in Ti 316 ± 43 pg/ml, and for antigen in Jurkat 19 ± 6 pg/ml; Figure 2 shows IFN-y production by primary splenocyte cultures of FLU-v and NRP vaccinated mice stimulated with Con A (10 pg/ml), soluble Lysozyme (5 pg/ml), purified 30 soluble FLU-v polypeptide preparation (P1, P2, P3, P4, P5 and P6 all together at 5 pg/ml) and HLA-matched TI (TI) and mismatched JURKAT (Ju) human cells either infected with influenza strains A/NewCaledonia/20/99, A/NYMC/X-147 or B/Johannesburg/5/99 or 16 3745052_1 (GHMatters) P78534.AU.1 transfected with Lysozyme according to the protocol described in Example 1 below (splenocyte to infected/transfected cell ratio is 10:1); IFN-y production is represented as the differential between the level of production in response to the antigen considered minus the IFN-y produced in response to either soluble Lysozyme or the corresponding cell transfected 5 with Lysozyme; background levels of Lysozyme mediated production of IFN-y were for soluble antigen 25 ± 10 pg/ml, for antigen in TI 316 ± 43 pg/ml, and for antigen in Jurkat 19 ± 6 pg/ml; and Figures 3A and 3B show survival of animals following a lethal challenge with Influenza 10 A/PR/8/34; animals were immunised subcutaneously with either FLU-v or NRP-v on days 1 and 15 and on day 20 all were challenged intranasally with 45 Pl of the virus (5x107 pfu per dose) under anaesthesia; animals in Fig 3A were inoculated intraperitoneally with 100 pg of rat anti-mouse CD8 sera on days 19 and 22; animals in Fig 3B were inoculated intraperitoneally with an irrelevant rat sera on days 19 and 22; the arrow indicates the date of 15 intranasal challenge whilst the diamonds indicate the date animals were inoculated with the anti-CD8 sera. The polypeptide described above typically comprises one or more (preferably two or more) epitopes. These epitopes are preferably T cell epitopes, such as cytotoxic T lymphocyte 20 (CTL) epitopes. Generally the polypeptide is immunogenic to an influenza virus strain, and preferably to a plurality of influenza virus strains. In the present context, a polypeptide immunogenic to an influenza virus strain is understood to mean a polypeptide that is part of an influenza virus protein and that elicits an immune system response, such as by exhibiting CTL reactivity when bound to an MHC. One method for determining whether a polypeptide 25 possesses such immunogenicity is set out in Experiment 1 below. However, the present invention is not limited to such methods, and the skilled person may select any known method for determining immunogenicity, as desired. In the present invention, the polypeptide comprises two or more sequences as described 30 above. Typically, two, three, four, five or more such sequences may be present in the polypeptide, if desired. The more such epitopes are present, the greater the breadth of 17 3745052_1 (GHMatters) P78534.AU.1 protection afforded within a population of humans and/or animals individuals with differing HLAs or MHCs. The polypeptide according to the present invention may also comprise one or more further 5 sequences that are not epitopes, if desired. Typically the further sequences are from one or more influenza virus proteins. These sequences may be situated between two or more of the sequences (the epitopes) described above, or may be situated at one or both ends of the polypeptide. The presence of such further sequences should not affect the function of the polypeptide, provided that the polypeptide as a whole does not become too large, interfering 10 with the presentation of the epitopes in the vertebrate's immune system. In specific embodiments of the invention, when the polypeptide is homologous to SEQ ID 1, the further sequences are preferably one or more from an influenza M1 protein (preferably from an influenza A strain), when the polypeptide is homologous to SEQ ID 2, the further sequences are preferably one or more from an influenza M1 protein (preferably from an influenza B 15 strain), when the polypeptide is homologous to SEQ ID 3, the further sequences are preferably one or more from an influenza NP protein (preferably from an influenza A strain), when the polypeptide is homologous to SEQ ID 4, the further sequences are preferably one or more from an influenza NP protein (preferably from an influenza B strain), when the polypeptide is homologous to SEQ ID 5, the further sequences are preferably one or more 20 from an influenza PB1 protein, and when the polypeptide is homologous to SEQ ID 6, the further sequences are preferably one or more from an influenza M2 protein. In the most preferred embodiments, the further sequences from the above-mentioned proteins are ones within the following consensus sequences, or ones having at least 60% homology 25 with a sequence within the following consensus sequences: M1 Influenza A Consensus - SEQ ID 7 MSLLTEVETYVLSIVPSGPLKAEIAQRLEDVFAGKNTDLEALMEWLKTRPILSPLTKG ILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDKAVKLYRKLKREITFHGAKEI 30 ALSYSAGALASCMGLIYNRMGAVTTEVAFGLVCATCEQIADSQHRSHRQMVATTNP LIKHENRMVLASTTAKAMEQMAGSSEQAAEAMEIASQARQMVQAMRTVGTHPSSS TGLRDDLLENLQTYQKRMGVQMQRFK 18 3745052_1 (GHMatters) P78534.AU.1 Ml Influenza B Consensus - SEQ ID 8 MSLFGDTIAYLLSLTEDGEGKAELAEKLHCWFGGKEFDLDSALEWIKNKRCLTDIQK ALIGASICFLKPKDQERKRRFITEPLSGMGTTATKKKGLILAERKMRRCVSFHEAFEIA EGHESSALLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHSHRAHSRAARSSVP 5 GVRREMQMVSAMNTAKTMNGMGKGEDVQKLAEELQSNIGVLRSLGASQKNGEGI AKDVMEVLKQSSMGNSALVKKYL NP Influenza A Consensus- SEQ ID 9 MASQGTKRSYEQMETDGDRQNATEIRASVGKMIDGIGRFYIQMCTELKLSDYEGRLI 10 QNSLTIEKMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRVDGKWMRELVLYDK EEIRRIWRQANNGEDATAGLTHMMIWHSNLNDATYQRTRALVRTGMDPRMCSLMQ GSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGRKTRSAYERMCN ILKGKFQTAAQRAMVDQVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVY GPAVSSGYDFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAF 15 EDLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMGSSTLELRSGYWAIRTRSGGN TNQQRASAGQISVQPTFSVQRNLPFEKSTVMAAFTGNTEGRTSDMRAEIIRMMEGAK PEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN NP Influenza B Consensus- SEQ ID 10 20 MSNMDIDGINTGTIDKTPEEITSGTSGTTRPIIRPATLAPPSNKRTRNPSPERATTS SEA DVGRKTQKKQTPTEIKKSVYNMVVKLGEFYNQMMVKAGLNDDMERNLIQNAHAV ERILLAATDDKKTEFQKKKNARDVKEGKEEIDHNKTGGTFYKMVRDDKTIYFSPIRI TFLKEEVKTMYKTTMGSDGFSGLNHIMIGHSQMNDVCFQRSKALKRVGLDPSLISTF AGSTLPRRSGATGVAIKGGGTLVAEAIRFIGRAMADRGLLRDIKAKTAYEKILLNLK 25 NKCSAPQQKALVDQVIGSRNPGIADIEDLTLLARSMVVVRPSVASKVVLPISIYAKIP QLGFNVEEYSMVGYEAMALYNMATPVSILRMGDDAKDKSQLFFMSCFGAAYEDLR VLSALTGTEFKPRSALKCKGFHVPAKEQVEGMGAALMSIKLQFWAPMTRSGGNEV GGDGGSGQISCSPVFAVERPIALSKQAVRRMLSMNIEGRDADVKGNLLKMMNDSM AKKTNGNAFIGKKMFQISDKNKTNPVEIPIKQTIPNFFFGRDTAEDYDDLDY 30 19 3745052_1 (GHMatters) P78534.AU.1 PB] Influenza Consensus- SEQ ID 11 MDVNPTLLFLKVPAQNAISTTFPYTGDPPYSHGTGTGYTMDTVNRTHQYSEKGKWT TNTETGAPQLNPIDGPLPEDNEPSGYAQTDCVLEAMAFLEESHPGIFENSCLETMEVV QQTRVDKLTQGRQTYDWTLNRNQPAATALANTIEVFRSNGLTANESGRLIDFLKDV 5 MESMDKEEMEITTHFQRKRRVRDNMTKKMVTQRTIGKKKQRVNKRGYLIRALTLN TMTKDAERGKLKRRAIATPGMQIRGFVYFVETLARSICEKLEQSGLPVGGNEKKAKL ANVVRKMMTNSQDTELSFTITGDNTKWNENQNPRMFLAMITYITKNQPEWFRNILSI APIMFSNKMARLGKGYMFESKRMKLRTQIPAEMLASIDLKYFNESTRKKIEKIRPLLI DGTASLSPGMMMGMFNMLSTVLGVSILNLGQKKYTKTTYWWDGLQSSDDFALIVN 10 APNHEGIQAGVDRFYRTCKLVGINMSKKKSYINKTGTFEFTSFFYRYGFVANFSMEL PSFGVSGINESADMSIGVTVIKNNMINNDLGPATAQMALQLFIKDYRYTYRCHRGDT QIQTRRSFELKKLWDQTQSKAGLLVSDGGPNLYNIRNLHIPEVCLKWELMDEDYRG RLCNPLNPFVSHKEIESVNNAVVMPAHGPAKSMEYDAVATTHSWIPKRNRSILNTSQ RGILEDEQMYQKCCNLFEKFFPSSSYRRPVGISSMVEAMVSRARIDARIDFESGRIKK 15 EEFSEIMKICSTIEELRRQKK M2 Influenza Consensus- SEQ ID 12 MSLLTEVETPIRNEWGCRCNDSSDPLVVAASIIGILHLILWILDRLFFKCIYRLFKHGL KRGPSTEGVPESMREEYRKEQQNAVDADDSHFVSIELE 20 The homology referred to above in respect of these sequences is preferably 75%, 85%, 95% or substantially 100%. In the present invention, the influenza strain is not especially limited, and the polypeptides 25 may be immunogenic against, and/or derived from, any known influenza strain. Preferably, however, the relevant strain is an Influenza A or Influenza B strain. Future influenza strains that have mutated from any of these existing strains may also be ones against which the polypeptides are immunogenic, or from which the polypeptides are derived. 30 The proteins within which the sequences defining the polypeptides of the present invention are situated are selected from M1, NP, PB and M2 proteins from any influenza virus strain (especially A and B strains) (the consensus sequences of which for all analysed sequences, or alternatively the positions of which within the protein, are described above). The following 20 3745052_1 (GHMatters) P78534.AU.1 specific proteins were analysed by the inventors, and preferably the influenza virus proteins referred to in the invention are selected from these specific proteins, or mutations from these proteins. Thus, the specific sequences homologous to SEQ ID 1-6 described above are preferably the ones at the appropriate positions within the following proteins. Similarly, the 5 sequences of the present invention defined by the residue positions within proteins from any influenza strain, namely residues 36-75 of M1 protein (especially infuenza A Ml), residues 124-158 of M1 protein (especially in influenza B MI), residues 255-275 of NP protein (especially in influenza A NP), residues 306-326 of NP protein (especially in influenza B NP), residues 395-428 of PBl protein, and residues 32-55 of M2 protein, are preferably those 10 within the following specific proteins. The list is in the form |version number (gi number) database identification (e.g. gb for GenBank)|NCBI accession numberloptional further information (e.g. the accession number of the nucleotide sequence from which the protein sequence is derived). The sequences and corresponding influenza strains from which they derive can all be found from the public NCBI protein database, which may be accessed 15 online at the following URL address http://www.ncbi.nlm.nih.gov/entrez/query/static/help/helpdoc.html#Protein. The protein database contains sequence data from the translated coding regions from DNA sequences in GenBank, EMBL, and DDBJ as well as protein sequences submitted to Protein Information Resource (PIR), SWISS-PROT, Protein Research Foundation (PRF), and Protein Data Bank 20 (PDB) (sequences from solved structures). Ml proteins |27530653|dbjlBAC54009. 1; |27530634|dbjlBAC53998. 1; |53829719|gblAAU94746. 1; |53829716|gblAAU94744.1l; |53829713|gblAAU94742.1l; 153829710|gblAAU94740.1l; 25 |53829707|gblAAU94738. 1; |538297041gblAAU94736. 1; 153829701 gbIAAU94734. 1; |53829698|gblAAU94732. 1; |53829695|gblAAU94730. 1; |53829692|gblAAU94728. 1; 153829689|gblAAU94726. 11; |53829686|gblAAU94724. 1; 153829683|gblAAU94722. 1; |8486160|ref]NP_056664.1l; |30466242|reflNP_848689. 1; |30349250|gblAAP22121.1l; 130466211 reflNP_848672.1l; |30349219|gblAAP22104.1 ; 30 |4761025|gblAAD29208.1lAF100392_1|; |4761022|gblAAD29206.1lAF100391_1|; 14761019|gblAAD29204.1lAF100390_ll; |47610161gblAAD29202.1lAF100389_1|; 14761013[gblAAD29200.1lAF100388_ll; |47610101gblAAD29198.1lAF100387_1|; |47610071gblAAD29196.1lAF100386_1|; |4761004|gblAAD29194.1lAF100385_1|; |4761001|gblAAD29192.1|AF100384_1|; 14760998|gblAAD29190.1lAF100383_11; 35 |4760995|gblAAD29188.1lAF1003821|; |4760992|gblAAD29186.1lAF100381_1|; 14760989|gblAAD29184.1lAF100380_1I; |47609861gblAAD29182.1lAF100379_1|; |4760983|gblAAD29180.1lAF1003781 l; |4760980|gblAAD29178.1lAF1003771 l; |47609771gblAAD29176.1 AF 100376_1|; |4760974|gblAAD29174.1 AF100375_1|; 21 3745052L1 (GHMatters) P78534.AU.1 4760971 IgbAAD29172.1 IAF1OO3741 1; 12862823 IdbjIBAB32623.1; 1286282OldbjIBAB32621. 11; 12862817ldbj IBAB32619.1 1; 157O2O961gblAAD4714.1 1; 5134O7851gblAAUO1OO1. .1; 15OO594381gblAAT6945 1.11; 15OO5940OgbAAT69429.1 1; 5OO594191gblAAT6944O. 11; 1325 1961gblAAA67 100.11; 13252O21gblAAA43726.1 1; 5 1388231spIPO34891VMT1_1NBLEI; 1388241spIPO68161VMT11INBSII; 1388221spIP1388O1VMT1_1 NBADI; 138821 IspIP138791VMT1JINBACI; 3251981gblAAA66416. 11; 13251941gblAAA66414. 11; 19O49382ldbj IBAA99399.1; 57643681gblAAD51265.1 IAF1532571 1; 1764433151gbIABA42441.1; 764433121gbIABA42439.1 1; 1764433O91gbIABA42437.1 1; 1764433O61gbIABA42435.1; 10 1764433O31gbIABA42433.1 1; 1216364551gblAAM7OOO3.1 IAF457712_1; 2163645O~gblAAM7OOOO.1 IAF4577101 1; 1216364341gblAAM69991 .1 IAF4577031 1; 216364161gblAAM6998 1.1 IAF4576951 1; 1216363981gblAAM6997 1.1 IAF4576871 1; 216363781gblAAM6996O.1 IAF4576781 1; 19802291 IgblAAF99672.1I AF2585231 1; 98O22881gblAAF9967O.1I AF2585221 1; 157643741gblAAD51269.1 IAF153259_1; 15 158O52891gblAAD51928.1 IAF1443O61 1; 15764371 IgblAAD51267.1 IAF153258_1; 716553841gblAAZ3874. 11; 1716553791gblAAZ38738. 11; 171655371 IgblAAZ38736.1 1; 716553561gblAAZ38734. 11; 171655345 IgblAAZ38732. 11; 171655341 IgblAAZ38730.1 1; 71655320~gblAAZ38728. 11; 1738529571ref]YP_308671 .11; 1739126881ref]YP_308854.11; 288494091gblAAO52887.1 IAF5090441 1; 157324221gblAAD49093.1 IAF 156470_21; 20 157324191gblAAD4909 1.1 IAF 156469_21; 157324161gblAAD49089.1 JAR156468_21; 281943541gblAAO33517.1 IAF4740581 1; 128194351 IgblAAO33515.1 IAF474057_1; 281943481gblAAO33513.1 IAF4740561 1; 128194345 IgblAAO3351 1.1 IAF474055_1; 281943421gblAAO33509.1 IAF4740541 1; 1281943391gblAAO33507.1 IAF474053_1; 281943361gblAAO33505.1 IAF4740521 1; 128194333 IgblAAO33503.1 IAF47405 111; 25 128194330~gblAAO3350 1.1 IAF4740501 1; 1281943271gblAAO33499.1 IAF474049_1; 2884945 1 IgblAAO52908.1 IAF5090651 1; 1288494491gblAA052907. 1 IAF509064_1 1; 288494471gblAAO52906. 1 IAF5090631 1; 128849445 gblAA052905.1 IAF509062_1 1; 28849443 IgblAAO52904. 1 IAF509061_1 1; 128849441 IgblAAO52903. 1 IAF509060_1 1; 288494391gblAAO52902. 1 IAF5090591 1; 1288494371gblAAO5290 1.1 IAF509058_1 1; 30 128849435 IgblAAO52900. 1 IAF5090571 1; 128849433 IgblAAO52899. 1 IAF509056_1 1; 2884943 1 IgblAAO52898. 1 IAF5090551 1; 1288494291gblAAO52897. 1 IAF509054_1 1; 288494271gblAAO52896. 1 IAF5090531 1; 128849425 IgblAAO52895. 1 IAF509052_1 1; 28849423 IgblAAO52894. 1 IAF50905 1_1; 128849421 IgblAAO52893. 1 IAF509050_1 1; 288494191gblAAO52892.1 IAF5090491 1; 1288494171gblAAO5289 1.1 IAF509048_1; 35 128849415 IgblAAO52890.1 IAF5090471 1; 128849413 IgblAAO52889.1 IAF509046_1; 28849411 IgblAAO52888. 1 IAF5090451 1; 1288494071gblAAO52886. 1 IAF509043_1 1; 288494051gblAAO52885. 1 IAF5090421 1; 128849403 IgblAAO52884. 1 IAF509041_1 1; 28849401 IgblAAO52883.1 IAF5090401 1; 157324071gblAAD49083.1 IAF 156465_21; 5732425 IgblAAD49095.1 IAF 156471_21; 15732413 IgblAAD49087.1 JAR156467_21; 40 157324 10lgbAAD49085.1 IAF 156466_21; 157324041gblAAD4908 1.1 JAR156464_21; 5732401 IgblAAD49079. 1 IAF 156463_21; 15732398 IgblAAD49077. 1 JAR156462_21; 5732395 IgblAAD49075.1 IAF 156461_21; 157323921gblAAD49073.1 JAR156460_21; 57323891gblAAD4907 1.1 IAF 156459_21; 157323861gblAAD49069.1 JAR156458_21; 324263 IgbIAAA43254. 11; 1379330771gblAAO46713. 11; 1379330741gblAAO4671 1.11; 45 137933071 IgblAAO46709.1 1; 1379330681gblAAO46707. 11; 1379330651gblAAO46705.1 1; 379330621gblAAO46703.1 1; 1379330591gbAAO46701. .1; 1379330561gblAAO46699.1 1; 379330531gblAAO46697.1 1; 137933050~gblAAO46695. 11; 13793 3047 1gb IAAO46693.1 1; 379330441gblAAO4669 1.11; 137933041 IgblAAO46689. 11; 1379330381gblAAO46687.1 1; 379330351gblAAO46685.1 1; 1379330321gblAAO46683. 11; 1379330291gblAAO4668 1.11; 22 3745052_1 (GH Matters) P78534.AU.1 |37933026|gblAAO46679.1|; |37933023|gblAAO46677.1|; 137933020|gblAAO46675.1|; |37933017|gblAAO46673.1 ; |37933014|gblAAO46671 .1; 137933011 gblAAO46669.1 ; |37933008|gblAAO46667.1 ; |37933005|gblAAO46665. 1; |37933002|gblAAO46663.1 ; |37932999|gblAAO4666 1.1|; |37932996|gblAAO46659. 1; 137932993|gblAAO46657. 1; 5 1379329901gblAAO46655.1 ; |37932987|gblAAO46653. 1; |37932984|gblAAO4665 1.1|; |37785163|gblAAO46420.1 ; |3778516OgblAAO46418. 1; |37785157|gblAAO46416.1 ; |37785154|gblAAO46414.1|; 137785151|gblAAO46412.1|; 137785145|gblAAO46408.1|; |37785142|gblAAO46406.1 ; |37785139|gblAAO46404. 1; |37785136|gblAAO46402.1 ; |37785133|gblAAO46400.1 ; |37785130|gblAAO46398. 1; |37785127|gblAAO46396.1 ; 10 |37785124|gblAAO46394.1 ; 137785121 gblAAO46392. 1; |37785118|gblAAO46390.1 ; |37785115|gblAAO46388.1 ; |37785112|gblAAO46386. 1; |37785109|gblAAO46384.1 ; |37785106|gblAAO46382.1 ; |37785103|gblAAO46380. 1; 137785 100|gblAAO46378.1 ; |37785097|gblAAO46376.1|; |37785094|gblAAO46374.1|; 137785091|gblAAO46372.1|; |37785088|gblAAO46370.1 ; |37785085|gblAAO46368. 1; |37785082|gblAAO46366.1 ; 15 |37785079|gblAAO46364.1 ; |37785076|gblAAO46362. 1; 137785073|gblAAO46360.1 ; |37785070|gblAAO46358.1|; |37785067|gblAAO46356.1|; |37785064|gblAAO46354.1|; 137785061 gblAAO46352.1 ; |37785058|gblAAO46350. 1; |37785055|gblAAO46348.1 ; |37785053|gblAAO46347.1|; |37785049|gblAAO46344.1|; |37785046|gblAAO46342.1|; |13925107|gblAAK49251.1|AF255374_1|; 1324383|gblAAA43336.1|; 20 |324322|gblAAA43294. 1; |325068|gblAAA43674. 1; |324395|gblAAA43344.1 ; 1324371 gblAAA43316.1|; |324334|gblAAA43302. 1; |324316|gblAAA43290.1 ; 13243 10|gblAAA43286. 1; |324299|gblAAA43277.1 ; 11065886|gblAAG28376.1|AF188004_1|; 11065883|gblAAG28374.1|AF188003_1|; |483855|gblAAC79577.1 ; |2833661 gblAAC34265.1 ; 173665375|gblAAZ79394.1 ; 25 |30025987|gblAAP045 10.1|; |66734259|gblAAY53536.1 ; |37785148|gblAAO46410. 1; |7429156|pir||PN0086|; |58618460|gblAAW80728. 1; |58618458|gblAAW80727.1 ; |13925103|gblAAK49249.1|AF255373_1|; |50365716|gblAAT76159.1|; 18140844|gblAAL60445.1|AF398876_1|; |20065772|gblAAM09298.1|; |20065769|gblAAM09296.1 ; |324406|gblAAA4335 1.1; |324398|gblAAA43347. 1; 30 |324392|gblAAA43342. 1; |324389|gblAAA43340. 1; |324386|gblAAA43338.1 ; 13243801gblAAA43334. 1; |324377|gblAAA43332. 1; |324374|gblAAA43318.1|; |324344|gblAAA43307. 1; 1324331 gblAAA43300. 1; |324328|gblAAA43298.1 ; |324319|gblAAA43292. 1; 1324313|gblAAA43288. 1; |324307|gblAAA43282.1 ; |324304|gblAAA43280. 1; |27596998|reflNP_775536.1|; |61612084|gblAAX47287. 1; 35 |63054907|gblAAY28990. 1; 160473 emblCAA30892. 1; |60470|emblCAA30890. 1; |60467|emblCAA30888. 1; |60464|emblCAA30886. 1; 160461 emblCAA30884. 1; |60458|emblCAA30882. 1; |45124752|emblCAF33014.1 ; 194145|pir|lJN0392|; |75117|pir||MFIV1Kl; |7444522|pir||T09279|; |77195|pir||S04050|; |77193|pir||S04052|; |77191|pir||S04058|; |77189|pir||S04056|; |56548894|gblAAV97612. 1; 40 |56548892|gblAAV9761 1.1|; 1565488901gblAAV97610. 1; |56548888|gblAAV97609.1 ; |58618456|gblAAW80726.1|; |51094108|gblAAS89185.2|; |51859837|gblAAU11202.1|; |51859834|gblAAU1 1200.1|; 151859831 gblAAU1 1198.1|; |51859825|gblAAU1 1194.1|; |51859822|gblAAU11192.1|; |51859819|gblAAU11190.1|; |51859816|gblAAU11188.1|; |51859813|gblAAU11186.1|; 151859810|gblAAU11184.1|; |51859807|gblAAU11182.1|; 45 |51859804|gblAAU1180.1|; 151859801|gblAAU1178.1|; |51859798|gblAAU1176.1|; |51859792|gblAAU1 1172.1|; |51859789|gblAAU1 1170.1|; |51859786|gblAAU1 1168.1|; |51859783|gblAAU11166.1|; |33318239|gblAAQ04993.1|AF508704_1|; |33318237|gblAAQ04992.1 AF508703_1 ; 133318235|gblAAQ04991.1 AF508702_1 ; 133318233|gblAAQ04990.1 AF508701_1 ; 133318231 gblAAQ04989.1 AF508700_1 ; 23 3745052_1 (GHMatters) P78534.AU.1 |33318229|gblAAQ04988.1|AF508699_1|; |33318227|gblAAQ04987.1|AF508698_1|; |33318225|gblAAQ04986.1|AF508697_1|; 133318223|gblAAQ04985.1|AF508696_1|; 133318221|gblAAQ04984.1|AF508695_1|; |33318219|gblAAQ04983.1|AF508694_1|; |33318217|gblAAQ04982.1|AF508693_1|; 133318215|gblAAQ04981.1|AF508692_1|; 5 133318213|gblAAQ04980.1|AF508691_1|; |33318207|gblAAQ04977.1|AF508688_1|; |33318205|gblAAQ04976.1|AF508687_1|; |33318199|gblAAQ04973.1|AF508684_1|; |41207456|gblAAR99627.1|; |29539573|gblAAO88261.1|AF342818_1|; |14587042|gblAAK70447.1|AF386772_1|; 14587039|gblAAK70445.1|AF386771_1|; |14587036|gblAAK70443.1|AF386770_1|; 14587033|gblAAK70441.1|AF386769_1|; 10 1458703OgblAAK70439.1|AF386768_1|; 14587027|gblAAK70437.1|AF386767_1|; |14587024|gblAAK70435.1|AF386766_1|; 14587021|gblAAK70433.1|AF386765_1|; |27462132|gblAAO15336.1|AF225529_1|; |27462129|gblAAO15334.1|AF225528_1|; |27462126|gblAAO15332.1|AF225527_1|; |27462123|gblAAO15330.1|AF225526_1|; |21693175|gblAAM75161.1 AF389121_1|; |14009743|gblAAK51748.1|; 15 |1400974OgblAAK51746.1|; |14009737|gblAAK51744.1|; |14009734|gblAAK51742.1|; |14009731|gblAAK51740.1|; |14009728|gblAAK51738.1|; |14009725|gblAAK51736.1|; |14009722|gblAAK51734.1|; 14009719|gblAAK51732.1|; 14009716|gblAAK51730.1|; 14097640|gblAAD00149. 1; 14097637|gblAAD00147.1|; 14097634|gblAAD00145.1|; 14097631 gblAAD00143. 1; 14097628|gblAAD00141.1|; 14097625|gblAAD00139.1|; 20 14097622|gblAAD00137. 1; 14097619|gblAAD00135.1|; 14097616|gblAAD00133.1|; 14097613|gblAAD0013 1.1; 14097610|gblAAD00129. 1; |3929612|gblAAC80167.1 ; |3929609|gblAAC80165.1 ; |3929606|gblAAC80163. 1; 13929603|gblAAC80161 .1; |3929600|gblAAC80159.1 ; |3929597|gblAAC80157. 1; |3929594|gblAAC80155. 1; |3722202|gblAAC63485.1 ; |3722199|gblAAC63483. 1; |3722196|gblAAC63481.1|; 25 |3722193|gblAAC63479.1 ; |3414662|gblAAC31296.1|; |3414659|gblAAC31294.11; |3414653|gblAAC31290.1|; |3414650|gblAAC31288.1|; |3414647|gblAAC31286.11; |3414635|gblAAC31278.1|; |3414629|gblAAC31274.1|; |3414626|gblAAC31272.1|; |60818|emblCAA41928.1|; |75118|pir||MFIV1Fl; |235419|gblAAB19773.1|; |138819|splP05777|VMT1_IAWIL|; 138817|splP03485|VMT1_IAPUEl; 30 13242601gblAAA43252.1|; |324258|gblAAA43251.1|; 138812|splP05775|VMT1_IAFPW|; |1912412|gblAAB50992.1|; 1912409|gblAAB50990.1|; 1912406|gblAAB50988.1|; |1912403|gblAAB50986.1|; 1912400|gblAAB50984.1|; |407933|gblAAB39915.11; |406039|gblAAA67337. 1; |325082|gblAAA43682. 1; |324364|gblAAA43313.1|; |324266|gblAAA43256.1|; |323978|gblAAA43092.1|; |62901345|splQ77Y95|VMT1_IAHO3|; 35 |60416244|splP69276|VMT1_IASINI; |60416243|splP69275|VMT1_IAFOW|; |54039855|splP63234|VMT1_IAPOCl; |549378|splP35937|VMT1_IAUSS|; |549377|splP36347|VMT1_IACKBl; 138820|splP05776|VMT1_IAZIll; |138815|splP08381|VMT1_IAMANI; 138808|splP03487|VMT1_IABAN|; |138807|splP21429|VMT1_IAANNI; 138813|splP26127|VMT1_IALE1|; 40 |54039857|splP67865|VMT1_IALE3|; |54039856|splP67864|VMT1_IALE2|; |138811|splP03488|VMT1_IAFPR|; |414307|gblAAA91325.1|; |414304|gblAAA91323.1|; |13182927|gblAAK14989.1|AF231361_2|; 13182921|gblAAK14985.1|AF231359_2|; |8307813|gblAAF74336.1|AF084284_1|; |8307810|gblAAF74334.1|AF084283_1|; |8307807|gblAAF74332. 1 AF084282_1 ; |4584939|gblAAD2521 1.1 AF073200_1 ; 45 1710135 10|dbjlBAE07204. 1; 19857035|emblCAC04083. 1; 19857038|emblCAC04085.1 ;1; |54299846|gblAAV32646. 1; |54299832|gblAAV32638. 1; |52078188|gblAAU25869. 1; |52078168|gblAAU25858.1 ; |52078150|gblAAU25848. 1; |30522966|gblAAO6561 1.1|; 18486123|reflNP_040978.1|; |58531182|dbjlBAD89349.1|; |58531164|dbjlBAD89339.1|; |58531146|dbjlBAD89329.1 ; |58531128|dbjlBAD89319.1|; |58531096|dbjlBAD89309. 1; 24 3745052_1 (GHMatters) P78534.AU.1 425212941gblAAS 18237. 11; 13852457Oldbj IBADO2365.1 1; 138524552ldbj IBADO2355. 11; 45849541gblAAD2522 1.1 IAF0732051 1; 14584951 IgblAAD25219. 1 IAF073204_1 1; 45849481gblAAD25217. 1 IAF0732031 1; 14584945 IgblAAD25215. 1 IAF073202_1 1; 45849421gblAAD25213.1 IAFO732O11 1; 145849361gblAAD252O9.1 IAFO73199_1; 5 145849331gblAAD252O7. 1 IAF073 198_11; 1458493O1gblAAD25205. 1 IAF073 197_1; 45849271gblAAD252O3. 1 IAF073 196_11; 145849241gblAAD252O1 .1 IAF073 195_1; 4584921 IgblAAD25199.1 IAFO731941 1; 145849181gbAAD25197.1 IAFO73193_1; 45849151gbAAD25195.1 IAFO731921 1; 145849121gbAAD25193.1 IAFO73191_1; 45849O91gbAAD25191.1 IAFO7319_1 1; 145849O61gbAAD25189.1 IAFO73189_1; 10 145849O31gbAAD25187.1 IAFO731881 1; 1458490O~gbAAD25185.1 IAFO73187_1; 45848971gAAD25183.1 IAFO731861 1; 145848941gAAD2518 1.1 IAFO73185_1; 4584891 IgbAAD25179.1 IAFO731841 1; 145848881gbAAD25177.1 IAFO73183_1; 45848851gAAD25175.1 IAFO731821 1; 145848821gAAD25173.1 IAF07318 111; 45848791gbAAD25 171.1 IAF073 180_1; 1779173381gbIABBO5217. 11; 15 1779173 191gbABBO52O6. 11; 1779173O~gbIABBO5 195.11; 17786949O1gbIABB05 184.11; 778634931gbIABBO5OO6. 11; 1778634741gblABBO4995. 11; 177863455 IgbIABBO4984.1 1; 778634361gbIABBO4973. 11; 1778634171gblABB04962. 11; 177863398 IgbIABB0495 1.11; 778633791gbIABB04940. 11; 1778633601gbIABB04929. 11; 177863341 IgbIABB0491 8.11; 778633221gbIABB04907. 11; 177861 8691gbIABB04372. 11; 177861 850~gbIABB04361 .11; 20 17786183 1 IgbIABB04350. 11; 1778618121gbIABB04339. 11; 177861793 IgbIABB04328.1 1; 778617741gbIABB043 17.11; 177861755 IgbIABB04306. 11; 1778617361gbIABB04295.1 1; 778617171gbIABB04284. 11; 1777474621gblABB03146. 11; 177747443 IgbIABB03135.1 1; 777474241gbIABB03 124.11; 1777474041gblABB03 113.11; 177747385 IgbIABB03 102.11; 777473661gbIABB03091. .1; 1777473471gbIABB03080. 11; 1777473281gbIABB03069.1 1; 25 1777473 07 1gb JABB03 05 8. 11; 17774728 8 1gb JABB03 047. 11; 1777472691gbIABB03036.1 1; 7774725 0 1gb JABB03 025. 11; 177747231 IgblABB03014. 11; 1777472121gbIABB03003.1 1; 777471931gbIABB02992. 11; 1777471741gbIABB02981. 11; 177747153 IgbIABB02970.1 1; 777471341gbIABB02959. 11; 177747115 IgbIABB02948. 11; 1777470961gbIABB02937.1 1; 777470751gbIABB02925. 11; 1777470561gblABB029 14.11; 1777470371gbIABB02903.1 1; 30 177746991 IgbIABB02892. 11; 1777469721gbIABB0288 1.11; 177746953 IgbIABB02870.1 1; 777469341gbIABB02859. 11; 177746915 IgbIABB02848. 11; 1777468941gbIABB02837.1 1; 777468751gbIABB02826. 11; 1777468561gbIABB028 15.11; 1777468371gbIABB02804.1 1; 7774681 81gbIABB02793. 11; 1777467991gbIABB02782.1 1; 177543685 IgbIABA87254. 11; 77543665 IgbIABA87243 .11; 177543645 IgbIABA87232.1 1; 177543363 IgbIABA87092. 11; 35 1775433441gbIABA8708 1.11; 177543300~gbIABA87058.1 1; 1775432441gbIABA87046. 11; 764643 51 gb JABA43 3 37.11; 17645 3795 1gb JABA4320 1.11; 1764468221gbIABA43 190.11; 76446801 IgbIABA43179.1 1; 1764464281gbIABA43168.1 1; 1764463861gbIABA42979.1; 764463 141gbABA42940.1 1; 1764462951gbIABA42929.1 1; 1764435291gbIABA42576. 11; 76443510OgbIABA42565.1 1; 176443491 IgbIABA42554.1 1; 1764434721gbIABA42543.1; 40 176443453 IgbIABA42532.1 1; 1764434341gbIABA4252 1.11; 176443415 IgbIABA425 10.1; 764433961gbIABA42499.1 1; 1764433771gbIABA42488.1 1; 1764433581gbIABA42477.1; 764433391gbIABA42466.1 1; 1764433201gbIABA42455.1 1; 176443271 IgbIABA42444.1; 764432521gbIABA42413.1 1; 1764432331gbIABA42402.1 1; 1764432141gbIABA42391.1; 764431951gbIABA42380.1 1; 1764431761gbIABA42369.1 1; 176440841 IgbIABA42358.1; 4 764266691gbIABA42347.1 1; 1764185491gbIABA42336.1 1; 176411033 IgbIABA42325.1; 764104011 gblABA42314.1 1; 1764031021gbIABA42303.1 1; 1763815041gbIABA42292.1; 763740571gbIABA4228 1.11; 1763660711 gblABA42270.1 1; 1763660521gbIABA42259. 11; 763660331gbIABA42248.1 1; 1763660141gbIABA42237.1 1; 1757503471gbIABA26800. 11; 757503281gbIABA26789.1 1; 1757503091gbIABA26778.1 1; 175750290~gbIABA26767. 11; 25 3745052_1 (GH Matters) P78534.AU.1 |75750271 gblABA26756.1|; |75750252|gblABA26745.1 ; 175750233|gblABA26734. 1; |75750214|gblABA26723.1 ; |75750195|gblABA26712.1 ; |75750176|gblABA26701 .1; |72623449|gblAAZ74618.1|; 175218743|gblABA18168.1|; |75217099|gblABA18157.1|; 175216125|gblABA8146.1|; |7521594OgblABA8135.1|; |75215199|gblABA8124.1|; 5 |75214317|gblABA8113.1|; 175212621|gblABA18038.1|; 175206495|gblABA18027.1|; |75181140|gblABA12782.1|; |75181097|gblABA12774.1|; 175180915|gblABA12763.1|; |75180819|gblABA12752.1 ; |75180514|gblABA12741.1|; |75172966|gblABA12730. 1; |75171345|gblABA12718.1|; |75171062|gblABA12708.1|; 175168355|gblABA12697.1|; |74477288|gblABA08520.1|; |74477269|gblABA08509.1|; |74477248|gblABA08498.1|; 10 |74477229|gblABA08487.1|; |74477210|gblABA08476.1|; 174477191|gblABA08465.1|; 174422755|gblABA06543.1|; |74422586|gblABA06511.1|; |73919152|reflYP_308841.1|; |32141423|reflNP_859036.1|; |73765595|gblAAZ85127.1|; |73763197|gblAAZ83978.1 ; |73762504|gblAAZ83689. 1; 173762293|gblAAZ83650. 1; |73761787|gblAAZ83383.1 ; |73761720|gblAAZ83372. 1; 173761598|gblAAZ83324. 1; |73761579|gblAAZ83313.1|; 15 |73761560|gblAAZ83300. 1; |73761522|gblAAZ83278. 1; |73761499|gblAAZ83267.1 ; |73761476|gblAAZ83254. 1; |73761457|gblAAZ83243. 1; 173666615|gblAAZ8003 1.1|; |73666596|gblAAZ80019. 1; |73666577|gblAAZ80008. 1; |73666558|gblAAZ79997. 1; |73666539|gblAAZ79986. 1; |73665974|gblAAZ79975. 1; |73665924|gblAAZ79964. 1; |73665876|gblAAZ79946. 1; |73665868|gblAAZ79942. 1; 1736658301gblAAZ79630. 1; 20 |73665827|gblAAZ79628. 1; |73665806|gblAAZ79616. 1; |73665787|gblAAZ79605. 1; |73665768|gblAAZ79594. 1; |73665749|gblAAZ79583. 1; 1736657301gblAAZ79572.1 ; 173665711 gblAAZ79561 .1; |73665692|gblAAZ79550. 1; 173665673 gblAAZ79539.1 ; |73665654|gblAAZ79528. 1; 173665635|gblAAZ79517.1|; |73665612|gblAAZ79506.1 ; |67644047|gblAAY78940. 1; |62198978|gblAAX76734. 1; |72602389|gblAAZ74607. 1; 25 |72602370|gblAAZ74596. 1; 172602351 gblAAZ74585. 1; |72602238|gblAAZ74574. 1; |72598156|gblAAZ74563.1|; 172597908|gblAAZ74552.1|; 172582113|gblAAZ74541.1|; |72580904|gblAAZ74530.1|; |72578614|gblAAZ74519.1|; |72572288|gblAAZ74508.1|; |72572210|gblAAZ74497. 1; |72568982|gblAAZ74486. 1; |72565898|gblAAZ74475. 1; |72562517|gblAAZ74464.1|; 172556623|gblAAZ74453.1|; 1725543701gblAAZ74442.1|; 30 |72552876|gblAAZ7443 1.1; |72552072|gblAAZ74420. 1; 172549571 gblAAZ74409. 1; 172545851|gblAAZ74398.1|; |72545117|gblAAZ74387.1|; 172542981|gblAAZ74375.1|; |72539892|gblAAZ74364. 1; 172539853|gblAAZ74353.1 ; 171000195|dbjlBAE07159.1 ; |71842589|gblAAZ43406. 1; |71842570|gblAAZ43395. 1; 171842551 gblAAZ43384.1 ; |71842528|gblAAZ43371.1|; |71571147|gblAAZ38651.1|; 171568545|gblAAZ38639.1|; 35 |71564882|gblAAZ38628.1|; 171564863|gblAAZ38617.1|; |71564844|gblAAZ38606.1|; |71564825|gblAAZ38595.1|; |71564806|gblAAZ38584.1|; |71564787|gblAAZ38573.1|; |71564768|gblAAZ38562.1|; |71564749|gblAAZ38551.1|; |71564730|gblAAZ38540.1|; |71564711|gblAAZ38529.1|; |71564692|gblAAZ38518.1|; 171564673|gblAAZ38507.1|; |71564654|gblAAZ38496.1|; 171564635|gblAAZ38485.1|; |71564616|gblAAZ38474.1|; 40 |71564597|gblAAZ38463. 1; |70907642|gblAAX56531.2|; |62198870|gblAAX76674.1 ; |68525442|gblAAY9877 1.1|; |68510079|gblAAY98407. 1; |68510060|gblAAY98397. 1; 168510041 gblAAY98387.1 ; 1685 10010|gblAAY98377. 1; |68509989|gblAAY98367.1 ; |68509957|gblAAY98357.1|; |68509895|gblAAY98340.1|; |68509732|gblAAY98330.1|; |68509376|gblAAY98320.1 ; |68509334|gblAAY98248. 1; |68509314|gblAAY98238.1 ; 45 |68509295|gblAAY98228.1 ; |68509275|gblAAY98218. 1; 168509251 gblAAY98208.1 ; |68509226|gblAAY98197.1 ; |68509209|gblAAY98188. 1; |68509188|gblAAY98178.1 ; |68509170|gblAAY98168.1 ; |68509152|gblAAY98158. 1; |68509134|gblAAY98148.1 ; |68509115|gblAAY98138.1 ; |68509097|gblAAY98128. 1; |68509079|gblAAY98118.1|; 168509061 gblAAY98108.1 ; 168509043|gblAAY98098. 1; 168509011 gblAAY98088.1 ; 26 3745052_1 (GHMatters) P78534.AU.1 |6850893OgblAAY98078.1 ; |68508893|gblAAY98068. 1; |68508816|gblAAY98058.1 ; |6850860O0gblAAY98048.1 ; |68508515|gblAAY98038. 1; |62199032|gblAAX76764.1 ; |62198816|gblAAX76644.1 ; |6197092OgblAAX57935. 1; |61970722|gblAAX57825.1 ; |61927526|gblAAX56471.1|; |59896446|gblAAX11576.1|; |68161822|emblCAJO1905.1|; 5 |67062583|gblAAY64403.1|; |67062042|gblAAY64393.1|; |67061886|gblAAY64383.1|; |6706109OgblAAY64373.1 ; |67060408|gblAAY64363. 1; 167060167|gblAAY64353.1|; 167059535|gblAAY64343.1|; |67058967|gblAAY64333. 1; |67058904|gblAAY64323.1 ; |67058349|gblAAY64313.1|; 167058331 gblAAY64303. 1; |67058313|gblAAY64293.1 ; |67058295|gblAAY64283. 1; |67058277|gblAAY64273. 1; |67057698|gblAAY64263. 1; 10 |67051336|gblAAY64253.1|; |67049849|gblAAY64243.1|; 167045888|gblAAY64233.1|; |67045467|gblAAY64223.1|; 167044510|gblAAY64213.1|; |67044334|gblAAY64203.1|; |67044258|gblAAY64193.1 ; |67044158|gblAAX57865.2|; 166947416|gblAAY59036.1|; |66475120|gblAAY47086.1 ; |66475102|gblAAY47076. 1; |66475058|gblAAY47053.1 ; 1664749901gblAAY47024. 1|; |66473597|gblAAY46437. 1; 1664735 79|gb AAY46427. 1|; 15 166473561 gblAAY46417.1 ; 166473491 gblAAY46392. 1; |66473469|gblAAY46382.1 ; |66473449|gblAAY46372.1|; |66356017|gblAAY45647.1|; |66354526|gblAAY44907.1|; |66354508|gblAAY44897.1 ; |66354010|gblAAY44797. 1; 1663539901gblAAY44786.1 ; |66353972|gblAAY44776.1|; |66353872|gblAAY44766.1|; |66353854|gblAAY44756.1|; 166346631 gblAAY44662. 1; 166346001 gblAAY44652. 1; |66327419|gblAAY44642. 1; 20 166319001 gblAAY44632.1 ; |66315204|gblAAY44622. 1; |66303354|gblAAY4461 1.1|; |3335425|gblAAC32090.1 ; |3335407|gblAAC32080.1 ; |63053665|gblAAY28639.1 ; |63029987|gblAAY27864.1|; |63053683|gblAAY28649.1|; |63053647|gblAAY28629.1|; |63053629|gblAAY28619.1|; 163053611 gblAAY28609. 1; |63053528|gblAAY28592.1 ; |63053496|gblAAY28582.1|; |63053478|gblAAY28572.1|; |63053459|gblAAY28562.1|; 25 |63047644|gblAAY28552.1|; |63038347|gblAAY28542.1|; |63034457|gblAAY28532.1|; |63034439|gblAAY28522.1 ; |63034224|gblAAY28503. 1; 163034195|gblAAY28406.1 ; |63034177|gblAAY28396.1 ; |63034158|gblAAY28386. 1; |63034140|gblAAY28376.1 ; |63034120|gblAAY28365.1 ; |63034104|gblAAY28356. 1; |63034086|gblAAY28346.1 ; |63034068|gblAAY28336.1 ; |63034050|gblAAY28326. 1; |63034032|gblAAY28316.1|; 30 |63034014|gblAAY28306.1 ; |63033973|gblAAY28296. 1; |63033955|gblAAY28286.1 ; |63033937|gblAAY28276.1 ; |63033917|gblAAY28266. 1; |63033414|gblAAY28015.1 ; |63033396|gblAAY28005.1 ; |63033377|gblAAY27995. 1; |63031460|gblAAY27960.1 ; |63029969|gblAAY27854.1 ; |63029949|gblAAY27844. 1; 162871285|gblAAY18586.1|; |62871262|gblAAY18565.1|; 162870083|gblAAY18197. 1; 162870065|gblAAY18187.1|; 35 |62870047|gblAAY18177.1|; |62870029|gblAAY18167.1|; 162870011|gblAAY18157.1|; 162869993|gblAAY18147.1|; 162869975|gblAAY18137. 1; |62869957|gblAAY18127.1|; |62869939|gblAAYl8117.1|; 162869921 gblAAY18107. 1; 162869903|gblAAY18097.1|; |62869884|gblAAY18087.1|; |62198924|gblAAX76704. 1; |62198798|gblAAX76634.1 ; |62198780|gblAAX76624.1 ; |61620943|gblAAX47526. 1; |62199014|gblAAX76754.1 ; 40 |60683805|gblAAX34062.1 ; 159940441 gblAAX12762. 1; |438072|emblCAA81464. 1; |40353079|emblCAF02292. 1; |39840728|emblCAC95058. 1; |22859490|emblCAD30544. 1; |22859486|emblCAD30542. 1; |22859483|emblCAD30540. 1; |22859480|emblCAD30538. 1; |22859477|emblCAD30536.1 ; |20068129|emblCAC87410.1|; |20068120|emblCAC87404. 1; |20068108|emblCAC87396. 1; |20068105 emblCAC87394. 1; |20068099|emblCAC87390. 1; 45 |20068093|emblCAC87386. 1; 19913218|emblCAD20332. 1; 19913212|emblCAD20326. 1; |14275729|emblCAC40057. 1; 14275702|emblCAC40043.1 ; 12038900|emblCAC 19700.1|; 19857032|emblCAC0408 1.1; |62198996|gblAAX76744. 1; |62198960|gblAAX76724. 1; |62198942|gblAAX76714.1|; |62198906|gblAAX76694.1|; |62198888|gblAAX76684.1|; |62198852|gblAAX76664.1 ; |62198834|gblAAX76654. 1; |61970938|gblAAX57945.1 ; 27 3745052_1 (GHMatters) P78534.AU.1 6197O8841gblAAX57915.1 1; 16197O8661gblAAX579O5. 11; 16197O8481gblAAX57895.1 1; 6197O83O~gblAAX57885.1 1; 16197O8121gblAAX57875. 11; 16197O7761gblAAX57855.1 1; 6197O7581gblAAX57845.1 1; 16197O74O~gblAAX57835. 11; 16197O7O41gblAAX57815.1 1; 6197O6861gblAAX578O5.1 1; 16197O6681gblAAX57795. 11; 16197O65O~gblAAX57785.1 1; 5 16197O6321gblAAX57775.1 1; 16197O6141gblAAX57765. 11; 1619705 96 1gb JAAX5 775 5.11; 6197O5781gblAAX57745.1 1; 16197O56O~gblAAX57735. 11; 1619705 40O1gb JAAX5 7724.11; 6197O5241gblAAX57715.1 1; 16197O5O61gblAAX577O5. 11; 16197048 8 1gb JAAX5 7695.11; 6197O47O~gblAAX57685.1 1; 16197O4521gblAAX57675. 11; 16197O4341gblAAX57665.1 1; 6197O4161gblAAX57655.1 1; 16197O3981gblAAX57645. 11; 1619282O21gblAAX566O1.1 1; 10 1619281451gblAAX5659 1.11; 161928O941gblAAX56581. 11; 161928O481gblAAX56571.1 1; 6192799O~gblAAX5656 1.11; 1619279391gblAAX56551. 11; 161927891 IgblAAX5654 1.11; 619277961gblAAX5652 1.11; 1619277441gblAAX565 1. 11; 161927695 IgblAAX565 1.11; 61927633 IgblAAX5649 1.11; 1619275791gblAAX56481. 11; 161927471 IgblAAX5646 1.11; 619274191gblAAX5645 1.11; 1619273671gblAAX56441. 11; 1619273 19 1gb JAAX5 643 1.11; 15 1619272721gblAAX5642 1.11; 161927225 1gb IAAX5 6411. 11; 161927170O1gb JAAX5 641.11; 619271221gblAAX5639 1.11; 161927073 1gb IAAX563 81. 11; 16162O9941gblAAX47536.1 1; 6162O91O~gblAAX47516.1 1; 1611048891gblAAX38238. 11; 160738750~gblAAX35872.1 1; 607387321gblAAX35862.1 1; 1607387 141gbAAX35852. 11; 1607386961gblAAX35842.1 1; 607386781gblAAX35832.1 1; 160738660~gblAAX35822. 11; 1599405331gbAAX128 12.11; 20 1599405 151gbAAX12802.1 1; 1599404971gblAAX12792. 11; 1599404791gblAAX12782.1 1; 599404591gblAAX12772.1 1; 1599404231gblAAX12752. 11; 1599404051gblAAX12742.1 1; 599403871gblAAX12732.1 1; 1598965541gblAAX1 1636.11; 1598965361gblAAX1 1626.11; 598965 181gblAAX1 1616.11; 159896500~gblAAX1 1606.11; 1598964821gblAAX1 1596.11; 598964641gblAAX1 1586.11; 1598964281gblAAX1 1566.11; 159896410OgblAAX1 1556.11; 25 1598963921gblAAX1 1546.11; 1598963741gblAAX1 1536.11; 1598963561gblAAX1 1526.11; 598963381gblAAX1 1516.11; 1598963201gblAAXI 1506.11; 1598963021gblAAX1 1496.11; 598962841gblAAX1 1486.11; 1598962661gblAAX1 1476.11; 1598962481gblAAX1 1466.11; 598962301gblAAXI 1456.11; 1619709021gblAAX57925.1 1; 1506599541gblAAT8068 1.11; 552332231gblAAV48543.1 1; 13383295 Idbj IBAB39520.1 1; 13383292ldbjlBAB395 18.11; 30 160767251gblAAL14093. 1 IAF222823_1 1; 160767231gblAAL14092.1 IAF222822_1 1; 131829241gbAAK14987.1 JAF231360_21; 131829181gblAAK14983.1 IAF231358_21; 98871871gblAAG01788.1 IAF2514301 1; 19887170~gblAAG01779.1 IAF251422_1; 98871531gblAAG01770.1 IAF2514141 1; 198871361gblAAG01761.1 IAF251406_1; 98871191gblAAG01752.1 IAF2513981 1; 19887105 IgblAAG01745.1 IAF251391_1; 35 184528351gblAAF75113.1I AR115287_11; 184528321gblAAF751 11.1 JAR115286_1; 3243571gblAAA19197. 11; 13243541gblAAA19195. 11; 132435 1 IgblAAA19193.1 1; 142782931pdb~ 1EA31; 142782921pdb~ 1EA31; 1540398541spIP63233 IVMT1_IAUDOI; 502346521gblAAT70535. 11; 154610025 IgblAAV351 10.1; 19422 101 IgbAAL87877.1I AF4556871 1; 19422095 IgblAAL87874.1 IAF455684_1; 40 19422093 IgbAAL87873.1I AF4556831 1; 12264401prfVI1512373AI; 502347721gblAAT706 15. 11; 1502347661gblAAT7061 1.11; 150234763 IgblAAT70609.1 1; 50234760~gblAAT70607. 11; 1502347571gblAAT70605.1 1; 1502347541gblAAT70603.1 1; 5023475 1 IgblAAT70601. .1; 1502347481gblAAT70599.1 1; 150234745 IgblAAT70597.1 1; 502347421gblAAT70595. 11; 1502347391gblAAT70593.1 1; 1502347361gblAAT70591 .11; 45 1502347331gblAAT70589. 11; 1502347241gblAAT70583.1 1; 150234721 IgblAAT7058 1.11; 502347181gblAAT70579. 11; 150234715 IgblAAT70577.1 1; 1502347121gblAAT70575.1 1; 502347091gblAAT70573. 11; 1502347061gblAAT7057 1.11; 50234700~gblAAT70567.1 1; 502346971gblAAT70565. 11; 150234688 IgblAAT70559.1 1; 150234685 IgblAAT70557.1 1; 502346821gblAAT70555. 11; 1502346791gblAAT70553.1 1; 150234673 IgblAAT70549.1 1; 28 3745052_1 (GH Matters) P78534.AU.1 5O23467O~gblAAT7O547. 11; 15O2346671gblAAT7O545.1 1; 15O2346641gblAAT7O543.1 1; 50234661 IgblAAT7O541. .1; 15O2346581gblAAT7O539.1 1; 150234655 IgblAAT7O537.1 1; 5O2346491gblAAT7O533. 11; 15O2346461gblAAT7O53 1.11; 150234643 IgblAAT7O529.1 1; 5O23464O~gblAAT7O527. 11; 15O2346371gblAAT7O525.1 1; 15O2346341gblAAT7O523.1 1; 5 15023463 1 IgblAAT7O521. .1; 15O2346281gblAAT7O5 19.11; 150234625 IgblAAT7O5 17.11; 5O2346221gblAAT7O515. 11; 15O2346191gblAAT7O513.1 1; 15O2346161gblAAT7O51 1.11; 5O2346131gblAAT7O5O9. 11; 15O23461O~gblAAT7O5O7.1 1; 15O2346O71gblAAT7O5O5.1 1; 5O2346O41gblAAT7O5O3. 11; 15O2346O~gblAAT7O5OO.1 1; 1345977671gblAAQ7744O.1 1; 345977641gblAAQ7743 8.11; 134597761 IgblAAQ77436. 11; 1345977581gblAAQ77434.1 1; 10 1345977551gblAAQ77432.1 1; 1213596721gblAAM49561 .1 IAF468843_1 1; 213266891gblAAL75849. 11; 194221071gblAAL87880.1 IAF455690_1 1; 194221051gbAAL87879.1I AF4556891 1; 194221031gblAAL87878.1 IAF455688_1; 194220991gbAAL87876.1I AF4556861 1; 194220971gblAAL87875.1 IAF455685_1; 98639271gblAAG01222.1 IAF2167351 1; 198639091gblAAG01212.1 IAF216727_1; 15 198638901gblAAG01202.1 IAF2167191 1; 185154261gblAAF75995.1 IAF250125_1; 4682991gblAAA62336. 11; 14682941gblAAA62333. 11; 13243371gblAAA43304.1 1; 577471 IgblAAA56808. 11; 15774681gblAAA56806. 11; 14138561gblAAA43250.1 1; 3244081gblAAA43352. 11; 13242901gblAAA43272. 11; 13242871gblAAA43270.1 1; 3242841gblAAA43268. 11; 132428 1 IgblAAA43266. 11; 13242781gblAAA43264.1 1; 20 13242751gblAAA43262.11; 13242721gblAAA43260.11; 13242691gblAAA43258.1. M2 proteins 5853 1181 Idbj IBAD89348.1 1; 158531 163 Idbj IBAD8933 8.11; 158531 145 Idbj IBAD89328. 11; 90493 81 Idbj IBAA99398.1 1; 15764375 Igb IAAD51270.1I AF 153259_21; 25 157643691gblAAD51266.1 IAF 153257_21; 1764433161gbIABA42442.1; 764433131gbIABA42440.1 1; 176443310OgbIABA42438.1 1; 1764433071gbIABA42436.1; 764433041gbIABA42434.1 1; 1216364561gblAAM70004.1 IAF457712_21; 2163645 1 gbAAM70001.1 IAF457710_21; 1216364351gblAAM69992.1 IAF4577032; 216364171gblAAM69982. 1 IAF457695_21; 1216363991gblAAM69972. 1 IAF45768721; 30 1216363791gbAAM69961.1 IAF457678_21; 198022921gblAAF99673.1I AF25852321; 98022891gblAAF99671.1I AF258522_21; 15805290~gbAAD51929.1 IAF144306_2; 57643721gbAAD51268.1 IAF153258_21; 157643661gbAAD51264.1 IAF153256_2; 716553851gblAAZ38741. 11; 171655380~gblAAZ38739. 11; 1716553721gblAAZ38737.1 1; 716553571gblAAZ38735. 11; 1716553461gblAAZ38733. 11; 1716553421gblAAZ3873 1.11; 35 171655321 IgblAAZ38729. 11; 1738529581ref]YP_308670.11; 1739126871ref]YP_308853.11; 5732421 IgbAAD49092.1 IAF1564701 1; 157324181gbAAD49090.1 IAF156469_1; 57324151gbAAD49088.1 IAF1564681 1; 128194355 IgblAAO33518.1 IAF474058_2; 281943521gblAAO33516.1 IAF474057_21; 1281943491gblAAO33514.1 IAF474056_21; 281943461gblAAO33512.1 IAF474055_21; 128194343 IgblAAO335 10.1 IAF474054_21; 40 128194340~gblAAO33508.1 AF47405321; 1281943371gblAAO33506.1 IAF474052_21; 281943341gblAAO33504.1 IAF474051_21; 128194331 IgblAAO33502.1 IAF474050_21; 281943281gblAAO33500.1 IAF474049_21; 157324061gblAAD49082.1 IAF156465_1; 57324241gbAAD49094.1 IAF1564711 1; 157324121gbAAD49086.1 IAF156467_1; 57324091gblAAD49084. 1 IAF1564661 1; 15732403 IgblAAD49080. 1 IAF156464_1 1; 45 15732400~gblAAD49078. 1 IAF1564631 1; 157323971gblAAD49076. 1 IAF156462_1 1; 57323941gbAAD49074.1 IAF1564611 1; 15732391 IgbAAD49072.1 IAF156460_1; 57323881gbAAD49070.1 IAF1564591 1; 15732385 IgbAAD49068.1 IAF156458_1; 3242621gbIAAA43253. 11; 1379330781gblAAO46714. 11; 137933075 IgblAAO46712.1 1; 29 3745052_1 (GH Matters) P78534.AU.1 |37933072|gblAAO46710.1|; |37933069|gblAAO46708. 1; |37933066|gblAAO46706.1 ; |37933063|gblAAO46704.1|; |3793306OgblAAO46702.1|; |37933057|gblAAO46700.1|; |37933054|gblAAO46698.1 ; 137933051 gblAAO46696. 1; |37933048|gblAAO46694.1 ; |37933045|gblAAO46692.1|; |37933042|gblAAO46690.1|; |37933039|gblAAO46688.1|; 5 |37933036|gblAAO46686.1|; |37933033|gblAAO46684.1|; |3793303OgblAAO46682.1|; |37933027|gblAAO46680.1 ; |37933024|gblAAO46678. 1; 137933021 gblAAO46676.1 ; |37933018|gblAAO46674.1 ; |37933015|gblAAO46672. 1; 137933012|gblAAO46670.1 ; |37933009|gblAAO46668.1|; |37933006|gblAAO46666.1|; 137933003|gblAAO46664.1|; |3793300O0gblAAO46662. 1; |37932997|gblAAO46660. 1; |37932994|gblAAO46658. 1; 10 137932991 gblAAO46656.1 ; |37932988|gblAAO46654. 1; |37932985|gblAAO46652.1 ; |37785164|gblAAO46421.1|; 137785161|gblAAO46419.1|; |37785158|gblAAO46417.1|; |37785155|gblAAO46415.1 ; |37785152|gblAAO46413. 1; |37785146|gblAAO46409.1 ; |37785143|gblAAO46407.1 ; |37785140|gblAAO46405. 1; |37785137|gblAAO46403.1 ; |37785134|gblAAO46401.1|; 137785131 gblAAO46399. 1; |37785128|gblAAO46397.1 ; 15 |37785125|gblAAO46395.1 ; |37785122|gblAAO46393. 1; |37785119|gblAAO46391.1|; |37785116|gblAAO46389.1 ; |37785113|gblAAO46387. 1; 1377851 10|gblAAO46385.1 ; |37785107|gblAAO46383.1 ; |37785104|gblAAO46381.1|; 137785101 gblAAO46379.1 ; |37785098|gblAAO46377.1 ; |37785095|gblAAO46375. 1; |37785092|gblAAO46373.1 ; |37785089|gblAAO46371.1|; |37785086|gblAAO46369. 1; 137785083|gblAAO46367.1 ; 20 |37785080|gblAAO46365.1 ; |37785077|gblAAO46363. 1; |37785074|gblAAO46361.1|; 137785071 gblAAO46359.1 ; |37785068|gblAAO46357. 1; |37785065|gblAAO46355.1 ; |37785062|gblAAO46353.1 ; |37785059|gblAAO4635 1.1; |37785056|gblAAO46349.1 ; |37785052|gblAAO46346.1|; |37785050|gblAAO46345.1|; |37785047|gblAAO46343.1|; |13925108|gblAAK49252.1|AF255374_2|; 13274621|gblAAK18004.1|AF255370_2|; 25 13274618|gblAAK18002.1|AF255369_2|; |75125|pir||MMIV2|; |324324|gblAAA43295.11; |324382|gblAAA43335. 1; 1324321 gblAAA43293. 1; |325067|gblAAA43673.1 ; |324394|gblAAA43343. 1; 13243701gblAAA43315.1|; 1324333|gblAAA43301.1|; 1324315|gblAAA43289. 1; |324309|gblAAA43285. 1; |324298|gblAAA43276.1 ; |483856|gblAAC79578.1|; |2833662|gblAAC34266.1|; |73665376|gblAAZ79395.1|; 30 |30025988|gblAAP045 11.1; |37785149|gblAAO4641 1.1|; |47716780|gblAAT37567.1 ; |7429157|pir||PN0087|; |77204|pir||S04051|; 13925128|gblAAK49260. 1; |13925121|gblAAK49257.1 ; 13925114|gblAAK49254.1|; |13925104|gblAAK49250.1|AF2553732|; 13925100|gblAAK49248.1|AF255372_2|; |13925097|gblAAK49246.1|AF255371_2|; 13925093|gblAAK49244.1|AF255368_2|; 35 13925089|gblAAK49242.1|AF255367_2|; 13925085|gblAAK49240.1|AF255366_2|; |13925081|gblAAK49238.1|AF255365_2|; 13925077|gblAAK49236.1|AF255364_2|; |13925073|gblAAK49234.1|AF2553632|; 1 1065887|gblAAG28377.1|; 1 1065884|gblAAG28375.1 ; |3414657|gblAAC31293.1|; 13414645|gblAAC31285.1|; |3414642|gblAAC31283.1|; |3414639|gblAAC31281.1|; 13414633|gblAAC31277.1|; 40 194167|pir||S14617|; |324400|gblAAA43348. 1; 150365715|gblAAT76158.1 ; |18140845|gblAAL60446. 1 AF398876_2|; |20065773 gblAAM09299. 1; |20065770|gblAAM09297.1|; 1324405|gblAAA43350.1|; |324397|gblAAA43346.1|; 1324391 gblAAA43341.1|; |324388|gblAAA43339. 1; |324385|gblAAA43337.1 ; |324379|gblAAA43333. 1; |324376|gblAAA4333 1.1; 1324373|gblAAA43317.1|; 45 1324343|gblAAA43306. 1; 13243301gblAAA43299. 1; |324327|gblAAA43297.1 ; |324318|gblAAA43291 .1; |324312|gblAAA43287. 1; |324306|gblAAA43281.1|; 1324303|gblAAA43279. 1; |27596999|reflNP_775535.1|; |63054906|gblAAY28989. 1; |60474|emblCAA30893. 1; 160471 emblCAA30891.1|; 160468|emblCAA30889. 1; 160465|emblCAA30887. 1; |60462|emblCAA30885. 1; |60459|emblCAA30883. 1; 30 3745052_1 (GHMatters) P78534.AU.1 |45124753|emblCAF33015.1 ; 1348621 pir||C45539|; 1 12614|pir||PNO084|; 194146|pirlJN0393|; |75128|pir||MFIVPR|; |75126|pir||MFIV62|; |7444523|pir||T09280|; |77201|pir||SO4061 ; |77198|pir||SO4057|; |51094109|gblAAS89186.2|; |51859838|gblAAU1 1203.1|; |51859835|gblAAU1 1201.1|; |51859832|gblAAU1 1199.1|; 5 |51859826|gblAAU11195.1|; |51859823|gblAAU11193.1|; |51859820|gblAAU11191.1|; |51859817|gblAAU11189.1|; |51859814|gblAAU11187.1|; 151859811|gblAAU11185.1|; |51859808|gblAAU11183.1|; |51859805|gblAAU11181.1|; |51859802|gblAAU11179.1|; |51859799|gblAAU1 1177.1|; |51859793|gblAAU1 1173.1|; |51859790|gblAAU1 1171.1|; |51859787|gblAAU1 1169.1|; |51859784|gblAAU1 1167.1|; |41207455|gblAAR99626. 1; 10 |29539574|gblAAO88262.1|AF342818_2|; 14587043|gblAAK70448.1|AF386772_2|; |14587040|gblAAK70446.1|AF386771_2|; 14587037|gblAAK70444.1|AF386770_2|; |14587034|gblAAK70442.1|AF386769_2|; 14587031|gblAAK70440.1|AF386768_2|; |14587028|gblAAK70438.1|AF386767_2|; 14587025|gblAAK70436.1|AF386766_2|; |14587022|gblAAK70434.1|AF386765_2|; |27462133|gblAAO15337.1|AF225529_2|; 15 |27462130|gblAAO15335.1 AF225528_2|; |27462127|gblAAO15333.1 AF225527_2|; |27462124|gblAAO15331.1|AF225526_2|; |21693176|gblAAM75162.1|AF389121_2|; |14009744|gblAAK51749.1|; 14009741|gblAAK51747.1|; 14009738|gblAAK51745.1|; |14009735|gblAAK51743.1|; 14009732|gblAAK51741.1|; 14009729|gblAAK51739.1|; |14009726|gblAAK51737.1|; 14009723|gblAAK51735.1|; 14009720|gblAAK51733.1|; 20 14009717|gblAAK51731.1|; 14097641 gblAAD00150. 1; |4097638|gblAAD00148.1 ; |4097635|gblAAD00146. 1; |4097632|gblAAD00144. 1; |4097629|gblAAD00142. 1; |4097626|gblAAD00140. 1; 14097623|gblAAD00138.1 ; |4097620|gblAAD00136.1 ; |4097617|gblAAD00134. 1; |4097614|gblAAD00132.1 ; 14097611 gblAAD00130.1 ; |3929613|gblAAC80168.1 ; |3929610|gblAAC80166. 1; |3929607|gblAAC80164. 1; 25 |3929604|gblAAC80162.1 ; 13929601 gblAAC80160. 1; |3929598|gblAAC80158. 1; |3929595|gblAAC80156.1 ; 13722203|gblAAC63486. 1; |3722200|gblAAC63484. 1; |3722197|gblAAC63482.1 ; |3722194|gblAAC63480. 1; 13414663|gblAAC31297.11; |3414660|gblAAC31295.1|; |3414654|gblAAC31291.1|; 13414651 gblAAC31289.11; |3414648|gblAAC31287.1|; |3414636|gblAAC31279.1|; |3414630|gblAAC31275.11; 30 |3414627|gblAAC31273.1|; |60819|emblCAA41929.1 ; |395148|emblCAA31779.11; |54039852|splP63231 |VMT2_IAUDO|; 138836|splP05780|VMT2_IAWIL|; |235418|gblAAB19772. 1; 138828|splP03492|VMT2_IAFPR|; |138829|splP05778|VMT2_IAFPW|; |554653|gblAAA43274.1|; |324292|gblAAA43273.11; |324289|gblAAA43271.1|; |324286|gblAAA43269. 1; 1324283|gblAAA43267. 1; 35 13242801gblAAA43265. 1; |324277|gblAAA43263. 1; |324274|gblAAA43261.1|; 1324271 gblAAA43259. 1; |324268|gblAAA43257.1|; |54036546|splO70632|VMT2_IAHO3|; |1912411|gblAAB50991.1|; 1912408|gblAAB50989.1|; 1912405|gblAAB50987.1|; |1912402|gblAAB50985.1|; 1912399|gblAAB50983.1|; |407934|gblAAB39916. 1; |406040|gblAAA67336. 1; 1325083|gblAAA43683. 1; |324888|gblAAA43577.1 ; 40 |324363|gblAAA43312.1|; |324265|gblAAA43255. 1; |323977|gblAAA43091.1|; |138833|splP06821|VMT2_IAPUEl; 138825|splP21430|VMT2_IAANNI; |54039853|splP63232|VMT2_IAPOCl; |549380|splP35938|VMT2_IAUSS|; |549379|splP36348|VMT2_IACKBl; 138837|splP05779|VMT2_IAZI1l; |138834|splP10920|VMT2_IASINI; 138832|splP08382|VMT2_IAMANI; 45 138827|splP10921|VMT2_IAFOW|; 138826|splP03491|VMT2_IABAN|; |54039859|splP67867|VMT2_IALE3 ; |54039858|splP67866|VMT2_IALE2|; |138830|splP26129|VMT2_IALE1|; 13182926|gblAAK14988.1|AF231361_1|; |13182920|gblAAK14984.1|AF231359_1|; |8307814|gblAAF74337.1|AF084284_2|; 18307811|gblAAF74335.1|AF0842832|; |8307808|gblAAF74333.1|AF084282_2|; 31 3745052_1 (GHMatters) P78534.AU.1 458494O1gblAAD25212. 1 JAFO732OO_21; 19857O34lembICACO4O82. 11; 9857O37lembICACO4O84. 11; 1542998471gblAAV32647.1 1; 154299833 IgblAAV32639. 11; 52078 1891gblAAU2587O.1 1; 152078 1691gblAAU25859. 11; 15207815 1 IgblAAU25849.1 1; 5658327O1ref]NPO04O979.21; 158531 127ldbjlBAD893 18.11; 15853 1O95ldbj IBAD893O8. 11; 5 15O9566341gblAAT9O835. 11; 138524569ldbj IBADO2364.1 1; 138524551 Idbj IBADO2354.1 1; 4584955 IgblAAD25222. 1 IAFO732O5_21; 145849521gblAAD25220. 1 IAFO732O4_21; 45 849491gblAAD252 18.1 AFO732O321; 145849461gblAAD252 16.1 IAFO732O2_21; 45849431gblAAD25214.1 JAFO732O1_21; 145849371gblAAD2521O.1 JAFO73199_21; 45849341gblAAD252O8. 1 IAF073 198_21; 14584931 IgblAAD252O6. 1 AF073 197 21; 10 145849281gblAAD25204. 1 IAF073 196_21; 14584925 IgblAAD25202. 1 IAF073 195_21; 45849221gbAAD25200.1 IAF073194_21; 145849191gblAAD25198.1 AF07319321; 45849161gbAAD25196.1 IAF073192_21; 14584913 IgbAAD25194.1 JAF073191_2; 4584910~gbAAD25192.1 JAF073190_21; 145849071gbAAD25190.1 JAF073189_2; 45849041gbAAD25188.1 IAF073188_21; 14584901 IgbAAD25186.1 AF0731872; 15 145848981gbAAD25184.1 IAF073186_21; 14584895 IgblAAD25182.1 IAF073185_21; 45848921gbAAD25180.1 IAF073184_21; 145848891gbAAD25178.1 AF0731832; 45848861gbAAD25176.1 IAF073182_21; 14584883 IgbAAD25174.1 IAF073181_2; 45848801gblAAD25 172.1 JAF073 180_21; 1779173391gbIABB05218. 11; 77917320~gbIABB05207. 11; 177917301 IgblABB05 196.11; 177869491 IgbIABB05 185.11; 20 1778634941gbIABB05007. 11; 177863475 IgbIABB04996. 11; 1778634561gbIABB04985.1 1; 778634371gbIABB04974. 11; 177863418 8gbIABB04963. 11; 1778633991gbIABB04952.1 1; 778633801gbIABB04941. 11; 177863361 IgbIABB04930. 11; 1778633421gbIABB04919.1 1; 778633231gbIABB04908. 11; 177861 870~gbIABB04373. 11; 177861851 IgbIABB04362.1 1; 77861 8321gbIABB0435 1.11; 177861813 IgbIABB04340. 11; 1778617941gbIABB04329.1 1; 25 1778617751gbIABB043 18.11; 1778617561gbIABB04307. 11; 1778617371gbIABB04296.1 1; 778617181gbIABB04285. 11; 177747463 IgbIABB03147. 11; 1777474441gbIABB03136.1 1; 777474251gbIABB03 125.11; 177747405 IgbIABB03 114.11; 1777473861gbIABB03 103.11; 777473 67 1gb JABB03 092. 11; 17774734 8 1gb JABB03 08 1.11; 1777473291gbIABB03070.1 1; 777473081gbIABB03059. 11; 1777472891gbIABB03048. 11; 1777472701gbIABB03037.1 1; 30 177747251 gblABB03026. 11; 1777472321gbIABB03015. 11; 177747213 IgbIABB03004.1 1; 777471941gblABB02993. 11; 177747175 IgbIABB02982. 11; 1777471541gbIABB02971.1 1; 777471351gbIABB02960. 11; 1777471161gblABB02949. 11; 1777470971gblABB02938.1 1; 777470761gblABB02926. 11; 1777470571gblABB029 15.11; 1777470381gbIABB02904. 1 ; 777469921gbIABB02893. 11; 177746973 IgbIABB02882. 11; 1777469541gbIABB0287 1.11; 35 177746935 IgbIABB02860. 11; 1777469161gblABB02849. 11; 177746895 IgbIABB02838.1 1; 777468761gbIABB02827. 11; 1777468571gbIABB028 16.11; 1777468381gbIABB02805.1 1; 777468 191gbIABB02794. 11; 177746800~gbIABB02783.1 1; 1775436861gbIABA87255. 11; 775436661gbIABA87244.1 1; 1775436461gbIABA87233.1 1; 1775433641gbIABA87093. 11; 775433451gbIABA87082.1 1; 177543301 IgbIABA87059.1 1; 177543245 IgbIABA87047. 11; 40 1764643521gbIABA43338.1 1; 1764537961gbIABA43202.1 1; 176446823 IgbIABA43 191.11; 764468021gbIABA43180.1 1; 1764464291gbIABA43169.1 1; 1764463871gbIABA42980.1; 764463151gbIABA42941.1 1; 1764462961gbIABA42930.1 1; 1764435301gbIABA42577.1; 76443511 IgbIABA42566.1 1; 1764434921gbIABA42555.1 1; 176443473 IgbIABA42544.1; 764434541gbIABA42533.1 1; 1764434351gbIABA42522.1 1; 176443416 IgbIABA4251 1.1; 45 1764433971gbIABA42500.1 1; 1764433781gbIABA42489.1 1; 1764433591gbIABA42478. 11; 764433401gbIABA42467.1 1; 176443321 IgbIABA42456.1 1; 1764432721gbIABA42445.1; 76443253 IgbIABA42414.1 1; 1764432341gbIABA42403.1 1; 176443215 IgbIABA42392.1; 764431961gbIABA4238 1.11; 1764431771gbIABA42370.1 1; 1764408421gbIABA42359.1; 764266701gbIABA42348.1 1; 176418550~gbIABA42337.1 1; 1764110341gbIABA42326.1; 32 3745052_1 (GH Matters) P78534.AU.1 |76410402|gblABA42315.1|; |76403103|gblABA42304.1|; 176381505|gblABA42293.1|; |76374058|gblABA42282. 1; |76366072|gblABA42271.1|; 176366053 gblABA42260. 1; |76366034|gblABA42249.1 ; |76366015|gblABA42238.1 ; |75750348|gblABA26801 .1; |75750329|gblABA26790.1 ; 1757503 1O|gblABA26779.1 ; 175750291 gblABA26768. 1; 5 |75750272|gblABA26757.1 ; |75750253|gblABA26746.1 ; |75750234|gblABA26735. 1; |75750215|gblABA26724.1 ; |75750196|gblABA26713.1 ; |75750177|gblABA26702. 1; |75180515|gblABA12742.1|; |75172967|gblABA12731.1|; |75171346|gblABA12719.1|; |75171063|gblABA12709.1|; |75168356|gblABA12698.1|; |74477289|gblABA08521.1|; 1744772701gblABA08510.1|; |74477249|gblABA08499.1|; 1744772301gblABA08488.1|; 10 174477211|gblABA08477.1|; |74477192|gblABA08466.1|; |74422756|gblABA06544.1|; |74422587|gblABA06512.1|; |73919153|reflYP_308840.1|; |32141422|reflNP_859035.1|; |73765596|gblAAZ85128.1|; 173763198|gblAAZ83979. 1; 173762505 gblAAZ83690.1 ; |73762294|gblAAZ8365 1.1; 173761788|gblAAZ83384. 1; 173761721 gblAAZ83373.1 ; |73761599|gblAAZ83325. 1; |73761580|gblAAZ83314.1|; 173761561 gblAAZ83301.1|; 15 |73761523|gblAAZ83279. 1; |73761500|gblAAZ83268. 1; |73761477|gblAAZ83255.1 ; |73761458|gblAAZ83244. 1; |73666616|gblAAZ80032. 1; |73666597|gblAAZ80020. 1; |73666578|gblAAZ80009. 1; |73666559|gblAAZ79998. 1; 1736665401gblAAZ79987. 1; |73665975|gblAAZ79976. 1; 173665925 gblAAZ79965. 1; |73665877|gblAAZ79947. 1; |73665869|gblAAZ79943. 1; 173665831 gblAAZ7963 1.1; |73665828|gblAAZ79629. 1; 20 |73665807|gblAAZ79617. 1; |73665788|gblAAZ79606. 1; |73665769|gblAAZ79595.1 ; 1736657501gblAAZ79584. 1; 173665731 gblAAZ79573. 1; |73665712|gblAAZ79562.1 ; |73665693|gblAAZ7955 1.1; |73665674|gblAAZ79540. 1; 173665655 gblAAZ79529. 1; |73665636|gblAAZ79518.1|; 173665613|gblAAZ79507. 1; 167644048|gblAAY78941.1|; |62198979|gblAAX76735. 1; |72602390|gblAAZ74608. 1; 172602371 gblAAZ74597. 1; 25 |72602352|gblAAZ74586. 1; |72602239|gblAAZ74575. 1; |72598157|gblAAZ74564. 1; |72597909|gblAAZ74553.1|; |72582114|gblAAZ74542.1|; 172580905|gblAAZ74531.1|; 172578615|gblAAZ74520.1|; |72572289|gblAAZ74509.1|; 172572211|gblAAZ74498.1|; |72568983|gblAAZ74487. 1; |72565899|gblAAZ74476. 1; |72562518|gblAAZ74465. 1; |72556624|gblAAZ74454. 1; 172554371 gblAAZ74443. 1; |72552877|gblAAZ74432. 1; 30 |72552073|gblAAZ74421.1|; |72549572|gblAAZ74410.1|; |72545852|gblAAZ74399.1|; |72545118|gblAAZ74388. 1; |72542982|gblAAZ74376. 1; 172539893 gblAAZ74365. 1; |72539854|gblAAZ74354. 1; |71000194|dbjlBAE07158. 1; |71842590|gblAAZ43407.1 ; 171842571|gblAAZ43396.1|; |71842552|gblAAZ43385.1|; |71842529|gblAAZ43372.1|; |71571148|gblAAZ38652.1|; |71568546|gblAAZ38640.1|; 171564883|gblAAZ38629.1|; 35 |71564864|gblAAZ38618.1|; 171564845|gblAAZ38607.1|; |71564826|gblAAZ38596.1|; |71564807|gblAAZ38585.1|; |71564788|gblAAZ38574.1|; |71564769|gblAAZ38563.1|; |71564750|gblAAZ38552.1|; 171564731|gblAAZ38541.1|; |71564712|gblAAZ38530.1|; |71564693|gblAAZ38519.1|; |71564674|gblAAZ38508.1|; 171564655|gblAAZ38497.1|; |71564636|gblAAZ38486.1|; 171564617|gblAAZ38475.1|; 171564598|gblAAZ38464.1|; 40 170907643|gblAAX56532.2|; 162198871 gblAAX76675. 1; 168525443|gblAAY98772.1 ; |68510080|gblAAY98408.1 ; 168510061 gblAAY98398. 1; |68510042|gblAAY98388.1 ; 1685 10011 gblAAY98378.1 ; |68509990|gblAAY98368. 1; |68509958|gblAAY98358.1 ; |68509896|gblAAY98341.1|; |68509733|gblAAY9833 1.1; |68509377|gblAAY98321.1|; |68509335|gblAAY98249.1 ; |68509315|gblAAY98239. 1; |68509296|gblAAY98229.1 ; 45 |68509276|gblAAY98219.1|; |68509252|gblAAY98209. 1; |68509227|gblAAY98198.1|; |68509210|gblAAY98189.1 ; |68509189|gblAAY98179. 1; 168509171 gblAAY98169.1 ; |68509153|gblAAY98159.1 ; |68509135|gblAAY98149. 1; |68509116|gblAAY98139.1 ; |68509098|gblAAY98129.1|; |68509080|gblAAY98119.1|; |68509062|gblAAY98109.1|; |68509044|gblAAY98099. 1; |68509012|gblAAY98089. 1; 16850893 1 gblAAY98079. 1; 33 3745052_1 (GHMatters) P78534.AU.1 685O88941gblAAY98O69.1 1; 1685088 171gblAAY98O59. 11; 168508601 IgblAAY98O49.1 1; 685085 161gblAAY98O39.1 1; 162199O331gblAAX76765. 11; 1621988 171gblAAX76645.1 1; 61970921 IgblAAX57936.1 1; 16197O7231gblAAX57826. 11; 1619275 27 1gb JAAX5 6472.11; 598964471gblAAX1 1577.11; 167O625841gblAAY644O4. 11; 167O62O431gblAAY64394.1 1; 5 167O618871gblAAY64384.1 1; 167061091 IgblAAY64374. 11; 167O6O4O91gblAAY64364.1 1; 67060 1681gblAAY64354.1 1; 167O595361gblAAY64344. 11; 167O589681gblAAY64334.1 1; 67O589O51gblAAY64324.1 1; 167O5835O~gblAAY643 14.11; 167O583321gblAAY643O4.1 1; 670583 141gblAAY64294.1 1; 1670582961gblAAY64284. 11; 1670582781gblAAY64274.1 1; 670576991gblAAY64264.1 1; 1670513371gblAAY64254. 11; 167049850~gblAAY64244.1 1; 10 1670458891gblAAY64234.1 1; 1670454681gblAAY64224. 11; 1670445111 gb JAAY64214.1 1; 670443351gblAAY64204.1 1; 1670442591gblAAY64194. 11; 1670441591gblAAX57866.21; 669474171gblAAY59037.1 1; 166475121 IgblAAY47087. 11; 166475 103 IgblAAY47077.1 1; 664750591gblAAY47054.1 1; 166474991 IgblAAY47025. 11; 1664735981gblAAY46438.1 1; 664735801gblAAY46428.1 1; 1664735621gblAAY464 18. 11; 1664734921gblAAY46393.1 1; 15 1664734701gblAAY46383.1 1; 1664734501gblAAY46373. 11; 1663560181gblAAY45648.1 1; 663545271gblAAY44908.1 1; 1663545091gblAAY44898. 11; 166354011 IgblAAY44798.1 1; 66353991 IgblAAY44787.1 1; 166353973 IgblAAY44777. 11; 166353873 IgblAAY44767.1 1; 66353855 IgblAAY44757.1 1; 1663466321gblAAY44663. 11; 1663460021gblAAY44653.1 1; 663274201gblAAY44643.1 1; 1663 190021gblAAY44633. 11; 1663 15205 IgblAAY44623.1 1; 20 166303355 IgblAAY44612.1 1; 133354261gblAAC32091. 11; 13335408 IgblAAC3208 1.11; 630536661gblAAY28640.1 1; 1630299881gblAAY27865. 11; 1630536841gblAAY28650.1 1; 630536481gblAAY28630.1 1; 163053630~gblAAY28620. 11; 1630536 121gblAAY286 10.11; 630535291gblAAY28593.1 1; 1630534971gblAAY28583. 11; 1630534791gblAAY28573.1 1; 63053460~gblAAY28563.1 1; 1630476451gblAAY28553. 11; 1630383481gblAAY28543.1 1; 25 1630344581gblAAY28533.1 1; 163034440~gblAAY28523. 11; 163034225 IgblAAY28504.1 1; 630341961gblAAY28407.1 1; 1630341781gblAAY28397. 11; 1630341591gblAAY28387.1 1; 63034141 IgblAAY28377.1 1; 163034121 IgblAAY28366. 11; 163034105 IgblAAY28357.1 1; 630340871gblAAY28347.1 1; 1630340691gblAAY28337. 11; 16303405 1 IgblAAY28327.1 1; 630340331gblAAY283 17.11; 1630340151gblAAY28307. 11; 1630339741gblAAY28297.1 1; 30 1630339561gblAAY28287.1 1; 1630339381gblAAY28277. 11; 1630339181gblAAY28267.1 1; 630334151gblAAY28016.1 1; 1630333971gblAAY28006. 11; 1630333781gblAAY27996.1 1; 63031461 IgblAAY2796 1.11; 63029970~gblAAY27855. 11; 163029950~gblAAY27845.1 1; 628712861gblAAY1 8587.11; 1628712631gblAAY1 8566. 11; 1628700841gblAAY1 8198.11; 628700661gblAAY1 8188.11; 1628700481gblAAY1 8178. 11; 162870030~gblAAY1 8168.11; 35 1628700121gblAAY1 8158.11; 1628699941gblAAY1 8148. 11; 1628699761gblAAY1 8138.11; 628699581gblAAY1 8128.11; 1628699401gblAAYI18118. 11; 1628699221gblAAY1 8108.11; 628699041gblAAY1 8098.11; 1628698851gblAAY1 8088. 11; 1621989251gblAAX76705.1 1; 621987991gblAAX76635.1 1; 162198781 IgblAAX76625. 11; 1616209441gblAAX47527.1 1; 621990151gblAAX76755.1 1; 1606838061gblAAX34063. 11; 159940442 1gb IAAX 12763.11; 40 1438084lembICAA8 1472.1 1; 1438081 lembICAA8 1470.11; 1438078lembICAA8 1468. 11; 438075lembICAA81466.1 1; 1438071 lembICAA81463.1 1; 122859489lembICAD30543. 11; 22859487lembICAD30541 .11; 122859484lembICAD30539. 11; 122859481 lembICAD30537.1 1; 22859478lembICAD30535.1 1; 120068130lembICAC8741 1.11; 120068121 lembICAC87405. 11; 20068109lembICAC87397. 11; 120068106lembICAC87395.1 1; 120068 100lembICAC87391 .11; 45 120068094lembICAC87387. 11; 14275728lembICAC40056.1 1; 14275701 lembICAC40042.1 1; 12038901 lembICAC 19701. 11; 1985703 1 embICAC04080. 11; 1621989971gblAAX76745.1; 62198961 IgblAAX76725.1 1; 162198943 IgblAAX76715. 11; 1621989071gblAAX76695.1 1; 621988891gblAAX76685.1 1; 1621988531gblAAX76665. 11; 1621988351gblAAX76655.1 1; 619709391gblAAX57946.1 1; 1619708851gblAAX57916. 11; 1619708671gblAAX57906.1 1; 34 3745052_1 (GH Matters) P78534.AU.1 |61970849|gblAAX57896.1 ; 161970831 gblAAX57886. 1; 161970813|gblAAX57876.1 ; |61970777|gblAAX57856.1 ; |61970759|gblAAX57846. 1; 161970741 gblAAX57836.1 ; |61970705|gblAAX57816.1 ; |61970687|gblAAX57806. 1; |61970669|gblAAX57796.1 ; 161970651 gblAAX57786.1 ; 161970633|gblAAX57776. 1; 161970615|gblAAX57766.1 ; 5 |61970597|gblAAX57756.1 ; |61970579|gblAAX57746. 1; 161970561 gblAAX57736.1|; 161970541 gblAAX57725.1 ; 161970525|gblAAX57716. 1; 161970507|gblAAX57706.1|; |61970489|gblAAX57696.1 ; 161970471 gblAAX57686. 1; 161970453|gblAAX57676.1 ; 161970435|gblAAX57666.1 ; |61970417|gblAAX57656. 1; 161970399|gblAAX57646.1|; 161928203|gblAAX56602.1|; |61928146|gblAAX56592. 1; 161928095|gblAAX56582.1 ; 10 |61928049|gblAAX56572.1 ; 161927991 gblAAX56562. 1; |61927940|gblAAX56552.1 ; |61927892|gblAAX56542.1 ; |61927797|gblAAX56522. 1; 161927745|gblAAX56512.1|; |61927696|gblAAX56502.1 ; |61927634|gblAAX56492. 1; 161927580|gblAAX56482.1 ; |61927472|gblAAX56462.1|; |61927420|gblAAX56452.1|; |61927368|gblAAX56442.1|; |61927320|gblAAX56432.1|; |61927273|gblAAX56422.1|; 161927226|gblAAX56412.1|; 15 161927171|gblAAX56402.1|; 161927123|gblAAX56392.1|; |61927074|gblAAX56382.1|; |61620995|gblAAX47537.1|; 161620911|gblAAX47517.1|; |61104890|gblAAX38239.1|; 160738751 gblAAX35873.1 ; |60738733|gblAAX35863. 1; |60738715|gblAAX35853.1 ; |60738697|gblAAX35843.1 ; |60738679|gblAAX35833. 1; 160738661 gblAAX35823.1 ; |59940534|gblAAX12813.1 ; |59940516|gblAAX12803. 1; |59940498|gblAAX12793.1 ; 20 |59940480|gblAAX12783.1 ; |59940460|gblAAX12773. 1; 159940424|gblAAX12753.1|; |59940406|gblAAX12743.1 ; |59940388|gblAAX12733. 1; |59896555|gblAAX1 1637.1|; |59896537|gblAAX1 1627.1|; |59896519|gblAAX1 1617.1|; 159896501 gblAAX1 1607.1|; |59896483|gblAAX1 1597.1|; |59896465|gblAAX1 1587.1|; |59896429|gblAAX1 1567.1|; 159896411 gblAAX1 1557.1|; |59896393|gblAAX1 1547.1|; |59896375|gblAAX1 1537.1|; 25 |59896357|gblAAX1 1527.1|; |59896339|gblAAX1 1517.1|; 159896321 gblAAX1 1507.1|; |59896303|gblAAX1 1497.1|; |59896285|gblAAX1 1487.1|; |59896267|gblAAX1 1477.1|; |59896249|gblAAX1 1467.1|; 159896231 gblAAX1 1457.1|; |61970903|gblAAX57926.1 ; |55233224|gblAAV48544.1 ; 13383294|dbjlBAB39519.1|; 13383291 dbjlBAB39517.1|; |13182923|gblAAK14986.1|AF231360_1|; 13182917|gblAAK14982.1|AF231358_1|; 30 |8452836|gblAAF75114.1|AF115287_2|; 18452833|gblAAF75112.1|AF115286_2|; |414306|gblAAA91324. 1; 1414303|gblAAA91322. 1; |577472|gblAAA56809.1 ; |577469|gblAAA56807. 1; |577466|gblAAA56805. 1; |324356|gblAAA19196.1|; 1324353|gblAAA19194. 1; 13243501gblAAA19192. 1; 155139145|gblAAV41246.1 ; 155139143|gblAAV41245.1|; 150234651|gblAAT70534.1|; |54610026|gblAAV35111.1|; 35 14579589|gblAAK69310.1|AF385297_1|; 14579585|gblAAK69309.1|AF385295_1|; |21632613|gblAAL32486.1|; |226441|prf|1512373Bl; |57916088|gblAAW59411.1|; |57916040|gblAAW59401.1|; |57916001|gblAAW59394.1|; |50234771|gblAAT70614.1|; |50234765|gblAAT70610. 1; |50234762|gblAAT70608. 1; |50234759|gblAAT70606. 1; |50234756|gblAAT70604. 1; 150234753 gblAAT70602. 1; |50234750|gblAAT70600. 1; 40 |50234747|gblAAT70598. 1; |50234744|gblAAT70596. 1; 150234741 gblAAT70594. 1; |50234738|gblAAT70592. 1; 150234735 gblAAT70590. 1; |50234732|gblAAT70588. 1; |50234723|gblAAT70582. 1; |50234720|gblAAT70580. 1; |50234717|gblAAT70578. 1; |50234714|gblAAT70576. 1; 150234711 gblAAT70574.1 ; |50234708|gblAAT70572.1 ; |50234705|gblAAT70570. 1; |50234702|gblAAT70568. 1; |50234699|gblAAT70566. 1; 45 |50234696|gblAAT70564. 1; |50234687|gblAAT70558. 1; |50234684|gblAAT70556. 1; 150234681 gblAAT70554. 1; 150234678|gblAAT70552. 1; |50234672|gblAAT70548. 1; |50234669|gblAAT70546. 1; |50234666|gblAAT70544. 1; 150234663 gblAAT70542. 1; |50234660|gblAAT70540. 1; |50234657|gblAAT70538. 1; |50234654|gblAAT70536. 1; |50234648|gblAAT70532. 1; 150234645 gblAAT70530. 1; |50234642|gblAAT70528. 1; 35 3745052_1 (GHMatters) P78534.AU.1 |50234639|gblAAT70526. 1; |50234636|gblAAT70524. 1; 150234633 gblAAT70522. 1; |5023463OgblAAT70520. 1; |50234627|gblAAT70518.1|; |50234624|gblAAT70516.1|; 150234621 gblAAT70514.1|; 150234618|gblAAT70512.1|; 150234615|gblAAT705 10.1|; |50234612|gblAAT70508. 1; |50234609|gblAAT70506. 1; |50234606|gblAAT70504. 1; 5 |50234603|gblAAT70502. 1; 150234601 gblAAT70501.1|; 134597771 gblAAQ77443.1 ; |34597768|gblAAQ77441.1|; |34597765|gblAAQ77439. 1; |34597759|gblAAQ77435.1 ; |34597756|gblAAQ77433. 1; |21359673 gblAAM49562.1 |AF468843_2|; |2132669OgblAAL75850. 1; |15193277|gblAAK91757.1 ; 19994775|emblCAC07367.1 ; 19863928|gblAAG01223.1 AF216735_2|; 19863910|gblAAG01213.1 AF2167272|; 10 19863891|gblAAG01203.1|AF216719_2|; |7861793|gblAAF70407.1|AF203788_2|; |468300|gblAAA62337. 1; 1468295|gblAAA62334. 1; |324336|gblAAA43303.1 ; |413855|gblAAA43249. 11. NP proteins 15 |60476|emblCAA32437. 1; |30466237|reflNP_848686. 1; 130349245 gblAAP22118.1|; |30466222|reflNP_848678.1|; |30349230|gblAAP221 10.1|; 14760951|gblAAD29162.1|AF100364_1|; |4760969|gblAAD29171.1|AF100373_1|; |4760967|gblAAD29170.1|AF100372_1|; |4760965|gblAAD29169.1|AF100371_1|; |4760963|gblAAD29168.1|AF100370_1|; 14760961|gblAAD29167.1|AF100369_1|; 20 |4760959|gblAAD29166.1 |AF100368_1 ; |4760957|gblAAD29165.1 AF100367_1 ; |4760955|gblAAD29164.1 |AF100366_1 ; |4760953|gblAAD29163.1 AF100365_1 ; |4760949|gblAAD29161.1|AF100363_1|; |4760947|gblAAD29160.1|AF100362_1|; |4760945|gblAAD29159.1|AF100361_1|; |4760943|gblAAD29158.1|AF100360_1|; |4760941|gblAAD29157.1|AF100359_1|; |4760939|gblAAD29156.1|AF100358_1|; 25 |4760937|gblAAD29155.1|AF100357_1|; 19622313|gblAAF89732.1|AF170569_1|; |53829851 gblAAU94830.1 ; |53829849|gblAAU94829. 1; |53829847|gblAAU94828.1 ; |53829845|gblAAU94827.1 ; |53829843|gblAAU94826. 1; 153829841 gblAAU94825.1 ; |53829839|gblAAU94824.1 ; |53829837|gblAAU94823. 1; |53829835|gblAAU94822.1 ; |53829833|gblAAU94821.1|; 153829831 gblAAU94820. 1; |53829829|gblAAU94819.1|; 30 |53829827|gblAAU94818.1|; |20126592|gblAAK95899.1|; 12862815|dbjlBAB32618.1|; |12862813|dbjlBAB32617.1|; 12862811|dbjlBAB32616.1|; |51340783|gblAAU01000.1|; |50059414|gblAAT69437. 1; 150059395 gblAAT69426.1 ; 150059433|gblAAT69448.1 ; 139119|splP04665 VNUCINBLEl; |6647904|splO36433 VNUC_INBP9|; 139120|splP04666VNUCINBSII; 139118|sp lP13885|IVNUCINBADI; 35 139117|splP13884|VNUCINBACl; 139116|splP11 102|VNUCINBAAl; |325245|gblAAA43750. 1; |75750295|gblABA26770. 1; 175750276|gblABA26759. 1; |75750257|gblABA26748.1 ; 175750238|gblABA26737.1|; |75750219|gblABA26726. 1; |75750200|gblABA26715.1 ; 175750181 gblABA26704. 1; 172623471 gblAAZ74621.1|; |75218754|gblABA18171.1|; |75217117|gblABA18160.1|; |75216184|gblABA8149.1|; 40 |75215962|gblABA18138.1|; |75215227|gblABA18127.1|; |75214330|gblABA18116.1|; |75213014|gblABA18041.1|; |75206503|gblABA18030.1|; |75200474|gblABA16396. 1; |75181199|gblABA12788.1 ; 175181110|gblABA12777.1|; |75180930|gblABA12766. 1; |75180833|gblABA12755.1 ; |75180535|gblABA12744.1 ; |75172977|gblABA12733. 1; |75171378|gblABA12722.1|; |75171140|gblABA12711.1|; |75168380|gblABA12700.1|; 45 |74477293|gblABA08523.1|; |74477274|gblABA08512.1|; 174477253|gblABA08501.1|; |74477234|gblABA08490.1|; |74477215|gblABA08479.1|; |74477196|gblABA08468.1|; 1744227601gblABA06546.1|; |74422592|gblABA06514.1|; |73919147|reflYP_308843.1|; |73765600|gblAAZ85130.1|; |73763202|gblAAZ83981.1|; |73762509|gblAAZ83692.1 ; 36 3745052_1 (GHMatters) P78534.AU.1 |73762316|gblAAZ83653. 1; |73761792|gblAAZ83386. 1; |73761727|gblAAZ83375.1 ; |73761603|gblAAZ83327. 1; |73761584|gblAAZ83316.1|; 173761565|gblAAZ83303.1 ; |73761546|gblAAZ83292. 1; |73761527|gblAAZ83281.1|; |73761504|gblAAZ83270.1 ; |73761481 gblAAZ83257. 1; |73761462|gblAAZ83246. 1; 1736666201gblAAZ80034. 1; 5 |73666601 gblAAZ80022. 1; |73666582|gblAAZ8001 1.1; 173666563 gblAAZ80000.1|; |73666544|gblAAZ79989. 1; |73665979|gblAAZ79978. 1; |73665929|gblAAZ79967. 1; |73665886|gblAAZ79952. 1; |73665879|gblAAZ79948. 1; |73665839|gblAAZ79635. 1; |73665837|gblAAZ79634. 1; 173665811 gblAAZ79619. 1; |73665792|gblAAZ79608.1 ; |73665773|gblAAZ79597. 1; |73665754|gblAAZ79586. 1; 173665735|gblAAZ79575.1 ; 10 |73665716|gblAAZ79564. 1; |73665697|gblAAZ79553. 1; |73665678|gblAAZ79542.1 ; |73665659|gblAAZ7953 1.1; 1736656401gblAAZ79520. 1; |73665617|gblAAZ79509.1 ; |73665569|gblAAX76737.2|; |67644052|gblAAY78943. 1; |61612074|gblAAX47285.1 ; 161612071|gblAAX47284.1|; |72602394|gblAAZ74610.1|; 172602375|gblAAZ74599.1|; |72602356|gblAAZ74588. 1; |72602280|gblAAZ74577. 1; |72598222|gblAAZ74566. 1; 15 |72597929|gblAAZ74555.1|; |72582136|gblAAZ74544.1|; |72580950|gblAAZ74533.1|; |72578666|gblAAZ74522.1|; |72572309|gblAAZ74511.1|; 172572215|gblAAZ74500.1|; |72569024|gblAAZ74489. 1; |72565916|gblAAZ74478. 1; 172562585 gblAAZ74467. 1; |72556658|gblAAZ74456. 1; |72554392|gblAAZ74445. 1; 1725528901gblAAZ74434. 1; |72552088|gblAAZ74423.1|; |72549649|gblAAZ74412.1|; |72545874|gblAAZ74401.1|; 20 |72545212|gblAAZ74390. 1; |72543007|gblAAZ74378. 1; |72539897|gblAAZ74367. 1; |72539859|gblAAZ74356. 1; |71000188|dbjlBAE07156. 1; |71842594|gblAAZ43409.1 ; |71842575|gblAAZ43398. 1; |71842556|gblAAZ43387. 1; 171842533|gblAAZ43374.1 ; |71571156|gblAAZ38654.1|; |71568550|gblAAZ38642.1|; |71564887|gblAAZ38631.1|; |71564868|gblAAZ38620.1|; |71564849|gblAAZ38609.1|; |71564830|gblAAZ38598.1|; 25 171564811|gblAAZ38587.1|; |71564792|gblAAZ38576.1|; 171564773|gblAAZ38565.1|; |71564754|gblAAZ38554.1|; 171564735|gblAAZ38543.1|; |71564716|gblAAZ38532.1|; |71564697|gblAAZ38521.1|; |71564678|gblAAZ38510.1|; |71564659|gblAAZ38499.1|; |71564640|gblAAZ38488.1|; 171564621|gblAAZ38477.1|; |71564602|gblAAZ38466.1|; |70955500|gblAAZ16302. 1; |70955498|gblAAZ16301 .1; |70955496|gblAAZ16300.1 ; 30 |70955494|gblAAZ16299. 1; |70955492|gblAAZ16298. 1; |70955490|gblAAZ16297.1 ; |70955488|gblAAZ16296. 1; |70955486|gblAAZ16295. 1; 170955483|gblAAZ16294.1 ; |70955481 gblAAZ16293. 1; |70955479|gblAAZ16292. 1; |70907647|gblAAX56534.2|; |62198875|gblAAX76677.1 ; |68525447|gblAAY98774. 1; |68510084|gblAAY98410.1|; |68510066|gblAAY98400.1 ; |68510046|gblAAY98390. 1; 168510015|gblAAY98380.1 ; 35 |68509994|gblAAY98370. 1; |68509965|gblAAY98360. 1; |68509900|gblAAY98343. 1; |68509874|gblAAY98333.1 ; 168509381 gblAAY98323. 1; |68509342|gblAAY9825 1.1|; |68509319|gblAAY98241.1|; |68509300|gblAAY9823 1.1; |68509280|gblAAY98221.1|; |68509256|gblAAY9821 1.1|; |68509233|gblAAY98201 .1; |68509214|gblAAY98191.1|; |68509193|gblAAY98181.1|; |68509175|gblAAY98171.1|; |68509157|gblAAY98161.1|; 40 |68509139|gblAAY98151.1|; |68509120|gblAAY98141.1|; |68509102|gblAAY98131.1|; |68509084|gblAAY98121.1|; |68509066|gblAAY981 11.1|; |68509048|gblAAY98 101.1|; |68509018|gblAAY98091.1|; |68508938|gblAAY98081.1|; 168508901 gblAAY98071.1|; |68508822|gblAAY98061.1|; |68508607|gblAAY9805 1.1; 168508523|gblAAY98041.1|; 162198821 gblAAX76647.1 ; 161970925|gblAAX57938. 1; |61970727|gblAAX57828.1 ; 45 159896451 gblAAX1 1579.1|; |67527208|gblAAY68365. 1; |8894685|emblCAB95838. 1; |8894683|emblCAB95837. 1; 167062593 gblAAY64406. 1; 167062065 gblAAY64396. 1; |67061897|gblAAY64386.1 ; |67061102|gblAAY64376. 1; 167060418|gblAAY64366.1|; |67060182|gblAAY64356.1 ; |67059548|gblAAY64346. 1; |67058984|gblAAY64336.1 ; |67058924|gblAAY64326.1 ; |67058354|gblAAY64316.1|; |67058336|gblAAY64306.1 ; 37 3745052_1 (GHMatters) P78534.AU.1 |67058318|gblAAY64296.1 ; |6705830OgblAAY64286. 1; 167058282|gblAAY64276.1 ; 167057743|gblAAY64266.1|; |67051372|gblAAY64256. 1; 167050025|gblAAY64246. 1; 167045893|gblAAY64236.1|; |67045474|gblAAY64226.1|; 167044521|gblAAY64216.1|; |6704435OgblAAY64206.1 ; |67044263|gblAAY64196. 1; |67044163|gblAAX57868.2|; 5 166947421 gblAAY59039.1 ; 19187997|emblCAB95839.2|; |5463508OgblAAV36516.1|; |54635078|gblAAV36515.1|; |54635076|gblAAV36514.1|; |54635074|gblAAV36513.1|; |66475125|gblAAY47089.1 ; |66475107|gblAAY47079. 1; 166475063|gblAAY47056.1 ; 166474995 gblAAY47027. 1|; |66474977|gblAAY47017.1|; |66473602|gblAAY46440. 1|; |66473584|gblAAY46430. 1; |66473566|gblAAY46420. 1; |66473496|gblAAY46395. 1; 10 |66473474|gblAAY46385.1 ; |66473454|gblAAY46375. 1; 166356022|gblAAY45650.1|; 166354531 gblAAY44910.1|; 166354513|gblAAY44900. 1; 166354413|gblAAY44890.1 ; 166354015|gblAAY44800.1 ; 166353995|gblAAY44789. 1; |66353977|gblAAY44779.1 ; |66353877|gblAAY44769.1 ; |66353859|gblAAY44759. 1; |66346636|gblAAY44665.1 ; |66346024|gblAAY44655. 1; |66327442|gblAAY44645. 1; |66319022|gblAAY44635. 1; 15 |66315226|gblAAY44625.1 ; |66303368|gblAAY44614. 1; |63054909|gblAAY28991.1|; |63053670|gblAAY28642.1|; |63029992|gblAAY27867.1|; |63053688|gblAAY28652.1|; |63053652|gblAAY28632.1 ; |63053634|gblAAY28622. 1; |63053616|gblAAY28612.1|; |63053533|gblAAY28595.1 ; 163053501 gblAAY28585. 1; |63053483|gblAAY28575.1 ; |63053464|gblAAY28565.1 ; |63047668|gblAAY28555. 1; 163038371 gblAAY28545.1 ; 20 |63034462|gblAAY28535. 1; |63034444|gblAAY28525. 1; |63034229|gblAAY28506. 1; |63034200|gblAAY28409.1 ; |63034182|gblAAY28399. 1; 163034163|gblAAY28389.1 ; 163034145|gblAAY28379.1 ; |63034127|gblAAY28369. 1; |63034109|gblAAY28359.1 ; 163034091 gblAAY28349.1 ; 163034073|gblAAY28339. 1; 163034055|gblAAY28329.1 ; |63034037|gblAAY28319.1|; |63034019|gblAAY28309. 1; |63033978|gblAAY28299.1 ; 25 |63033960|gblAAY28289.1|; |63033942|gblAAY28279.1|; |63033922|gblAAY28269.1|; |63033419|gblAAY28018.1|; 163033401 gblAAY28008. 1; 163033382|gblAAY27998.1 ; |63033337|gblAAY27963.1|; |63029974|gblAAY27857.1|; |63029954|gblAAY27847.1|; |62871486|gblAAY18615.1|; |62871292|gblAAY18589. 1; |62871267|gblAAY18571.1|; |62870088|gblAAY18200.1|; |62870070|gblAAY18190. 1; |62870052|gblAAY18180.1|; 30 |62870034|gblAAY18170.1|; |62870016|gblAAY18160. 1; |62869998|gblAAY18150.1|; 1628699801gblAAY18140.1|; |62869962|gblAAYl8130. 1; |62869944|gblAAY18120.1|; |62869926|gblAAYl8110.1|; |62869908|gblAAYl8 100. 1; |62869889|gblAAY18090.1|; |62198929|gblAAX76707.1 ; |62198785|gblAAX76627. 1; 161620951 gblAAX47529.1 ; 160683810|gblAAX34065.1 ; |59940446|gblAAX12765. 1; |56311406|emblCAI29280. 1; 35 |56291614|emblCAE48277. 1; |62199037|gblAAX76767.1 ; |62199019|gblAAX76757. 1; 162199001|gblAAX76747.1|; 162198965|gblAAX76727.1|; |62198947|gblAAX76717.1|; 162198911 gblAAX76697.1 ; 162198893|gblAAX76687. 1; |62198857|gblAAX76667.1 ; |62198839|gblAAX76657.1 ; |62198803|gblAAX76637. 1; |61970943|gblAAX57948.1 ; |61970889|gblAAX57918.1|; 161970871 gblAAX57908. 1; 161970853|gblAAX57898.1 ; 40 161970835|gblAAX57888.1 ; |61970817|gblAAX57878. 1; 161970781 gblAAX57858.1 ; |61970763|gblAAX57848.1 ; |61970745|gblAAX57838. 1; |61970709|gblAAX57818.1 ; 161970691 gblAAX57808.1 ; 161970673|gblAAX57798. 1; 161970655|gblAAX57788.1 ; |61970637|gblAAX57778.1 ; |61970619|gblAAX57768. 1; 161970601 gblAAX57758.1 ; |61970583|gblAAX57748.1 ; |61970565|gblAAX57738. 1; |61970545|gblAAX57727.1 ; 45 |61970529|gblAAX57718.1|; 161970511 gblAAX57708. 1; 161970493|gblAAX57698.1 ; 161970475|gblAAX57688.1 ; |61970457|gblAAX57678. 1; |61970439|gblAAX57668.1 ; 161970421|gblAAX57658.1|; |61970412|gblAAX57653.1|; |61928216|gblAAX56604.1|; |61928159|gblAAX56594.1 ; |61928104|gblAAX56584. 1; |61928059|gblAAX56574.1 ; |61928002|gblAAX56564.1 ; 161927951 gblAAX56554. 1; 161927903|gblAAX56544.1 ; 38 3745052_1 (GHMatters) P78534.AU.1 |61927806|gblAAX56524.1 ; |61927757|gblAAX56514.1|; |61927708|gblAAX56504.1 ; |61927649|gblAAX56494.1|; |61927595|gblAAX56484.1|; 161927538|gblAAX56474.1|; |61927484|gblAAX56464.1 ; |61927432|gblAAX56454. 1; 1619273801gblAAX56444.1 ; 161927331|gblAAX56434.1|; 161927285|gblAAX56424.1|; |61927238|gblAAX56414.1|; 5 |61927182|gblAAX56404.1|; |61927135|gblAAX56394.1|; |61927085|gblAAX56384.1|; |61621003|gblAAX47539.1|; |61620918|gblAAX47519.1|; |61104894|gblAAX38241.1|; |60738755|gblAAX35875.1 ; |60738737|gblAAX35865. 1; |60738719|gblAAX35855.1 ; 160738701 gblAAX35845.1 ; |60738683|gblAAX35835. 1; |60738665|gblAAX35825.1 ; |59940538|gblAAX12815.1 ; |5994052OgblAAX12805. 1; 159940502|gblAAX12795.1|; 10 |59940484|gblAAX12785.1 ; |59940464|gblAAX12775. 1; |59940428|gblAAX12755.1 ; |5994041OgblAAX12745.1 ; |59940392|gblAAX12735. 1; |59896559|gblAAX1 1639.1|; 159896541 gblAAX1 1629.1|; |59896523|gblAAX1 1619.1|; |59896505|gblAAX1 1609.1|; |59896487|gblAAX1 1599.1|; |59896469|gblAAX1 1589.1|; |59896433|gblAAX1 1569.1|; |59896415|gblAAX1 1559.1|; |59896397|gblAAX1 1549.1|; |59896379|gblAAX1 1539.1|; 15 159896361 gblAAX1 1529.1|; |59896343|gblAAX1 1519.1|; |59896325|gblAAX1 1509.1|; |59896307|gblAAX1 1499.1|; |59896289|gblAAX1 1489.1|; 159896271 gblAAX1 1479.1|; |59896253|gblAAX1 1469.1|; |59896235|gblAAX1 1459.1|; |61970907|gblAAX57928.1 ; |56548910|gblAAV97620.1 ; |56548908|gblAAV97619. 1; |56548906|gblAAV97618.1 ; |56548904|gblAAV97617.1|; |56425053|gblAAV91225.1|; 156425051|gblAAV91224.1|; 20 |56425049|gblAAV91223.1|; |56425047|gblAAV91222.1|; 158429781|gblAAW78295.1|; |16076707|gblAAL14084.1|AF222814_1|; 13785215|emblCAC37326.1|; |12038908|emblCAC19705.1|; |12038906|emblCAC19704.1|; |12038892|emblCAC19696.1|; |8163867|gblAAF73888.1|AF222778_1|; 18163865|gblAAF73887.1|AF222777_1|; |8163863|gblAAF73886.1|AF222776_1|; 18163861|gblAAF73885.1|AF222775_1|; 25 |8163859|gblAAF73884.1|AF222774_1|; |8163857|gblAAF73883.1|AF222773_1|; |8163855|gblAAF73882.1|AF222772_1|; 18163853|gblAAF73881.1|AF222771_1|; 18163851|gblAAF73880.1|AF222770_1|; |8163849|gblAAF73879.1|AF222769_1|; |8163847|gblAAF73878.1|AF222768_1|; 10442686|gblAAG17432.1|AF285888_1|; 19887189|gblAAG1789.1|AF251431_1|; 19887172|gblAAG1780.1|AF251423_1|; 30 19887155|gblAAG1771.1|AF251415_1|; 19887138|gblAAG1762.1|AF251407_1|; 19887107|gblAAG1746.1|AF251392_1|; 19954391|gblAAG9040.1|; 19437966|gblAAF87508. 1 AF250480_1 ; 19437956|gblAAF87503. 1 AF250475_1 ; 19437954|gblAAF87502. 1 AF250474_1 ; 19437952|gblAAF87501.1 AF250473_1 ; 194379501gblAAF87500. 1 AF250472_1 ; 19437948|gblAAF87499. 1 AF250471_1 ; 35 19437946|gblAAF87498.1|AF250470_1|; |8515430|gblAAF75997.1|AF250127_1|; |5732295|gblAAD49023.1|AF156413_1|; |5732289|gblAAD49020.1|AF156410_1|; |5732299|gblAAD49025.1|AF156415_1|; |6048942|gblAAF02407.1|AF098627_1|; |6048938|gblAAF02405. 1 AF098625_1 ; |6048936|gblAAF02404. 1 AF098624_1 ; |6048934|gblAAF02403. 1 AF098623_1 ; |6048932|gblAAF02402. 1 AF098622_1 ; 40 |6048930|gblAAF02401 .1 AF098621_1 ; |6048928|gblAAF02400. 1 AF098620_1 ; |6048926|gblAAF02399.1|AF098619_1|; |6048924|gblAAF02398.1|AF098618_1|; |6048922|gblAAF02397.1|AF098617_1|; |5732287|gblAAD49019.1|AF156409_1|; |5732285|gblAAD49018.1|AF156408_1|; 15732283|gblAAD49017.1|AF156407_1|; |5732281|gblAAD49016.1|AF156406_1|; |5732277|gblAAD49014.1|AF156404_1|; 45 15732275|gblAAD49013.1|AF156403_1|; 15732273|gblAAD49012.1|AF156402_1|; |3722169|gblAAC63467.1 ; |3722167|gblAAC63466. 1; 13722165|gblAAC63465. 1; 13722163|gblAAC63464.1|; 13722161|gblAAC63463.1|; |3722159|gblAAC63462.1|; |3721982|gblAAC63428.1 ; |3721980|gblAAC63427. 1; |3721978|gblAAC63426. 1; |3721976|gblAAC63425.1 ; 150083251 gblAAT70220.1 ; |221296|dbjlBAA00035. 1; 39 3745052_1 (GHMatters) P78534.AU.1 1835738|gblAAC57416.1 ; |221294|dbjlBAA00034.1 ; |50261909|gblAAT72507.1 ; |325104|gblAAA73112.1|; |325097|gblAAA73 111.1; 1; >gil325095|gblAAA73105.11; |325089|gblAAA73 110.1; |325087|gblAAA73109.1|; 13248901gblAAA73104.1|; |324584|gblAAA73108.1|; |324582|gblAAA73107.1|; |324256|gblAAA73106.1|; 5 |61197036|gblAAX39501.1|; |61197032|gblAAX39499. 1; |75093|pir||VHIV8HI; 150083235|gblAAT70212. 1; |37813190|gblAAR04371.1|; 137813188|gblAAR04370. 1; |37813192|gblAAR04372.1 ; |60478|emblCAA33899. 1; 1324031 gblAAB59744. 1; 16589037|gblAAL26994.1|AF397199_1|; 16589034|gblAAL26993.1|AF397198_1|; |279784|pir||VHIVAKl; |279783|pir||VHIVXLl; 134597775 gblAAQ77445.1|; 10 134597773|gblAAQ77444.1 ; |29539576|gblAAO88263. 1 AF342819_1 ; |61197034|gblAAX39500.1 ; 19049384|dbjlBAA99400. 1; 171084275|gblAAZ23583.1 ; |71084269|gblAAZ23580. 1; |71084267|gblAAZ23579. 1; |55925904|gblAAV68025.1 ; |58374190|gblAAW72231.1|; |58618448|gblAAW80722.1|; |58618446|gblAAW80721.1|; |27596994|reflNP_775533.1|; |58618444|gblAAW80720.1 ; 15 |21693171|gblAAM75159.1|AF389119_1|; |75108|pir||VHIVN8|; |75107|pir||VHIVX|; |75104|pir||VHIVN1|; |75103|pir||VHIVN2|; |75102|pir||VHIVN3|; |75101|pir||VHIVN6|; |75100|pir||VHIVN9|; |75094|pir||VHIVN7|; |320344|pir||A60028|; |320033|pir||VHIVM1|; |320032|pir||VHIVC1|; |75099|pir||VHIVX6|; |75095|pir||VHIVX2|; 166733741 gblAAY5263 1.1|; |66733739|gblAAY52630. 1; |66733737|gblAAY52629.1 ; 20 |66733735|gblAAY52628.1 ; |66733733|gblAAY52627. 1; 166733731 gblAAY52626.1 ; |66733729|gblAAY52625. 1; |66733727|gblAAY52624. 1; 166733725|gblAAY52623. 1; 166733723|gblAAY52622.1 ; 166733721 gblAAY52621.1|; |66733719|gblAAY52620.1 ; |66733717|gblAAY52619.1 ; |66733715|gblAAY52618. 1; |66733713|gblAAY52617.1 ; 166733711 gblAAY52616.1 ; |66733709|gblAAY52615. 1; |66733707|gblAAY52614.1 ; 25 |66733705|gblAAY52613.1 ; |66733703|gblAAY52612. 1; 166733701 gblAAY5261 1.1|; |66733699|gblAAY52610.1|; |66733697|gblAAY52609. 1; 166733695|gblAAY52608.1 ; 166733693|gblAAY52607.1 ; 166733691 gblAAY52606. 1; |66733689|gblAAY52605.1 ; |66733687|gblAAY52604.1 ; |73921307|reflYP_308871.1|; 1377854301gblAAO46552. 1; |37785428|gblAAO4655 1.1|; |37785426|gblAAO46550. 1; |37785424|gblAAO46549.1 ; 30 |37785422|gblAAO46548.1 ; 1377854201gblAAO46547. 1; |37785418|gblAAO46546.1 ; |37785416|gblAAO46545.1 ; |37785414|gblAAO46544. 1; |37785412|gblAAO46543.1 ; |37785410|gblAAO46542. 1; |37785408|gblAAO46541 .1; |37785406|gblAAO46540. 1; |37785404|gblAAO46539.1 ; |37785402|gblAAO46538. 1; |37785400|gblAAO46537.1 ; |37785398|gblAAO46536.1 ; |37785396|gblAAO46535. 1; |37785394|gblAAO46534.1 ; 35 |37785392|gblAAO46533.1 ; 1377853901gblAAO46532. 1; 137785388|gblAAO4653 1.1|; |37785386|gblAAO46530.1 ; |37785384|gblAAO46529. 1; |37785382|gblAAO46528.1 ; 1377853801gblAAO46527.1 ; |37785378|gblAAO46526. 1; |37785376|gblAAO46525.1 ; |37785374|gblAAO46524.1|; |37785372|gblAAO46523.1|; 1377853701gblAAO46522.1|; |37785368|gblAAO46521.1|; |37785244|gblAAO46460. 1; |37785242|gblAAO46459.1 ; 40 1377852401gblAAO46458.1|; |37785238|gblAAO46457. 1; |37785236|gblAAO46456.1 ; |37785234|gblAAO46455. 1; |37785232|gblAAO46454. 1; 1377852301gblAAO46453. 1; |37785228|gblAAO46452. 1; |37785226|gblAAO4645 1.1; |37785224|gblAAO46450. 1; |37785222|gblAAO46449. 1; 1377852201gblAAO46448. 1; |37785218|gblAAO46447. 1; |37785216|gblAAO46446.1 ; |37785214|gblAAO46445. 1; |37785212|gblAAO46444.1 ; 45 |37785210|gblAAO46443. 1; |37785208|gblAAO46442. 1; |37785206|gblAAO46441.1|; |37785204|gblAAO46440. 1; |37785202|gblAAO46439. 1; |37785200|gblAAO46438. 1; |37785198|gblAAO46437.1 ; |37785196|gblAAO46436. 1; |37785194|gblAAO46435.1 ; |37785192|gblAAO46434.1 ; |37785190|gblAAO46433. 1; |37785188|gblAAO46432.1 ; |37785186|gblAAO4643 1.1|; |37785184|gblAAO46430. 1; |37785182|gblAAO46429.1 ; 40 3745052_1 (GHMatters) P78534.AU.1 |3778518OgblAAO46428.1 ; |37785178|gblAAO46427. 1; |37785176|gblAAO46426.1 ; |37785174|gblAAO46425.1|; |37785172|gblAAO46424.1|; |3778517OgblAAO46423.1|; |37785168|gblAAO46422.1|; 13925172|gblAAK49279.1|AF255753_1|; |13274625|gblAAK18006.1|AF255749_1|; 13274623|gblAAK18005.1|AF255748_1|; 5 |31339496|gblAAP49080. 1; |31339492|gblAAP49078. 1; |66775627|gblAAY56368.1 ; |42661500|emblCAF31360.1|; |54126502|gblAAV30830. 1; 150234808|gblAAT70633.1 ; |18092172|gblAAL59145.1|AF398420_1|; |1809217OgblAAL59144.1|AF398419_1|; |8307799|gblAAF74328. 1 AF084278_1 ; |8307797|gblAAF74327. 1 AF084277_1 ; |8307795|gblAAF74326. 1 AF084276_1 ; |2833664|gblAAC34267. 1; 10 |54126537|gblAAV30838.1|; 173852953|reflYP_308667. 1; |32140159|reflNP_859032. 1; |30025978|gblAAPO4508. 1; |71013502|dbjlBAE07202.1 ; |62466165|gblAAX83408. 1; |62466157|gblAAX83404.1 ; |54610028|gblAAV35112.1|; |54299852|gblAAV32650.1 ; |54299838|gblAAV32642.1 ; |52078184|gblAAU25867. 1; 152078171 gblAAU25860.1 ; |52078148|gblAAU25847. 1; 147834203 gblAAT38823. 1; 1493572401gblAAT65380. 1; 15 |49357234|gblAAT65377. 1; |49357232|gblAAT65376.1 ; |49357224|gblAAT65372.1 ; |49357216|gblAAT65368. 1; |49357212|gblAAT65366.1 ; |49357208|gblAAT65364.1 ; |49357196|gblAAT65358. 1; |49357186|gblAAT65353.1 ; |49357184|gblAAT65352.1 ; |13925169|gblAAK49278.1|AF255752_1|; 13925167|gblAAK49277.1|AF255751_1|; |13925164|gblAAK49276.1|AF255750_1|; 13925161|gblAAK49275.1|AF255747_1|; 20 13925159|gblAAK49274.1|AF255746_1|; 13925156|gblAAK49273.1|AF255745_1|; |13925153|gblAAK49272.1|AF255744_1|; 13925151|gblAAK49271.1|AF255743_1|; |13925148|gblAAK49270.1|AF255742_1|; |38154862|gblAAR12367.1|; |38154860|gblAAR12366.1 ; |38154858|gblAAR12365.1 ; |38154856|gblAAR12364. 1; |38154854|gblAAR12363.1 ; |38154852|gblAAR12362.1 ; |38154850|gblAAR12361 .1; 25 |38154848|gblAAR12360.1 ; |38154846|gblAAR12359.1 ; |38154844|gblAAR12358. 1; |38154842|gblAAR12357.1 ; |38154840|gblAAR12356.1 ; |38154838|gblAAR12355. 1; |38154836|gblAAR12354.1 ; |38154834|gblAAR12353.1 ; |38154832|gblAAR12352. 1; |38154830|gblAAR12351.1|; |38154828|gblAAR12350.1|; |47156435|gblAAT12105.1|; |47156433|gblAAT12104.1|; 147156431|gblAAT12103.1|; |47156429|gblAAT12102.1|; 30 |47156427|gblAAT12101.1|; 147156425|gblAAT12100.1|; 147156423|gblAAT12099.1|; 147156421|gblAAT12098.1|; |47156419|gblAAT12097.1|; |47156417|gblAAT12096.1|; |47156415|gblAAT12095.1|; 147156413|gblAAT12094.1|; 147156411|gblAAT12093.1|; |47156409|gblAAT12092.1|; |47156407|gblAAT12091.1|; 147156405|gblAAT12090.1|; |47156403|gblAAT12089. 1; 147156401 gblAAT12088.1 ; |47156399|gblAAT12087.1 ; 35 |47156397|gblAAT12086. 1; |47156395|gblAAT12085.1 ; |30522970|gblAAO65613.1 ; |28849563|gblAAO52964.1 AF509121_1 ; 19422133|gblAAL87893.1 AF455703_1 ; |19422127|gblAAL87890.1|AF455700_1|; 19422125|gblAAL87889.1|AF455699_1|; |290762|gblAAA51501.1|; 19802278|gblAAF99666.1|AF258516_1|; |5732297|gblAAD49024.1|AF156414_1|; 15732293|gblAAD49022.1|AF156412_1|; 40 15732291|gblAAD49021.1|AF156411_1|; |6048944|gblAAF02408.1|AF098628_1|; |6048940|gblAAF02406.1|AF098626_1|; 15805283|gblAAD51925.1|AF144303_1|; |76800632|gblABA55723.1 ; |59803332|gblAAX07774. 1; 157916081 gblAAW59409. 1; 157916035|gblAAW59399.1 ; 157915988|gblAAW59391.1|; 147716775|gblAAT37564. 1; |42661498|emblCAF31359.1|; |60823|emblCAA36505.1 ; 160821 emblCAA36234. 1; 45 |58531177|dbjlBAD89346.1 ; |58531159|dbjlBAD89336.1 ; 158531141 dbjlBAD89326. 1; |58531123|dbjlBAD89316.1|; 158531091 dbjlBAD89306.1 ; |50956630|gblAAT90833. 1; |50234860|gblAAT70659. 1; |50234830|gblAAT70644. 1; |50234828|gblAAT70643. 1; |50234826|gblAAT70642. 1; |50234824|gblAAT70641.1|; |50234822|gblAAT70640. 1; |50234820|gblAAT70639. 1; 150234818|gblAAT70638.1 ; |50234816|gblAAT70637.1 ; 41 3745052_1 (GHMatters) P78534.AU.1 502348 141gblAAT7O636. 11; 1502348 121gblAAT7O635.1 1; 1502348 1O~gblAAT7O634.1 1; 5O2348O61gblAAT7O632. 11; 15O2348O41gblAAT7O63 1.11; 15O2348O21gblAAT7O63O.1 1; 5O2348O~gblAAT7O629. 11; 150234798 IgblAAT7O628.1 1; 15O2347961gblAAT7O627.1 1; 5O2347941gblAAT7O626. 11; 15O2347921gblAAT7O625.1 1; 15O23479O~gblAAT7O624.1 1; 5 15O2347781gblAAT7O618. 11; 15O2347761gblAAT7O617.1 1; 15O2347741gblAAT7O616.1 1; 425212921gblAAS 18236. 11; 138524558 Idbj IBADO2358.1 1; 13852454Oldbj IBADO2348. 11; 617789Oldbj IBAA86O69.1 1; 16177888 Idbj IBAA86O68. 11; 16177886ldbj IBAA86O67. 11; 6177884ldbj IBAA86O66.1 1; 128194391 IgblAAO3354O.1I AF474O7_1 1; 28 1943871gblAAO33539. 1 IAF4740691 1; 124286O7O~gblAAN4683O. 11; 10 14579581 IgbAAK693O8.1 IAF3852931 1; 1814O8261gblAAL6436.1 IAF398867_1; 18O74925lembICAC84253.11; 18O74923lembICAC84252.11; 18O74921lembICAC84251.11; 18O74919lembICAC8425O.11; 18O74917lembICAC84249.11; 18O74915lembICAC84248.11; 18O74913lembICAC84247.11; 18O74911lembICAC84246.11; 18O749O9lembICAC84245.11; 845283O1gblAAF75 110.1 AF1 15285_1; 184528281gblAAF7S 109.1 AFi 15284_1; 15 1779173431gbIABB05220.11; 1779173241gblABB05209. 11; 177917305 IgbIABB0S 198.11; 778694951gbIABB0S 187.11; 1778634981gbIABB05009.11; 1778634791gbIABB04998.1 1; 778634601gbIABB04987. 11; 177863441 IgblABB04976. 11; 1778634221gbIABB04965.1 1; 778634031gbIABB04954. 11; 1778633841gbIABB04943. 11; 177863365 IgbIABB04932.1 1; 778633461gbIABB04921. 11; 1778633271gbIABB04910. 11; 177861 8741gbIABB04375.1 1; 20 1778618551gbIABB04364. 11; 1778618361gbIABB04353. 11; 1778618171gbIABB04342.1 1; 778617981gbIABB0433 1.11; 1778617791gblABB04320. 11; 177861760gbIABB04309.1 1; 77861741 gbIABB04298.11; 1778617221gblABB04287.11; 1777474671gbIABB03149.11; 777474481gbIABB03 138.11; 1777474291gblABB03 127.11; 1777474091gbIABB03 116.11; 777473901gbIABB03 105.11; 177747371 IgbIABB03094. 11; 1777473521gbIABB03083.1 1; 25 1777473331gbIABB03072. 11; 1777473 121gbABB03061. .1; 177747293 IgbIABB03050.1 1; 77747274 1gb ABB03 03 9. 11; 17774725 5 1gb ABB03 02 8. 11; 1777472361gbIABB03017.1 1; 77747217 1gb ABB03 006. 11; 177747198 1gb ABB02995. 11; 1777471791gbIABB02984.1 1; 77747158 1gb ABB02973.11; 1777471391gblABB02962.11; 177747120 gb ABB0295 1.11; 77747 1011gb ABB02940.11; 177747080~gblABB02928.11; 177747061 gbIABB02917.11; 30 1777470421gblABB02906. 11; 1777469961gblABB02895. 11; 1777469771gbIABB02884. 1 ; 777469581gbIABB02873. 11; 1777469391gbIABB02862. 11; 1777469201gbIABB0285 1.11; 777468991gbIABB02840. 11; 1777468801gbIABB02829. 11; 177746861 IgbIABBO28 18.11; 777468421gbIABB02807. 11; 177746823 IgbIABB02796. 11; 1777468041gbIABB02785.1 1; 775436901gbIABA87257.1 1; 1775436701gbIABA87246.1 1; 1775436501gbIABA87235. 11; 35 1775433681gbIABA87095 .11; 1775433491gbIABA87084.1 1; 177543305 IgbIABA87061. .1; 775432491gbIABA87049.11; 1764644031gbIABA43340.11; 176454181 gbIABA43204.11; 764468271gbIABA43193.11; 1764468061gbIABA43182.11; 176446435 gbIABA43171.11; 76446410~gbIABA42993.11; 176446391 gbIABA42982.11; 1764463191gbIABA42943.1; 76446300~gbIABA42932.1 1; 1764435341gbIABA42579.1 1; 1764435 15 gbIABA42568. 11; 40 176443496gbIABA42557.1 1; 176443477gbIABA42546.1 1; 1764434581gbIABA42535. 11; 764434391gbIABA42524.11; 1764434201gbIABA42513.11; 176443401 gbIABA42502.11; 764433821gbIABA4249 1.11; 176443363 gbIABA42480.11; 1764433441gbIABA42469.1; 764433251gbIABA42458.11; 1764432761gbIABA42447.11; 1764432571gbIABA42416.1; 764432381gbIABA42405.11; 1764432191gbIABA42394.11; 176443200~gbIABA42383.1; 45 176443181 gbIABA42372.11; 176440953 gbIABA4236 1.11; 176426705 gbIABA42350.1; 764186821gbIABA42339.11; 1764111091gbIABA42328.11; 176410460~gbIABA42317.1; 764032271gbIABA42306.11; 1763815431gbIABA42295.11; 1763740971gbIABA42284.1; 76366076gbABA42273 .1 1; 176366057gbIABA42262. 1 ; 763660381gbIABA4225 1.11; 763660191gbIABA42240.1 1; 1757503521gbIABA26803.1 1; 175750333 gbIABA26792. 11; 42 3745052_1 (GH Matters) P78534.AU.1 757503 141gbIABA2678 1.11; 1584297731gblAAW78291. .1; 158429761 IgblAAW78285.1 1; 584297591gblAAW78284.1 1; 15O5426431gblAAT78586.1 1; 150083045 IgbAAT7O174.1 1; 5OO591881gblAAT69352. 11; 155273941 IgblAAV48837.1 1; 155233233 IgblAAV48549.1 1; 537657271gblAAU934O5.1 1; 1510941 131gblAAS89187.21; 15185987O~gblAAU1 1219.11; 5 1518598681gblAAU1 1218.11; 1518598661gblAAU1 1217.11; 1518598641gblAAU1 1216.11; 518598621gblAAU1 1215.11; 15185986O~gblAAU1 1214.11; 1518598581gblAAU1 1213.11; 518598561gblAAU1 1212.11; 1518598541gblAAU1 1211.11; 1518598521gblAAU1 12 10.11; 51859850~gblAAU1 1209.11; 1518598481gblAAU1 1208.11; 1518598461gblAAU1 1207.11; 518598441gblAAU1 1206.11; 1518598421gblAAU1 1205.11; 151859840~gblAAU1 1204.11; 10 150365720~gblAAT76161. 11; 1478349481gblAAT39109.1 1; 1478349461gblAAT39108.1 1; 478349441gblAAT39107. 11; 1478349341gblAAT39102.1 1; 1478349321gblAAT39101 .11; 338673591gblAAQ55062.1 1; 145124766lembICAF33022.1 1; 145124750lembICAF33013. 11; 45124746lembICAF3301 1.11; 1333180651gblAAQ04906.1 IAF508617_1; 333180631gblAAQ04905.1 IAF5086161 1; 1333180591gblAAQ04903.1 IAF508614_1; 15 1333180551gAAQ0490 1.1 IAF5086121 1; 133318053 IgblAAQ04900.1 IAF50861 111; 333180491gblAAQ04898.1 IAF5086091 1; 133318045 IgblAAQ04896.1 IAF508607_1; 33318043 IgblAAQ04895.1 IAF5086061 1; 133318041 IgblAAQ04894.1 IAF508605_1; 412074771gblAAR99630.11; 140732903lembICAF04486.11; 14275699lembICAC40041 .11; 219023181gblAAM78513.1 IAF4836041 1; 13383285 IdbjlBAB39514.1 1; 20 13383283ldbjlBAB39513. 11; 1553 1266lembICAB50887. 11; 300439241gblAAG01I753.21AF2513991 1; 1288495991gblAAO52982.1 IAF509139_1; 28849561 IgblAO052963.1 IAF5091201 1; 1288495591gblAAO52962.1 IAF509119_1; 288495571gblAAO5296 1.1 IAF5091 18_1; 128849555 IgblAAO52960.1 IAF5091 17_1; 288202861gblAAO46832.1 1; 1288202841gblAAO4683 1.11; 1288202821gblAAO46830.1 1; 25 128820280~gblAAO46829.1 1; 1288202781gblAAO46828. 11; 1288202761gblAAO46827.1 1; 288200471gblAAO46826.1 1; 128819610~gblAAO46825. 11; 128818981 IgblAAO46824.1 1; 184961 10lembICAD20329.1 1; 127462153 IgbAO015349.1I AF225537_1; 2746215 1 gbAO015348.1 IAF2255361 1; 1274621491gblAAO15347.1 IAF225535_1; 274621471gbAO015346.1 IAF2255341 1; 122859439lembICAD30201.1; 30 122859437lembICAD30200.1 1; 121359670~gbAAM49560.1 IAF468842_1; 20068061lembICAC85241 .1; 120068055lembICAC85238.11; 120068051lembICAC85236.11; 20068049lembICAC85235. 11; 120068037lembICAC85229.11; 19913216lembICAD20330.11; 19913210lembICAD20324.11; 1196978061gblAAL31404.11; 1196978041gblAAL31403.11; 196978021gblAAL31402.11; 119697800~gblAAL31401.11; 1196977981gblAAL31400.11; 35 196977961gblAAL31399.11; 196977941gblAAL3 1398.11; 194221391gbAAL87896.1IAF455706_11; 194221371gblAAL87895.1IAF455705_1; 194221351gbAAL87894.1IAF455704_11; 194221311gblAAL87892.1IAF455702_1; 194221291gbAAL87891.1IAF455701_11; 160767091gblAAL14085.1IAF222815_1. 40 PB] Proteins 538299051gblAAU94857.1 1; 1538299031gblAAU94856. 11; 153829901 IgblAAU94855.1 1; 538298991gblAAU94854.1 1; 1538298971gblAAU94853. 11; 1538298951gblAAU94852.1 1; 538298931gblAAU9485 1.11; 153829891 IgblAAU94850. 11; 1538298891gblAAU94849.1 1; 538298871gblAAU94848.1 1; 1538298851gblAAU94847. 11; 1538298831gblAAU94846.1 1; 45 153829881 IgblAAU94845.1 1; 196223171gblAAF89734.1 IAF170571_1; 5585 12ldbjlBAA00002.1 1; 18486165 jrefNP 056657.11; 1304662291ref]NP_848682.11; 304662141ref]NP_848674.1 1; 1303492371gblAAP22114.1 1; 1303492221gblAAP22106.1 1; 3252761gblAAA43767. 11; 1670901pirlP1IVBLI; 1500594271gblAAT69445.1 1; 43 3745052_1 (GH Matters) P78534.AU.1 |50059408|gblAAT69434. 1; |50059389|gblAAT69423. 1; |6318399|gblAAF06876. 1 AF102007_1 ; |6318397|gblAAF06875. 1 AF102006_1 ; |6318395|gblAAF06874.1|AF102005_1|; 16318393|gblAAF06873.1|AF102004_1|; 16318391|gblAAF06872.1|AF102003_1|; |6318389|gblAAF06871.1|AF102002_1|; 5 |6318387|gblAAF06870.1|AF102001_1|; 16318385|gblAAF06869.1|AF102000_1|; |6318383|gblAAF06868.1|AF101999_1|; 16318381|gblAAF06867.1|AF101998_1|; |6318379|gblAAF06866.1|AF101997_1|; |6318377|gblAAF06865.1|AF101996_1|; |6318375|gblAAF06864.1|AF101995_1|; 16318373|gblAAF06863.1|AF101994_1|; 16318371|gblAAF06862.1|AF101993_1|; |6318369|gblAAF06861.1|AF101992_1|; 10 |6318367|gblAAF06860. 1 AF101991_1 ; |68655094|emblCAG965 10.1|; |20126603|gblAAK95906.1 ; 151340771 gblAAU00993. 1; |133529|splP13872|RRP1_INBADI; 133530|splP07832|RRP1INBLEl; |6647764|splO36430|RRP1_INBP9|; 133528|splP13871 RRP1_INBACl; 18486151|reflNP_056659.1|; 16318433|gblAAF06893.1|AF102024_1|; 15 16318431|gblAAF06892.1|AF102023_1|; |6318429|gblAAF06891.1|AF102022_1|; |6318427|gblAAF06890.1|AF102021_1|; 16318425|gblAAF06889.1|AF102020_1|; 16318423|gblAAF06888.1|AF102019_1|; 16318421|gblAAF06887.1|AF102018_1|; |6318419|gblAAF06886.1|AF102017_1|; |6318417|gblAAF06885.1|AF102016_1|; 16318415|gblAAF06884.1|AF102015_1|; 16318413|gblAAF06883.1|AF102014_1|; 20 16318411|gblAAF06882.1|AF102013_1|; |6318409|gblAAF06881.1|AF102012_1|; |6318407|gblAAF06880.1|AF102011_1|; 16318405|gblAAF06879.1|AF102010_1|; 16318403|gblAAF06878.1|AF102009_1|; 16318401|gblAAF06877.1|AF102008_1|; |325278|gblAAA43768. 1; |2463656|gblAAB72043. 1; 18140834|gblAAL60440.1|AF398871_1|; 18140822|gblAAL60434.1|AF398865_1|; 25 194379601gblAAF87505. 1 AF250477_1 ; 13249401gblAAA4363 1.11; 19049388|dbjlBAA99402.1 ; 171084265|gblAAZ23578.1 ; 171084263|gblAAZ23577.1 ; 171084261 gblAAZ23576. 1; |71084259|gblAAZ23575. 1; |71084257|gblAAZ23574.1 ; |71084255|gblAAZ23573.1|; 171084253|gblAAZ23572.1|; 171084251|gblAAZ23571.1|; |73665386|gblAAZ79400. 1; |55925912|gblAAV68029.1 ; |55925878|gblAAV68012.1|; 30 |55925862|gblAAV68004.1 ; 1559258501gblAAV67998. 1; |55925834|gblAAV67990.1 ; 19802300|gblAAF99677. 1 AF258527_1 ; 19802298|gblAAF99676. 1 AF258526_1 ; |58374186|gblAAW72229.1|; |29539584|gblAAO88267.1|AF342823_1|; 1377854601gblAAO46566.1 ; |37785458|gblAAO46565. 1; |37785456|gblAAO46564.1 ; |37785454|gblAAO46563.1 ; |37785452|gblAAO46562. 1; 1377854501gblAAO46561.1|; 35 |37785448|gblAAO46560.1 ; |37785446|gblAAO46559. 1; |37785444|gblAAO46558.1 ; |37785442|gblAAO46557.1 ; 1377854401gblAAO46556. 1; |37785438|gblAAO46555.1 ; |37785436|gblAAO46554.1 ; |37785434|gblAAO46553. 1; |37785044|gblAAO46341.1|; |37785042|gblAAO46340.1 ; |37785040|gblAAO46339. 1; |37785038|gblAAO46338.1 ; |37785036|gblAAO46337.1|; |37785034|gblAAO46336.1|; |37785032|gblAAO46335.1|; 40 |37785030|gblAAO46334.1 ; |37785028|gblAAO46333. 1; |37785026|gblAAO46332.1 ; |37785024|gblAAO46331.1|; |37785022|gblAAO46330.1|; |37785020|gblAAO46329.1|; |37785018|gblAAO46328.1 ; |37785016|gblAAO46327. 1; |37785014|gblAAO46326.1 ; |37785012|gblAAO46325.1 ; |37785010|gblAAO46324. 1; |3523119|gblAAC34271.1|; |54126556|gblAAV30842.1 ; |52078177|gblAAU25863. 1; |52078159|gblAAU25853.1 ; 45 152078141 gblAAU25843.1 ; 147834373|gblAAT38884. 1; 154126513|gblAAV30834. 1; |31442137|emblCAD92258.1 ; |30522957|gblAAO65606. 1; |5732325|gblAAD49038.1|AF156428_1|; 15732323|gblAAD49037.1|AF156427_1|; |5732321|gblAAD49036.1|AF156426_1|; |73912683|reflYP_308851.1|; |18074831|emblCAC84862.1|; 18074829|emblCAC84861.1|; 18074827|emblCAC84913.1|; 44 3745052_1 (GHMatters) P78534.AU.1 |18074825|emblCAC84912.1|; |18074823|emblCAC84911.1|; |18074821|emblCAC84910.1|; |18074819|emblCAC84909. 1; |18074817|emblCAC84908. 1; |77543697|gblABA87261.1|; |77543677|gblABA87250.1|; |77543657|gblABA87239. 1; |77543377|gblABA87099. 1; |77543356|gblABA87088.1 ; |77543312|gblABA87065.1 ; |77543256|gblABA87053. 1; 5 |76786707|gblABA55039. 1; |76464433|gblABA43344. 1; 176454573 gblABA43208. 1; |76446442|gblABA43175.1|; |76446417|gblABA42997.1|; |76446398|gblABA42986.1|; |76446326|gblABA42947.1|; |76446307|gblABA42936.1|; 176443541|gblABA42583.1|; |76443522|gblABA42572.1|; |76443503|gblABA42561.1|; |76443484|gblABA42550.1|; |76443465|gblABA42539.1|; |76443446|gblABA42528.1|; |76443427|gblABA42517.1|; 10 |76443408|gblABA42506.1|; |76443389|gblABA42495.1|; 1764433701gblABA42484.1|; 176443351|gblABA42473.1|; |76443332|gblABA42462.1|; 176443283|gblABA42451.1|; |76443264|gblABA42420.1 ; |76443245|gblABA42409.1 ; |76443226|gblABA42398. 1; |76443207|gblABA42387.1|; |76443188|gblABA42376.1|; 176441125|gblABA42365.1|; |76426762|gblABA42354.1|; |76418836|gblABA42343.1|; 176411281|gblABA42332.1|; 15 |76410537|gblABA42321.1|; |76403298|gblABA42310.1|; |7638163OgblABA42299.1|; |76366083|gblABA42277.1 ; |76366064|gblABA42266. 1|; 176366045 gblABA42255.1|; |76366026|gblABA42244. 1; |75750359|gblABA26807. 1; |75750340|gblABA26796. 1; |75750321 gblABA26785.1 ; |75750302|gblABA26774.1 ; 175750283 gblABA26763. 1; |75750264|gblABA26752.1 ; |75750245|gblABA26741.1|; |75750226|gblABA26730. 1; 20 |75750207|gblABA26719.1 ; |75750188|gblABA26708. 1; 172623485|gblAAZ74625.1 ; |75218844|gblABA18175.1|; 175217161|gblABA18164.1|; 175216235|gblABA8153.1|; |75215980|gblABA8142.1|; |75215317|gblABA8131.1|; |75214459|gblABA8120.1|; |75213056|gblABA18045.1|; 175206531 gblABA18034.1|; |75200787|gblABA16472. 1; |75181281|gblABA12792.1|; |75181143|gblABA12784.1|; |75180947|gblABA12770.1|; 25 175180861 gblABA12759.1 ; |75180593|gblABA12748.1 ; 175173041 gblABA12737. 1; |75171464|gblABA12726.1|; 175171319|gblABA12716.1|; |75168429|gblABA12704.1|; |74477300|gblABA08527.1|; 1744772601gblABA08505.1|; 174477241|gblABA08494.1|; |74477222|gblABA08483.1|; |74477203|gblABA08472.1|; |74422768|gblABA06550.1|; |74422600|gblABA06518.1|; |73919149|reflYP_308847.1|; |32140170|reflNP_859040.1|; 30 |73765607|gblAAZ85134.1|; |73763209|gblAAZ83985. 1; |73762516|gblAAZ83696.1 ; |73762335|gblAAZ83657. 1; |73761799|gblAAZ83390. 1; |73761738|gblAAZ83379.1 ; |73761610|gblAAZ8333 1.1; 173761591 gblAAZ83320. 1; |73761572|gblAAZ83307.1 ; |73761553|gblAAZ83296. 1; |73761534|gblAAZ83285. 1; 173761511 gblAAZ83274.1 ; |73761488|gblAAZ83261 .1; |73761469|gblAAZ83250. 1; |73666629|gblAAZ80038.1 ; 35 |73666608|gblAAZ80026. 1; |73666589|gblAAZ80015. 1; 1736665701gblAAZ80004. 1; 173666551 gblAAZ79993. 1; |73665986|gblAAZ79982. 1; |73665938|gblAAZ79971.1|; 173665901 gblAAZ79960. 1; 173665893 gblAAZ79956. 1; |73665854|gblAAZ79644. 1; 173665851 gblAAZ79642. 1; |73665818|gblAAZ79623. 1; |73665799|gblAAZ79612.1 ; 1736657801gblAAZ79601 .1; 173665761 gblAAZ79590. 1; |73665742|gblAAZ79579.1 ; 40 |73665723|gblAAZ79568. 1; |73665704|gblAAZ79557. 1; 173665685 gblAAZ79546. 1; |73665666|gblAAZ79535. 1; |73665647|gblAAZ79524. 1; |73665624|gblAAZ79513.1|; |67644059|gblAAY78947.1|; |62198990|gblAAX76741.1|; 172602401|gblAAZ74614.1|; |72602382|gblAAZ74603. 1; 172602363 gblAAZ74592. 1; |72602312|gblAAZ7458 1.1|; |72598259|gblAAZ74570. 1; |72597976|gblAAZ74559. 1; |72582199|gblAAZ74548. 1; 45 |72581028|gblAAZ74537.1|; |72578717|gblAAZ74526.1|; 172572343|gblAAZ74515.1|; |72572222|gblAAZ74504. 1; |72569084|gblAAZ74493. 1; |72565969|gblAAZ74482. 1; 172562651|gblAAZ74471.1|; 172556693|gblAAZ74460.1|; |72554416|gblAAZ74449.1|; |72552919|gblAAZ74438.1|; |72552104|gblAAZ74427.1|; 172549761|gblAAZ74416.1|; |72545910|gblAAZ74405. 1; 172545373 gblAAZ74394. 1; 172543055 gblAAZ74382. 1; 45 3745052_1 (GHMatters) P78534.AU.1 |72539904|gblAAZ74371.1|; |72539866|gblAAZ74360.1|; 171842601|gblAAZ43413.1|; |71842582|gblAAZ43402.1|; 171842563|gblAAZ43391.1|; |7184254OgblAAZ43378.1|; |71571169|gblAAZ38658.1|; |71568557|gblAAZ38646.1|; |71564894|gblAAZ38635.1|; |71564875|gblAAZ38624.1|; 171564856|gblAAZ38613.1|; |71564837|gblAAZ38602.1|; 5 |71564818|gblAAZ38591.1|; |71564799|gblAAZ38580.1|; |7156478OgblAAZ38569.1|; |71564761|gblAAZ38558.1|; |71564742|gblAAZ38547.1|; 171564723|gblAAZ38536.1|; |71564704|gblAAZ38525.1|; 171564685|gblAAZ38514.1|; |71564666|gblAAZ38503.1|; |71564647|gblAAZ38492.1|; |71564628|gblAAZ38481.1|; |71564609|gblAAZ38470.1|; |62198882|gblAAX7668 1.1|; |68525456|gblAAY98778. 1; 168510091 gblAAY98414.1 ; 10 168510073|gblAAY98404.1 ; 168510053|gblAAY98394. 1; |68510022|gblAAY98384.1 ; 168510001 gblAAY98374.1 ; |68509974|gblAAY98364. 1; |68509908|gblAAY98347.1 ; |68509883|gblAAY98337.1 ; |68509389|gblAAY98327. 1; 168509351 gblAAY98255.1 ; |68509326|gblAAY98245. 1; |68509307|gblAAY98235. 1; |68509287|gblAAY98225. 1; |68509263|gblAAY98215.1 ; |6850924OgblAAY98205. 1; |68509224|gblAAY98196.1 ; 15 168509201|gblAAY98185.1|; |68509182|gblAAY98175.1|; |68509164|gblAAY98165.1|; |68509146|gblAAY98155.1 ; |68509127|gblAAY98145. 1; |68509109|gblAAY98135.1 ; 168509091 gblAAY98125.1 ; 168509073|gblAAY98115.1|; 168509055|gblAAY98105.1 ; |68509028|gblAAY98095. 1; |68508949|gblAAY98085. 1; 1685089 10|gblAAY98075. 1; 168508833|gblAAY98065.1 ; |68508618|gblAAY98055. 1; |68508532|gblAAY98045.1 ; 20 |67062609|gblAAY64410.1|; |67062088|gblAAY64400. 1; 167061918|gblAAY64390.1|; |67061126|gblAAY64380.1 ; |67060437|gblAAY64370. 1; |67060204|gblAAY64360.1 ; |67059004|gblAAY64340.1 ; 167058941 gblAAY64330. 1; 167058361 gblAAY64320.1 ; |67058343|gblAAY643 10.1|; |67058325|gblAAY64300. 1; |67058307|gblAAY64290.1 ; |67058289|gblAAY64280. 1; |67057788|gblAAY64270. 1; |67051428|gblAAY64260. 1; 25 |67050142|gblAAY64250.1 ; |67045900|gblAAY64240. 1; |67045484|gblAAY64230.1 ; |67044535|gblAAY64220.1|; |67044368|gblAAY64210.1|; |67044270|gblAAY64200.1|; |67044170|gblAAX57872.2|; |66947428|gblAAY59043. 1; |66475132|gblAAY47093. 1; |66475070|gblAAY47060. 1; |66474984|gblAAY47021 .1; |66473609|gblAAY46444. 1; 166473591 gblAAY46434.1 ; 166473573|gblAAY46424. 1; 166473503|gblAAY46399.1 ; 30 166473481 gblAAY46389.1 ; 166473461 gblAAY46379. 1; |66356029|gblAAY45654.1 ; |66354538|gblAAY44914.1|; 1663545201gblAAY44904. 1; |66354426|gblAAY44894.1 ; |66354022|gblAAY44804. 1; |66354002|gblAAY44793. 1; |66353984|gblAAY44783. 1; |66353884|gblAAY44773.1 ; |66353866|gblAAY44763. 1; |66346643|gblAAY44669.1 ; |66346057|gblAAY44659. 1; |66327477|gblAAY44649. 1; 166319071 gblAAY44639. 1; 35 |66315260|gblAAY44629.1 ; |66303399|gblAAY44618. 1; 163053695|gblAAY28656.1 ; |63053677|gblAAY28646.1|; |63053659|gblAAY28636.1|; 163053641|gblAAY28626.1|; |63053623|gblAAY28616.1|; |63053540|gblAAY28599. 1; |63053508|gblAAY28589.1 ; |63053490|gblAAY28579.1 ; 163053471 gblAAY28569. 1; |63047712|gblAAY28559.1 ; |63038408|gblAAY28549.1 ; |63034469|gblAAY28539. 1; 163034451 gblAAY28529.1 ; 40 |63034238|gblAAY285 10.1|; |63034207|gblAAY28413. 1; |63034189|gblAAY28403.1 ; |63034170|gblAAY28393.1 ; |63034134|gblAAY28373. 1; |63034118|gblAAY28364.1 ; |63034098|gblAAY28353.1 ; |63034080|gblAAY28343. 1; |63034062|gblAAY28333.1 ; |63034044|gblAAY28323.1 ; |63034026|gblAAY28313.1|; 163033985|gblAAY28303.1 ; |63033967|gblAAY28293.1 ; |63033949|gblAAY28283. 1; |63033929|gblAAY28273.1 ; 45 |63033426|gblAAY28022.1 ; |63033408|gblAAY28012.1|; |63033389|gblAAY28002.1 ; |63033344|gblAAY27967.1 ; |63029999|gblAAY27871 .1; 163029981 gblAAY27861.1|; 163029961|gblAAY27851.1|; 162871493|gblAAY18619.1|; 162871301|gblAAY18596.1|; 162871275|gblAAY18578.1|; 162870095|gblAAY18204. 1; |62870077|gblAAY18194.1|; |62870059|gblAAY18184.1|; 162870041|gblAAY18174.1|; 162870023|gblAAY18164.1|; 46 3745052_1 (GHMatters) P78534.AU.1 |62870005|gblAAY18154.1|; |62869987|gblAAY18144. 1; |62869969|gblAAY18134.1|; 162869951|gblAAY18124.1|; |62869933|gblAAYl8114.1|; |62869915|gblAAY18104.1|; |62869896|gblAAY18094.1|; |62199044|gblAAX76771.1|; |62199026|gblAAX76761.1|; |62198972|gblAAX76731.1|; |62198954|gblAAX76721.1|; |62198918|gblAAX76701.1|; 5 |6219890O0gblAAX76691.1|; |62198864|gblAAX76671.1|; |62198846|gblAAX76661.1|; |62198828|gblAAX7665 1.1|; |62198792|gblAAX7663 1.1; |6197095OgblAAX57952.1 ; |61970932|gblAAX57942.1 ; |61970914|gblAAX57932. 1; |61970896|gblAAX57922.1 ; |61970878|gblAAX57912.1 ; |6197086OgblAAX57902. 1; |61970842|gblAAX57892.1 ; |61970824|gblAAX57882.1 ; |61970788|gblAAX57862. 1; |6197077OgblAAX57852.1 ; 10 |61970752|gblAAX57842.1 ; |61970734|gblAAX57832. 1; |61970716|gblAAX57822.1 ; |61970698|gblAAX57812.1 ; |6197068OgblAAX57802. 1; |61970662|gblAAX57792.1 ; |61970644|gblAAX57782.1 ; |61970626|gblAAX57772. 1; |61970608|gblAAX57762.1 ; |6197059OgblAAX57752.1 ; |61970572|gblAAX57742. 1; |61970552|gblAAX5773 1.1|; |61970536|gblAAX57722.1 ; |61970518|gblAAX57712. 1; 161970500|gblAAX57702.1|; 15 |61970482|gblAAX57692.1 ; |61970464|gblAAX57682. 1; 161970446|gblAAX57672.1|; |61970428|gblAAX57662.1 ; |61970408|gblAAX5765 1.1; |6192824OgblAAX56608.1 ; |61928182|gblAAX56598.1|; |61928120|gblAAX56588.1|; |61928076|gblAAX56578.1|; |61928032|gblAAX56568.1 ; |61927970|gblAAX56558. 1; |61927920|gblAAX56548.1 ; |61927828|gblAAX56528.1 ; |61927777|gblAAX56518.1|; |61927726|gblAAX56508.1 ; 20 |61927673|gblAAX56498.1|; |61927614|gblAAX56488.1|; |61927556|gblAAX56478.1|; |61927508|gblAAX56468.1|; |61927454|gblAAX56458.1|; |61927398|gblAAX56448.1|; |61927350|gblAAX56438.1|; |61927302|gblAAX56428.1|; |61927256|gblAAX56418.1|; |61927208|gblAAX56408.1|; |61927153|gblAAX56398.1|; 161927104|gblAAX56388.1|; 161621015|gblAAX47543.1|; 161620963|gblAAX47533.1|; 161620931|gblAAX47523.1|; 25 161104901 gblAAX38245.1 ; |60738762|gblAAX35879. 1; |60738744|gblAAX35869.1 ; |60738726|gblAAX35859.1 ; |60738708|gblAAX35849. 1; |60738690|gblAAX35839.1 ; |60738672|gblAAX35829.1 ; |60683819|gblAAX34070. 1; |59940545|gblAAX12819.1 ; |59940527|gblAAX12809.1 ; |59940509|gblAAX12799. 1; 159940491 gblAAX12789.1 ; |59940473|gblAAX12779.1 ; |59940453|gblAAX12769. 1; |59940435|gblAAX12759.1 ; 30 |59940417|gblAAX12749.1 ; |59940399|gblAAX12739. 1; |59896566|gblAAX1 1643.1|; |59896548|gblAAX1 1633.1|; 1598965301gblAAX1 1623.1|; |59896512|gblAAX1 1613.1|; |59896494|gblAAX1 1603.1|; |59896476|gblAAX1 1593.1|; |59896458|gblAAX1 1583.1|; 1598964401gblAAX1 1573.1|; |59896422|gblAAX1 1563.1|; |59896404|gblAAX1 1553.1|; |59896386|gblAAX1 1543.1|; |59896368|gblAAX1 1533.1|; 1598963501gblAAX1 1523.1|; 35 |59896332|gblAAX1 1513.1|; |59896314|gblAAX1 1503.1|; |59896296|gblAAX1 1493.1|; |59896278|gblAAX1 1483.1|; 1598962601gblAAX1 1473.1|; |59896242|gblAAX1 1463.1|; |70907654|gblAAX56539.2|; |67059564|gblAAY64350. 1; |66475114|gblAAY47083.1 ; |5732303|gblAAD49027.1|AF156417_1|; |62199008|gblAAX76751.1|; |50235443|gblAAT70828. 1; |50083052|gblAAT70178.1 ; |51512158|gblAAU05322.1 ; 40 |33318109|gblAAQ04928.1|AF508639_1|; |33318107|gblAAQ04927.1|AF508638_1|; |33318105|gblAAQ04926.1|AF508637_1|; 133318103|gblAAQ04925.1|AF508636_1|; |33318097|gblAAQ04922.1|AF508633_1|; 133318095|gblAAQ04921.1|AF508632_1|; 133318091|gblAAQ04919.1|AF508630_1|; |33318089|gblAAQ04918.1|AF508629_1|; |33318085|gblAAQ04916.1|AF508627_1|; |41207493|gblAAR99632.1|; 45 |21902311|gblAAM78509.1|AF483601_1|; 18496104|emblCAD20323.1|; |12038896|emblCAC19698.1|; 10442693|gblAAG17436.1|AF285891_1|; 19887185|gblAAG1787.1|AF251429_1|; 19887168|gblAAG1778.1|AF251421_1|; 19887151|gblAAG1769.1|AF251413_1|; 19887134|gblAAG1760.1|AF251405_1|; 19887117|gblAAG1751.1|AF251397_1|; 19887103|gblAAG1744.1|AF251390_1|; 47 3745052_1 (GHMatters) P78534.AU.1 |8894712|emblCAB95865. 1; |8894710|emblCAB95864.1 ; |8894708|emblCAB95863.1 ; |8515437|gblAAF76001.1|AF250130_1|; |5732317|gblAAD49034.1|AF156424_1|; |5732327|gblAAD49039.1 |AF156429_1 ; |5732319|gblAAD49035.1 AF156425_1 ; |5732315|gblAAD49033.1|AF156423_1|; 15732313|gblAAD49032.1|AF156422_1|; 5 |5732311|gblAAD49031.1|AF156421_1|; |5732309|gblAAD49030.1|AF156420_1|; |5732307|gblAAD49029.1|AF156419_1|; 15732305|gblAAD49028.1|AF156418_1|; |5732301|gblAAD49026.1|AF156416_1|; |3722129|gblAAC63454.1|; |3722127|gblAAC63453.1 ; 13722125|gblAAC63452. 1; 13722123|gblAAC6345 1.11; 13722121|gblAAC63450.1|; |3722119|gblAAC63449.1|; |372195OgblAAC63412.1|; 10 |3721948|gblAAC63411.1|; |3721946|gblAAC63410.1|; |3721944|gblAAC63409.1|; |324978|gblAAA19212. 1; |324976|gblAAA1921 1.1; |324974|gblAAA19210.1 ; |5861843OgblAAW80713.1 ; |58618428|gblAAW80712.1 ; 121636441 gblAAM69995.1 AF457706_1 ; |21636405|gblAAM69975.1 AF4576901 |; |21636387|gblAAM69965.1 |AF457682_1 ; |21636367|gblAAM69954.1 |AF4576731 |; 15 |21636363|gblAAM69952.1 AF457671_1 ; |324966|gblAAA43644. 1; |27596988|reflNP_775530.1|; |63054913|gblAAY28993.1 ; 160547103|gblAAX23573.1 ; |58618426|gblAAW80711.1|; |21693165|gblAAM75156.1|AF389116_1|; |14009686|gblAAK51715.1|; 14009684|gblAAK51714.1|; 19954393|gblAAG09041.1|; |324968|gblAAA43645. 1; |324964|gblAAA43643. 1; |324962|gblAAA43642.1 ; 20 13249601gblAAA43641 .1; |324958|gblAAA43640. 1; |324956|gblAAA43639.1 ; |324954|gblAAA43638. 1; |324952|gblAAA43637. 1; 13249501gblAAA43636.1 ; |324948|gblAAA43635. 1; |324946|gblAAA43634. 1; |324944|gblAAA43633.1 ; |324942|gblAAA43632. 1; 133503|splP27153|RRP1_DHVI1l; |279899|pir|A60008|; |279898|pir|B6001 1; |67089|pir|P1IV61|; |77917350|gblABB05224. 1; 25 177917331 gblABB05213. 1; 1779173 12|gblABB05202. 1; |77869502|gblABB05191.1|; |77863505|gblABB05013. 1; |77863486|gblABB05002. 1; |77863467|gblABB04991.1|; |77863448|gblABB04980. 1; |77863429|gblABB04969. 1; |77863410|gblABB04958. 1; 177863391 gblABB04947. 1; |77863372|gblABB04936. 1; 177863353 gblABB04925. 1; |77863334|gblABB04914. 1; 177861881 gblABB04379. 1; |77861862|gblABB04368.1 ; 30 |77861843|gblABB04357. 1; |77861824|gblABB04346. 1; 177861805|gblABB04335.1 ; |77861786|gblABB04324. 1; |77861767|gblABB04313.1|; 177861748|gblABB04302. 1; |77861729|gblABB04291.1|; |77747474|gblABB03153.1|; 177747455|gblABB03142.1|; |77747436|gblABB03131.1|; |77747416|gblABB03120.1|; |77747397|gblABB03109.1|; |77747378|gblABB03098. 1; |77747359|gblABB03087. 1; 1777473401gblABB03076. 1; 35 |77747319|gblABB03065. 1; |77747300|gblABB03054. 1; 177747281 gblABB03043. 1; |77747262|gblABB03032. 1; 177747243 gblABB03021.1|; |77747224|gblABB03010.11; 177747205|gblABB02999. 1; |77747186|gblABB02988. 1; 177747165 gblABB02977. 1; |77747146|gblABB02966.1|; |77747127|gblABB02955.1|; |77747108|gblABB02944.1|; |77747087|gblABB02932. 1; 177747068|gblABB02921.1|; |77747049|gblABB02910.11; 40 177747003|gblABB02899. 1; |77746984|gblABB02888. 1; 177746965 gblABB02877. 1; |77746946|gblABB02866. 1; |77746927|gblABB02855.1|; |77746906|gblABB02844. 1|; |77746887|gblABB02833. 1; 177746868|gblABB02822. 1; |77746849|gblABB028 11.1|; |77746830|gblABB02800. 1; 177746811 gblABB02789. 1; |66733937|gblAAY52743. 1; |66733935|gblAAY52742.1 ; |66733933|gblAAY52741 .1; 166733931 gblAAY52740.1 ; 45 |66733929|gblAAY52739.1 ; |66733927|gblAAY52738. 1; |66733925|gblAAY52737.1 ; |66733923|gblAAY52736.1 ; 166733921 gblAAY52735. 1; |66733919|gblAAY52734.1 ; |66733917|gblAAY52733.1 ; |66733915|gblAAY52732. 1; |66733913|gblAAY5273 1.1|; 166733911 gblAAY52730.1 ; |66733909|gblAAY52729. 1; |66733907|gblAAY52728.1 ; |66733905|gblAAY52727.1 ; |66733903|gblAAY52726. 1; 166733901 gblAAY52725.1 ; 48 3745052_1 (GHMatters) P78534.AU.1 |66733899|gblAAY52724.1 ; |66733897|gblAAY52723. 1; |66733895|gblAAY52722.1 ; |66733893|gblAAY52721.1|; 166733891 gblAAY52720. 1; |66733889|gblAAY52719.1 ; |66733887|gblAAY52718.1|; |66733885|gblAAY52717. 1; |66733883|gblAAY52716.1 ; |13925401|gblAAK49363.1|AF258827_1|; 132746401gblAAK18014.1|AF258823_1|; 5 13274638|gblAAK18013.1|AF258822_1|; |50296446|gblAAT73499.1|; |8307775|gblAAF74316.1 AF084266_1 ; 18307773 gblAAF74315.1 AF084265_1 ; 18307771|gblAAF74314.1|AF084264_1|; |73852949|reflYP_308665.1|; |71013490|dbjlBAE07199. 1; 154610035|gblAAV35116.1|; |54299856|gblAAV32652. 1; |54299842|gblAAV32644.1|; 13925398|gblAAK49362.1|AF258826_1|; 10 13925395|gblAAK49361.1|AF258825_1|; 13925392|gblAAK49360.1|AF258824_1|; |13925389|gblAAK49359.1|AF258821_1|; 13925386|gblAAK49358.1|AF258820_1|; |13925383|gblAAK49357.1|AF258819_1|; 139253801gblAAK49356.1|AF258818_1|; |13925377|gblAAK49355.1|AF258817_1|; 13925374|gblAAK49354.1|AF258816_1|; 147156561|gblAAT12168.1|; |47156559|gblAAT12167.1|; |47156557|gblAAT12166.1|; 15 |47156555|gblAAT12165.1|; 147156553|gblAAT12164.1|; 147156551|gblAAT12163.1|; |47156549|gblAAT12162.1|; |47156547|gblAAT12161.1|; 147156545|gblAAT12160.1|; |47156543|gblAAT12159.1|; 147156541|gblAAT12158.1|; |47156539|gblAAT12157.1|; |47156537|gblAAT12156. 1; 147156535|gblAAT12155.1 ; 147156533|gblAAT12154.1 ; 14715653 1|gblAAT12153.1|; |47156529|gblAAT12152.1 ; |47156527|gblAAT1215 1.1|; 20 |47156525|gblAAT12150.1|; 147156523|gblAAT12149.1|; 147156521|gblAAT12148.1|; |1430831|emblCAA67498.1|; 19422189|gblAAL87925.1|AF455727_1|; |19422183|gblAAL87922.1|AF455724_1|; 19422181|gblAAL87921.1|AF455723_1|; |14532423|gblAAK64188.1|; 13661046|emblCAC37002.1|; |5805279|gblAAD51923.1|; |57916067|gblAAW59406.1 ; |57916013|gblAAW59396. 1; |57915966|gblAAW59388.1 ; 25 |47716769|gblAAT37561 .1; |58531173|dbjlBAD89344.1 ; 158531153|dbjlBAD89333.1 ; |58531135|dbjlBAD89323.1|; |58531117|dbjlBAD89313.1|; |58531085|dbjlBAD89303.1|; |50956624|gblAAT90830. 1; 150296498|gblAAT73525. 1; 150296468|gblAAT735 10.1|; |50296462|gblAAT73507. 1; 150296458|gblAAT73505.1 ; |50296456|gblAAT73504.1 ; |50296454|gblAAT73503. 1; |50296452|gblAAT73502.1 ; |50296450|gblAAT73501.1|; 30 |50296448|gblAAT73500. 1; |50296444|gblAAT73498. 1; |50296440|gblAAT73496. 1; |50296438|gblAAT73495. 1; |50296436|gblAAT73494. 1; |50296432|gblAAT73492. 1; |50296430|gblAAT73491 .1; |50296428|gblAAT73490. 1; |50296416|gblAAT73484. 1; |50296414|gblAAT73483. 1; |50296412|gblAAT73482. 1; |37963694|gblAAR05984.1 ; |37963692|gblAAR05983.1 ; |37963696|gblAAR05985.1 ; |38524562|dbjlBAD02360. 1; 35 |38524542|dbjlBAD02349. 1; |24286097|gblAAN46833. 1; |61612044|gblAAX47280. 1; |61612038|gblAAX47279.1|; |71000178|dbjlBAE07153.1|; 130025725|gblAAP04506.1|; |70905275|gblAAZ14161.1|; 170905273|gblAAZ14160.1|; 170905271|gblAAZ14159.1|; |70905269|gblAAZ14158. 1; |70905267|gblAAZ14157. 1; 170905265|gblAAZ14156.1 ; |70905263|gblAAZ14155.1|; 170905261|gblAAZ14154.1|; |70905259|gblAAZ14153.1|; 40 |70905257|gblAAZ14152. 1; 170905255|gblAAZ1415 1.1; 170905253|gblAAZ14150.1 ; |3335435|gblAAC32096.1 ; 13335415|gblAAC32085.1 ; 1565488701gblAAV97600.1 ; |56548868|gblAAV97599.1|; |56548866|gblAAV97598.1|; |56548864|gblAAV97597.1|; |56424948|gblAAV91207.1|; 156424946|gblAAV91206.1|; 156424942|gblAAV91204.1|; |50542650|gblAAT78590. 1; |50365727|gblAAT76165. 1; |47834828|gblAAT39049. 1; 45 |47834824|gblAAT39047. 1; |47834822|gblAAT39046. 1; |47834814|gblAAT39042. 1; |47834812|gblAAT39041 .1; |40732896|emblCAF04464. 1; 14275693|emblCAC40038. 1; |13383273|dbjlBAB39508.1|; 13383271|dbjlBAB39507.1|; 13661044|emblCAC37001.1|; |28823019|gblAAO46859.1 ; |28822828|gblAAO46858. 1; |28822609|gblAAO46857.1 ; |28822076|gblAAO46856.1 ; |28821871 gblAAO46855. 1; |28821644|gblAAO46854.1 ; 49 3745052_1 (GHMatters) P78534.AU.1 |28821462|gblAAO46853.1 ; |28821280|gblAAO46852. 1; |28821223|gblAAO4685 1.1|; |27462113|gblAAO15325.1|AF225521_1|; |27462111|gblAAO15324.1|AF2255201|; |27462109|gblAAO15323.1|AF2255191|; |27462107|gblAAO15322.1|AF2255181|; |21359664|gblAAM49557.1 AF4688391 |; |20068025|emblCAC84758. 1; 5 |20068023|emblCAC84686.1|; |20068021|emblCAC84757.1|; |20068019|emblCAC84756.11; |20068017|emblCAC84755.1|; |20068015|emblCAC84754.1|; |20068007|emblCAC84750. 1; |19697848|gblAAL31425.1|; 19697846|gblAAL31424.1|; 19697836|gblAAL31419.1|; |19422195|gblAAL87928.1|AF4557301|; 19422193|gblAAL87927.1|AF4557291|; |19422191|gblAAL87926.1|AF455728_1|; 19422187|gblAAL87924.1|AF455726_1|; 10 19422185|gblAAL87923.1|AF455725_1|; 16076717|gblAAL14089.1|AF2228191|; |16076715|gblAAL14088.1|AF2228181|; 13661048|emblCAC37003.1|; 184528501gblAAF75122.1|AF115293_1|; |8452848|gblAAF75121.1|AF115292_1|; |323669|gblAAA42968. 1; 133517|splP16508|RRP1_IAMANI; |133523|splP03430|RRP1_IAWIL|; |2506782|sp P16506|RRP1_IAKOR|; 15 133527|splP16512|RRP1_IAZTFl; 133526|splP165 10|RRP1_IAZONI; |133525|splP16509|RRP1_IAZH3|; 133524|sp P16514|RRP1_IAWIS1; |133522|splP16513|RRP1_IATKMl; |133521|splP16511|RRP1_IASINI; |133518|splP16507|RRP1_IAME8|; |133512|sp lP18882|RRP1_IAKIEl; |133511 splP16505|RRP1_IAHTEl; 133510|splP16504|RRP1_IAHLO|; 20 133509|splP16503|RRP1_IAGU2|; 133506|splP16502|RRP1_IABEII; |6647779|splQ82571|RRP1_IAFOMl; |6647775|splO91741|RRP1_IAKITl; |6647773|splO89749|RRP1_IACKHI; 133531|splP19703|RRP1_INCJJI; |133520|splP03431|RRP1_IAPUEl; 133519|splP03432|RRP1_IANT6|; |133505|splP21426|RRP1_IAANNI; |401026|splP31341|RRP1_IAVI7|; 25 133516|splP26121|RRP1_IALE3|; 133515|splP26120|RRP1_IALE2|; |133514|splP26119|RRP1_IALE1|; |133508|splP26118|RRP1_IADUN|; 134733402|gblAAQ81638.1|; |34733400|gblAAQ81637.11; 19863938|gblAAG01228.1|AF2167401|; 198639201gblAAG01218.1|AF2167321|; 19863902|gblAAG01208.1|AF2167241|; 19863883|gblAAG01198.1|AF2167161|; 30 13249801gblAAA43647.1|; 13249701gblAAA43646.1. The preferred influenza strains referred to in the present invention, for example against which the present polypeptides should be immunogenic, are those containing these specific proteins. The above accesion numbers specify explicitly the identity of the strain in addition to the 35 specific protein sequence. In some preferred embodiments the polypeptide according to the present invention may comprise one or more sequences as described above and having at least 60% homology with a consensus sequence over known human and avian influenza virus strains (or two or more 40 epitopes of 7 amino acids or more having at least 60% homology with such a sequence). In further preferred embodiments the polypeptide may comprise one or more sequences as described above and having at least 60% homology with a consensus sequence over known 50 3745052_1 (GHMatters) P78534.AU.1 human influenza virus strains (or two or more epitopes of 7 amino acids or more having at least 60% homology with such a sequence). The percent homology of a first polypeptide sequence to a second polypeptide sequence, as 5 referred to in the context of the present invention, is defined as the number of amino acid residues in the second sequence that match in both position and identity to those in the first sequence, divided by the total number of amino acid residues in the second polypeptide (both first and second polypeptides must have the same number of amino acid residues) and multiplied by 100. In the present invention, it is preferred that the polypeptide homology to 10 the defined sequences is 7 5% or more, 85% or more, 95% or more or 100% (or substantially 100%). The epitopes within the sequences defined above are not especially limited, provided that they contain 7 amino acid residues or more. Preferably the epitopes are of a length that is 15 appropriate for CTL epitopes in a particular vertebrate species, such as in a human, having a specific MHC. Typically the epitopes contain 8, 9, 10, or 11 amino acid residues, but may contain more if desired. Generally an appropriate epitope is one which is a CTL epitope in a vertebrate such as a human. 20 Typically, the polypeptide comprises between 7 and 100 amino acids, and preferably from 8-50 amino acids. The size should not be so great that useful epitopes suffer from competition with non-protective epitopes in the immune system (for this reason full proteins are not included), nor should the size be so small that only a very narrow range of protection is offered. More preferred ranges are from 8-40 amino acids, 15-40 amino acids and 15-35 25 amino acids. The most preferred length is from 20-35 amino acid residues. It is particularly preferred that the polypeptide consists of (or substantially consists of) a sequence selected from the sequences at the positions defined above in the specific list of proteins set out above. 30 In addition to the polypeptides described above, which should not be larger than 100 amino acid residues in length, the invention also provides multi-epitope immunogenic polypeptides comprising two or more polypeptides of the present invention. These multi-epitope polypeptides are not limited in size. Thus, they extend not only to the polypeptides having 51 3745052_1 (GHMatters) P78534.AU.1 from 7-100 amino acid residues as outlined above, but also to larger polypeptides, provided that these larger polypeptides comprise two or more units, each unit consisting of a polypeptide of the invention. Thus, a polypeptide having 100 repeating units of a 7-mer according to the present invention is encompassed by the present invention, as is a 5 polypeptide having, say 52 units of one 8-mer epitope, and 23 units of a second 10-mer epitope. Polypeptides of this type will not suffer from the competition problems associated with similar length polypeptides that comprise only one or two epitopes. For the avoidance of doubt, the multi-epitope polypeptide may comprise multiple copies of the same epitope, or single copies of a plurality of different epitopes, or multiple copies of 2 or more epitopes. 10 Also provided by the invention is a polypeptide composition comprising two or more different polypeptides as defined above. Thus, the polypeptide composition may comprise any number of polypeptides of the present invention together in the same mixture or formulation. The presence of a plurality of polypeptides together is useful since each may 15 elicit its own immune response, widening the protective effect of the composition. It is particularly preferred that the composition contains all of the sequences of SEQ ID 1-6 either each in a separate peptide or several in a smaller number of peptides (e.g. 3 combined in one larger peptide and the other three 3 in another larger peptide, etc.). 20 The invention also provides a polypeptide construct, which construct comprises a polypeptide as defined above and a carrier. The construct may be formed by combining two or more epitopes and/or a polypeptide as defined above with the carrier. The carrier may be a molecule, such as an adjuvant and/or an excipient. Combining in this context means either mixing together, or attaching together (e.g. via a covalent linkage). 25 The present invention further provides a polypeptide as defined above for use in medicine. Also provided is a medicament or vaccine composition against influenza, comprising a polypeptide as defined above, and one or more appropriate excipients and/or adjuvants, or a polypeptide construct as defined above and optionally one or more appropriate excipients 30 and/or adjuvants (if the carrier part of the construct is itself an excipient or adjuvant, then a further excipient or adjuvant may not be needed). The excipient or adjuvant is not especially limited, and any excipients or adjuvants used in medicaments and vaccines may be employed. The medicament or vaccine composition may be produced according to any 52 3745052_1 (GHMatters) P78534.AU.1 known method appropriately adapted to the present invention, such as by mixing a polypeptide of the invention with an appropriate excipient. A method of producing a polypeptide as defined above is also provided by the invention. 5 The method is not especially limited, and typically comprises joining two or more epitopes to form the polypeptide. The polypeptide may, however, be synthesised by direct chemical synthesis (e.g. incorporating one amino acid at a time until the full polypeptide is formed) or by recombinant methods. Such general methods are well known to the skilled person and may be adapted to the present invention as desired. In some instances, the polypeptide of the 10 present invention may comprise additional amino acid sequences at one or both termini to help in synthesis of the polypeptide. These additional sequences are preferably from 1-5 amino acids in length. Typically 3 amino acids are involved. For example, in one preferred embodiment, SEQ ID 6 comprises the amino acids AAS immediately prior to the IIG part of the sequence. 15 The invention still further provides use of a polypeptide or composition as defined above, in the manufacture of a medicament or vaccine, effective in the treatment or prevention of influenza. Also provided is a method of treating or preventing influenza, which method comprises administering a polypeptide, a composition, a medicament or a vaccine as defined 20 above to a vertebrate. The method of administration is not especially limited, and may comprise subcutaneous, intramuscuscular, intra-venous, intra-dermal, or intra-nasal administration, or may be administered orally (e.g. in the form of a pill or a liquid preparation), or may be in the form of a suppository, if desired. The form of such administration preparations is not especially limited, and known forms may be employed 25 with appropriate modifications that will be apparent to the skilled person. The dosage is not especially limited and may range from 1 pg to 100 g of the polypeptide per individual, depending upon the size, weight and species of the individual involved. The invention may be applied to any vertebrate, since the immune systems of vertebrates 30 operate in a related manner. Typically, the vertebrate referred to in the present context is a mammal, bird, a reptile or a fish. It is especially preferred that the vertebrate is a human, a domestic animal (such as a dog or a cat), a farm animal (such as a pig or a horse), a bovine 53 3745052_1 (GHMatters) P78534.AU.1 animal (such as cattle, or a cow), or fowl (such as a domestic bird, a farm bird, or a game bird). When the vertebrate is a bird, it is preferably a chicken, a turkey, a duck, or a goose. Examples of human MHCs (HLAs) that may be employed with the present invention include 5 the following: HLA-A A*010101, A*010102, A*010103, A*0102, A*0103, A*0104N, A*0106, A*0107, A*0108, A*0109, A*0110, A*02010101, A*02010102L, A*020102, A*020103, A*020104, 10 A*020105, A*020106, A*020107, A*020108, A*020109, A*020110, A*020111, A*0202, A*020301, A*020302, A*0204, A*0205, A*020601, A*020602, A*020603, A*0207, A*0208, A*0209, A*0210, A*0211, A*0212, A*0213, A*0214, A*0215N, A*0216, A*021701, A*021702, A*0218, A*0219, A*022001, A*022002, A*0221, A*0222, A*0224, A*0225, A*0226, A*0227, A*0228, A*0229, A*0230, A*0231, A*0232N, A*0233, 15 A*0234, A*023501, A*023502, A*0236, A*0237, A*0238, A*0239, A*0240, A*0241, A*0242, A*0243N, A*0244, A*0245, A*0246, A*0247, A*0248, A*0249, A*0250, A*0251, A*0252, A*0253N, A*0254, A*0255, A*0256, A*0257, A*0258, A*0259, A*0260, A*0261, A*0262, A*0263, A*0264, A*0265, A*0266, A*0267, A*0268, A*0269, A*0270, A*0271, A*0272, A*0273, A*03010101, A*03010102N, A*03010103, A*030102, 20 A*030103, A*0302, A*0303N, A*0304, A*0305, A*0306, A*0307, A*0308, A*0309, A*0310, A*0311N, A*0312, A*0313, A*0314, A*110101, A*110102, A*1102, A*1103, A*1104, A*1105, A*1106, A*1107, A*1108, A*1109, A*1110, A*1111, A*1112, A*1113, A*1114, A*1115, A*1116, A*1117, A*1118, A*1119, A*2301, A*2302, A*2303, A*2304, A*2305, A*2306, A*2307N, A*2308N, A*2309, A*2310, A*2311N, A*2312, A*24020101, 25 A*24020102L, A*240202, A*240203, A*240204, A*240205, A*240206, A*240301, A*240302, A*2404, A*2405, A*2406, A*2407, A*2408, A*2409N, A*2410, A*2411N, A*2413, A*2414, A*2415, A*2417, A*2418, A*2419, A*2420, A*2421, A*2422, A*2423, A*2424, A*2425, A*2426, A*2427, A*2428, A*2429, A*2430, A*2431, A*2432, A*2433, A*2434, A*2435, A*2436N, A*2437, A*2438, A*2439, A*2440N, A*2441, A*2442, 30 A*2443, A*2444, A*2445N, A*2446, A*250101, A*250102, A*2502, A*2503, A*2504, A*2601, A*2602, A*2603, A*2604, A*2605, A*2606, A*260701, A*260702, A*2608, A*2609, A*2610, A*2611N, A*2612, A*2613, A*2614, A*2615, A*2616, A*2617, A*2618, A*2619, A*2620, A*2621, A*2622, A*2623, A*29010101, A*29010102N, 54 3745052_1 (GHMatters) P78534.AU.1 A*290201, A*290202, A*290203, A*2903, A*2904, A*2905, A*2906, A*2907, A*2908N, A*2909, A*29 10, A*291 1, A*300 10 1, A*300102, A*30020 1, A*300202, A*3003, A*3004, A*3006, A*3007, A*3008, A*3009, A*3010, A*3011, A*3012, A*310102, A*3102, A*3103, A*3104, A*3105, A*3106, A*3107, A*3108, A*3109, A*3110, A*3201, A*3202, 5 A'*32O3, A*3204, A*3205, A*3206, A*3207, A*3208, A*3301, A*330301, A*330302, A*3304, A*3305, A*3306, A*3307, A*3401, A*3402, A*3403, A*3404, A*3405, A*3406, A*3601, A*3602, A*3603, A*3604, A*4301, A*6601, A*6602, A*6603, A*6604, A*680101, A*680102, A*680103, A*6802, A*680301, A*680302, A*6804, A*6805, A*6806, A*6807, A*6808, A*6809, A*6810, A*6811N, A*6812, A*6813, A*6814, 10 A*6815, A*6816, A*6817, A*6818N, A*6819, A*6820, A*6821, A*6822, A*6823, A*6824, A*6825, A*6826, A*6827, A*6901, A*7401, A*7402, A*7403, A*7404, A*7405, A*7406, A*7407, A*7408, A*7409, A*7410, A*8001. HLA-B 15 B'*O7O2O1, B*070202, B*070203, B*070204, B*0703, B*0704, B*0705, B*0706, B*0707, B*0708, B*0709, B*0710, B*0711, B*0712, B*0713, B*0714, B*0715, B*0716, B*0717, B*0718, B*0719, B*0720, B*0721, B*0722, B*0723, B*0724, B*0725, B*0726, B*0727, B*0728, B*0729, B*0730, B*0731, B*0732, B*0733, B*0734, B*0735, B*0736, B*0737, B*0738, B*0801, B*0802, B*0803, B*0804, B*0805, B*0806, B*0807, B*0808N, B*0809, 20 B*0810, B*0811, B*0812, B*0813, B*0814, B*0815, B*0816, B*0817, B*0818, B*0819N, B*0820, B*0821, B*0822, B*1301, B*1302, B*1303, B*1304, B*1306, B*1307N, B*1308, B*1309, B*1310, B*1311, B*1312, B*1313, B*1401, B*1402, B*1403, B*1404, B*1405, B*140601, B*140602, B*15010101, B*15010102N, B*150102, B*150103, B*150104, B*150105, B*1502, B*1503, B*1504, B*1505, B*1506, B*1507, B*1508, B*1509, B*1510, 25 B*151101, B*151102, B*1512, B*1513, B*1514, B*1515, B*1516, B*15170101, B*15170102, B*1518, B*1519, B*1520, B*1521, B*1523, B*1524, B*1525, B*1526N, B*1527, B*1528, B*1529, B*1530, B*1531, B*1532, B*1533, B*1534, B*1535, B*1536, B*1537, B*1538, B*1539, B*1540, B*1542, B*1543, B*1544, B*1545, B*1546, B*1547, B*1548, B*1549, B*1550, B*1551, B*1552, B*1553, B*1554, B*1555, B*1556, B*1557, 30 B*1558, B*1560, B*1561, B*1562, B*1563, B*1564, B*1565, B*1566, B*1567, B*1568, B*1569, B*1570, B*1571, B*1572, B*1573, B*1574, B*1575, B*1576, B*1577, B*1578, B*1579N, B*1580, B*1581, B*1582, B*1583, B*1584, B*1585, B*1586, B*1587, B*1588, B*1589, B*1590, B*1591, B*1592, B*1593, B*1594N, B*180101, B*180102, B*1802, 55 3745052_1 (GH Matters) P78534.AU.1 B*1803, B*1804, B*1805, B*1806, B*1807, B*1808, B*1809, B*1810, B*1811, B*1812, B*1813, B*1814, B*1815, B*1817N, B*1818, B*1819, B*1820, B*2701, B*2702, B*2703, B*2704, B*270502, B*270503, B*270504, B*270505, B*270506, B*270507, B*2706, B*2707, B*2708, B*2709, B*2710, B*2711, B*2712, B*2713, B*2714, B*2715, B*2716, 5 B*2717, B*2718, B*2719, B*2720, B*2721, B*2723, B*2724, B*2725, B*2726, B*350101, B*350102, B*3502, B*3503, B*3504, B*3505, B*3506, B*3507, B*3508, B*350901, B*350902, B*3510, B*3511, B*3512, B*3513, B*351401, B*351402, B*3515, B*3516, B*3517, B*3518, B*3519, B*3520, B*3521, B*3522, B*3523, B*3524, B*3525, B*3526, B*3527, B*3528, B*3529, B*3530, B*3531, B*3532, B*3533, B*3534, B*3535, B*3536, 10 B*3537, B*3538, B*3539, B*3540N, B*3541, B*3542, B*3543, B*3544, B*3545, B*3546, B*3547, B*3548, B*3549, B*3550, B*3551, B*3552, B*3553N, B*3701, B*3702, B*3703N, B*3704, B*3705, B*3706, B*3707, B*3801, B*380201, B*380202, B*3803, B*3804, B*3805, B*3806, B*3807, B*3808, B*3809, B*3810, B*390101, B*390103, B*390104, B*390201, B*390202, B*3903, B*3904, B*3905, B*390601, B*390602, 15 B*3907, B*3908, B*3909, B*3910, B*3911, B*3912, B*3913, B*3914, B*3915, B*3916, B*3917, B*3918, B*3919, B*3920, B*3922, B*3923, B*3924, B*3925N, B*3926, B*3927, B*3928, B*3929, B*3930, B*3931, B*3932, B*400101, B*400102, B*400103, B*400104, B*400105, B*400201, B*400202, B*4003, B*4004, B*4005, B*40060101, B*40060102, B*4007, B*4008, B*4009, B*4010, B*4011, B*4012, B*4013, B*401401, B*401402, 20 B*401403, B*4015, B*4016, B*4018, B*4019, B*4020, B*4021, B*4022N, B*4023, B*4024, B*4025, B*4026, B*4027, B*4028, B*4029, B*4030, B*4031, B*4032, B*4033, B*4034, B*4035, B*4036, B*4037, B*4038, B*4039, B*4040, B*4042, B*4043, B*4044, B*4045, B*4046, B*4047, B*4048, B*4049, B*4050, B*4051, B*4052, B*4053, B*4054, B*4055, B*4056, B*4057, B*4101, B*4102, B*4103, B*4104, B*4105, B*4106, B*4201, 25 B*4202, B*4204, B*420501, B*420502, B*4206, B*44020101, B*44020102S, B*440202, B*440203, B*440301, B*440302, B*4404, B*4405, B*4406, B*4407, B*4408, B*4409, B*4410, B*4411, B*4412, B*4413, B*4414, B*4415, B*4416, B*4417, B*4418, B*4419N, B*4420, B*4421, B*4422, B*4423N, B*4424, B*4425, B*4426, B*4427, B*4428, B*4429, B*4430, B*4431, B*4432, B*4433, B*4434, B*4435, B*4436, B*4437, B*4438, B*4439, 30 B*4440, B*4501, B*4502, B*4503, B*4504, B*4505, B*4506, B*4507, B*4601, B*4602, B*4603, B*4604, B*47010101, B*47010102, B*4702, B*4703, B*4704, B*4705, B*4801, B*4802, B*4803, B*4804, B*4805, B*4806, B*4807, B*4808, B*4809, B*4810, B*4901, B*4902, B*4903, B*5001, B*5002, B*5004, B*510101, B*510102, B*510103, B*510104, 56 3745052_1 (GHMatters) P78534.AU.1 B*510105, B*510201, B*510202, B*5103, B*5104, B*5105, B*5106, B*5107, B*5108, B*5109, B*5110, B*5111N, B*5112, B*511301, B*511302, B*5114, B*5115, B*5116, B*5117, B*5118, B*5119, B*5120, B*5121, B*5122, B*5123, B*5124, B*5126, B*5127N, B*5128, B*5129, B*5130, B*5131, B*5132, B*5133, B*5134, B*5135, B*5136, B*520101, 5 B'*52O1O2, B*520103, B*520104, B*5202, B*5203, B*5204, B*5205, B*5206, B*530101, B*530102, B*5302, B*5303, B*5304, B*5305, B*5306, B*5307, B*5308, B*5309, B*5401, B*5402, B*5501, B*5502, B*5503, B*5504, B*5505, B*5507, B*5508, B*5509, B*5510, B*5511, B*5512, B*5513, B*5514, B*5515, B*5516, B*5601, B*5602, B*5603, B*5604, B*560501, B*560502, B*5606, B*5607, B*5608, B*5609, B*5610, B*5611, B*5612, 10 B*5613, B*5614, B*570101, B*570102, B*5702, B*570301, B*570302, B*5704, B*5705, B*5706, B*5707, B*5708, B*5709, B*5801, B*5802, B*5804, B*5805, B*5806, B*5807, B*5808, B*5809, B*5810N, B*5901, B*670101, B*670102, B*6702, B*7301, B*7801, B*780201, B*780202, B*7803, B*7804, B*7805, B*8101, B*8102, B*8201, B*8202, B830 1. 15 HLA-C Cw*010201, Cw*010202, Cw*0103, Cw*0104, Cw*0105, Cw*0106, Cw*0107, Cw*0108, Cw*0109, Cw*O11O, Cw*020201, Cw*020202, Cw*020203, Cw*020204, Cw*020205, Cw*0203, Cw*0204, Cw*0205, Cw*0206, Cw*0207, Cw*0208, Cw*0209, Cw*030201, 20 Cw*030202, Cw*030301, Cw*030302, Cw*030303, Cw*0303 04, Cw*030401, Cw*030402, Cw*030403, Cw*0305, Cw*0306, Cw*0307, Cw*0308, Cw*0309, Cw*0310, Cw*0311, Cw*0312, Cw*0313, Cw*0314, Cw*0315, Cw*0316, Cw*0317, Cw*0318, Cw*04010101, Cw*04010102, Cw*040102, Cw*0403, Cw*040401, Cw*040402, Cw*0405, Cw*0406, Cw*0407, Cw*0408, Cw*0409N, Cw*0410, Cw*0411, Cw*0412, Cw*0413, Cw*0414, 25 Cw*0415, Cw*050101, Cw*050102, Cw*0502, Cw*0503, Cw*0504, Cw*0505, Cw*0506, Cw*0507N, Cw*0508, Cw*0509, Cw*0510, Cw*0602, Cw*0603, Cw*0604, Cw*0605, Cw*0606, Cw*0607, Cw*0608, Cw*0609, Cw*0610, Cw*0611, Cw*070101, Cw*070102, Cw*070103, Cw*07020101, Cw*07020102, Cw*07020103, Cw*0703, Cw*070401, Cw*070402, Cw*0705, Cw*0706, Cw*0707, Cw*0708, Cw*0709, Cw*0710, Cw*0711, 30 Cw*0712, Cw*0713, Cw*0714, Cw*0715, Cw*0716, Cw*0717, Cw*0718, Cw*0719, Cw*0720, Cw*0721, Cw*0722, Cw*0723, Cw*0724, Cw*0725, Cw*0726, Cw*0727, Cw*0728, Cw*0729, Cw*080101, Cw*080102, Cw*0802, Cw*0803, Cw*0804, Cw*0805, Cw*0806, Cw*0807, Cw*0808, Cw*0809, Cw*0810, Cw*0811, Cw*0812, Cw*120201, 57 3745052_1 (GH Matters) P78534.AU.1 Cw*120202, Cw*120203, Cw*120301, Cw*120302, Cw*120303, Cw*120401, Cw*120402, Cw*1205, Cw*1206, Cw*1207, Cw*1208, Cw*1209, Cw*1210, Cw*1211, Cw*1212, Cw*1213, Cw*1214, Cw*1215, Cw*140201, Cw*140202, Cw*140203, Cw*1403, Cw*1404, Cw*1405, Cw*150201, Cw*150202, Cw*1503, Cw*1504, Cw*150501, 5 Cw*150502, Cw*150503, Cw*150504, Cw*1506, Cw*1507, Cw*1508, Cw*1509, Cw*1510, Cw*1511, Cw*1512, Cw*1601, Cw*1602, Cw*160401, Cw*1606, Cw*1701, Cw* 1702, Cw* 1703, Cw* 180 1, Cw* 1802. HLA-E 10 E*O1O1, E*010301, E*010302, E*010303, E*0104. HLA-F F*O1O1O1, F*010102. 15 HLA-G G*O1O1O1, G*010102, G*010103, G*010104, G*010105, G*010106, G*010107, G*010108, G*0102, G*0103, G*010401, G*010402, G*010403, G*0105N, G*0106. HLA-DRA 20 DRA*0101, DRA*010201, DRA*010202. HLA-DRB 1 DRB*O1O1O1, DRB1*010102, DRB*010103, DRB*010201, DRB*010202, DRB*010203, DRB*010204, DRB*0103, DRB*0104, DRB*0105, DRB*0106, 25 DRB*0107, DRB*0108, DRB*0109, DRB*O11O, DRB*O111, DRB*030101, DRB*030102, DRB*030201, DRB*030202, DRB*0303, DRB*0304, DRB*030501, DRB*030502, DRB*0306, DRB*0307, DRB*0308, DRB*0309, DRB*0310, DRB*0311, DRB*0312, DRB*0313, DRB*0314, DRB*0315, DRB*0316, DRB*0317, DRB*0318, DRB*0319, DRB*0320, DRB*0321, DRB*0322, 30 DRB*0323, DRB*0324, DRB*0325, DRB*0326, DRB*0327, DRB*0328, DRB*040101, DRB*040102, DRB*0402, DRB*040301, DRB*040302, DRB*0404, DRB*040501, DRB*040502, DRB*040503, DRB*040504, DRB*0406, DRB*040701, DRB*040702, DRB*040703, DRB*0408, DRB*0409, DRB*0410, 58 3745052_1 (GH Matters) P78534.AU.1 DRB*0411, DRB1*0412, DRB*0413, DRB*0414, DRB*0415, DRB*0416, DRB*0417, DRB1*0418, DRB*0419, DRB*0420, DRB*0421, DRB*0422, DRB*0423, DRB1*0424, DRB*0425, DRB*0426, DRB*0427, DRB*0428, DRB*0429, DRB1*0430, DRB1*0431, DRB*0432, DRB*0433, DRB*0434, 5 DRB1*0435, DRB1*0436, DRB1*0437, DRB*0438, DRB*0439, DRB*0440, DRB*0441, DRB1*0442, DRB1*0443, DRB*0444, DRB*0445, DRB*0446, DRB*0447, DRB1*0448, DRB1*0449, DRB1*0450, DRB*070101, DRB*070102, DRB*0703, DRB1*0704, DRB1*0705, DRB*0706, DRB*0707, DRB*0708, DRB*080101, DRB1*080102, DRB1*080201, DRB*080202, DRB*080203, 10 DRB1*080302, DRB1*080401, DRB1*080402, DRB*080403, DRB*080404, DRB*0805, DRB1*0806, DRB1*0807, DRB*0808, DRB1*0809, DRB*0810, DRB1*0811, DRB1*0812, DRB1*0813, DRB*0814, DRB1*0815, DRB*0816, DRB1*0817, DRB1*0818, DRB1*0819, DRB*0820, DRB1*0821, DRB*0822, DRB*0823, DRB1*0824, DRB*0825, DRB*0826, DRB*0827, DRB*0828, 15 DRB1*0829, DRB*090102, DRB*090103, DRB*0902, DRB*0903, DRB*1001O1, DRBI* 100 102, DRB1*110101, DRB*110102, DRB*110103, DRB*110104, DRB*110105, DRB1*1102, DRB*1103, DRB*110401, DRB*110402, DRB*1105, DRBI* 11060 1, DRB1I* 110602, DRB1I* 1107, DRBI* 11080 1, DRBI* 110802, DRBI* 1109, DRB*111O, DRB1*1111, DRB1*111201, DRB1*111202, DRB*1113, DRB1*1114, 20 DRB1*1115, DRB1*1116, DRB1*1117, DRB*1118, DRB*1119, DRBI* 1120, DRB*1121, DRB1*1122, DRB1*1123, DRB*1124, DRBI* 1125, DRBI* 1126, DRB*112701, DRB1*112702, DRB*1128, DRB1*1129, DRB1*1130, DRB1*1131, DRB*1132, DRB1*1133, DRB1*1134, DRB*1135, DRB1*1136, DRB*1137, DRB1*1138, DRB1*1139, DRB1*1140, DRB*1141, DRB1I* 1142, DRBI* 1143, 25 DRB1*1144, DRB1*1145, DRB*1146, DRB*1147, DRB*1148, DRBI* 1149, DRB*1150, DRB*1151, DRB*1152, DRB*1153, DRB*1154, DRB*120101, DRB*120102, DRB1*120201, DRB1*120202, DRB*120302, DRB1*1204, DRB*1205, DRB*1206, DRB1*1207, DRB*1208, DRB*1209, DRB*1210, DRB*130101, DRB*130102, DRB1*130103, DRB*130201, DRB*130202, DRB*130301, 30 DRB*130302, DRB1*1304, DRB*1305, DRB1*1306, DRB*130701, DRB*130702, DRB*1308, DRB1*1309, DRB1*1310, DRB*1311, DRB*1312, DRB*1313, DRB*131401, DRB1*131402, DRB*1315, DRB*1316, DRB*1317, DRB1*1318, DRB*1319, DRB1*1320, DRB1*1321, DRB*1322, DRB*1323, DRB*1324, 59 3745052_1 (GH Matters) P78534.AU.1 DRB*1325, DRB1*1326, DRB*1327, DRB*1328, DRB*1329, DRB*1330, DRB*1331, DRB1*1332, DRB*1333, DRB*1334, DRB*1335, DRB*1336, DRB*1337, DRB1*1338, DRB*1339, DRB*1340, DRB*1341, DRBI* 1342, DRB*1343, DRB1I* 1344, DRB*1345, DRB*1346, DRB*1347, DRB*1348, 5 DRB1*1349, DRB1*1350, DRB*1351, DRB*1352, DRB*1353, DRB*1354, DRB*1355, DRB1*1356, DRB*1357, DRB*1358, DRB*1359, DRB*1360, DRB*1361, DRB*1362, DRB*1363, DRB*1364, DRB*1365, DRB*140101, DRB*140102, DRB1*1402, DRB*140301, DRB*140302, DRB*1404, DRB*140501, DRB*140502, DRB1*1406, DRB*140701, DRB*140702, DRB*1408, DRB*1409, 10 DRB*1410, DRB 1*1411, DRB1I* 1412, DRBI* 1413, DRBI* 1414, DRBI* 1415, DRB 1*1416, DRB 1*1417, DRB1I* 1418, DRBI* 1419, DRBI* 1420, DRBI* 142 1, DRB 1*1422, DRB 1*1423, DRB1I* 1424, DRBI* 1425, DRBI* 1426, DRBI* 1427, DRB 1*1428, DRB 1*1429, DRB1*1430, DRBI* 143 1, DRB*1432, DRB*1433, DRB*1434, DRB1*1435, DRB1*1436, DRB*1437, DRB*1438, DRB*1439, 15 DRB1I* 1440, DRB1I* 144 1, DRB1I* 1442, DRBI* 1443, DRBI* 1444, DRBI* 1445, DRB*1446, DRB1*1447, DRB1*1448, DRB1*150101, DRB*150102, DRB*150103, DRB*150104, DRB1*150105, DRB1*150201, DRB*150202, DRB*150203, DRB*1503, DRB1*1504, DRB1*1505, DRB*1506, DRB1*1507, DRB*1508, DRB*1509, DRB1*1510, DRB1*1511, DRB*1512, DRB1*1513, DRB*1514, 20 DRB1I* 1515, DRB1I* 1516, DRB1I* 160 10 1, DRB1I* 160102, DRB1I* 16020 1, DRBI* 160202, DRB1*1603, DRB1*1604, DRB1*160501, DRB*160502, DRB*1607, DRB*1608. HLA-DRB2-9 DRB2*O1O1, DRB3*O1O1O1, DRB3*01010201, DRB3*01010202, DRB3*010103, 25 DRB3*010104, DRB3*0102, DRB3*0103, DRB3*0104, DRB3*0105, DRB3*0106, DRB3*0107, DRB3*0108, DRB3*0109, DRB3*0110, DRB3*0111, DRB3*0201, DRB3*020201, DRB3*020202, DRB3*020203, DRB3*020204, DRB3*0203, DRB3*0204, DRB3*0205, DRB3*0206, DRB3*0207, DRB3*0208, DRB3*0209, DRB3*0210, DRB3*0211, DRB3*0212, DRB3*0213, DRB3*0214, DRB3*0215, DRB3*0216, 30 DRB3*0217, DRB3*0218, DRB3*0219, DRB3*030101, DRB3*030102, DRB3*0302, DRB3*0303, DRB4*01010101, DRB4*0102, DRB4*01030101, DRB4*01030102N, DRB4*010302, DRB4*010303, DRB4*010304, DRB4*0104, DRB4*0105, DRB4*0106, DRB4*0107, DRB4*0201N, DRB4*0301N, DRB5*010101, DRB5*010102, DRB5*0102, 60 3745052_1 (GH Matters) P78534.AU.1 DRB5*0103, DRB5*0104, DRB5*0105, DRB5*0106, DRB5*0107, DRB5*0108N, DRB5*0109, DRB5*O11ON, DRB5*O111, DRB5*0112, DRB5*0113, DRB5*0202, DRB5*0203, DRB5*0204, DRB5*0205, DRB6*O1O1, DRB6*0201, DRB6*0202, DRB7*O1O1O1, DRB7*010102, DRB8*O1O1, DRB9*O1O1. 5 HLA-DQA1 DQA*O1O1O1, DQA*010102, DQA*010201, DQA*010202, DQA*0103, DQA*010401, DQA*010402, DQA*0105, DQA*0106, DQA*0107, DQA*0201, DQA*030101, DQA*0302, DQA*0303, DQA*040101, DQA*040102, DQA*0402, 10 DQA*0403N, DQA*0404, DQA*050101, DQA*050102, DQA*0502, DQA*0503, DQAI* 05 04, DQAI* 05 05, DQAI* 060 10 1, DQAI* 060102, DQAI* 0602. HLA-DQB 1 DQB*020101, DQB*020102, DQB*0202, DQB*0203, DQB*030101, DQB*030102, 15 DQB*030201, DQB*030202, DQB*030302, DQB*030303, DQB*0304, DQB*030501, DQB*030502, DQB*030503, DQB*0306, DQB*0307, DQB*0308, DQB*0309, DQB*0310, DQB*0311, DQB*0312, DQB*0313, DQB*0401, DQB*0402, DQB*050101, DQB*050102, DQB*050201, DQB*050202, DQB*050301, DQB*050302, DQB*0504, DQB*060101, DQB*060102, 20 DQB*060103, DQB*0602, DQB*0603, DQB*060401, DQB*060402, DQB*060501, DQB*060502, DQB*0606, DQB*0607, DQB*0608, DQB*0609, DQB1*0610, DQB*061101, DQB*061102, DQB*0612, DQB*0613, DQB*0614, DQB*0615, DQB*0616, DQB*0617, DQB*0618, DQB*0619, DQB*0620, DQB*0621, DQB*0622, DQB*0623. 25 HLA-DPA1 DPA*010301, DPA*010302, DPA*010303, DPA1*0104, DPA*0105, DPA*0106, DPA*0107, DPA*0108, DPA*020101, DPA*020102, DPA*020103, DPA*020104, DPA*020105, DPA*020106, DPA*020201, DPA*020202, DPA*020203, 30 DPAI* 0203, DPAI* 03 01, DPAI* 03 02, DPAI* 03 03, DPAI* 040 1. 61 3745052_1 (GH Matters) P78534.AU.1 HLA-DPB1 DPB1*010101, DPB1*010102, DPB1*010103, DPB1*0102, DPB1*020102, DPB1*020103, DPB1*020104, DPB1*020105, DPB1*020106, DPB1*0202, DPB1*0203, DPB1*030101, DPB1*030102, DPB1*0302, DPB1*040101, DPB1*040102, DPB1*0402, DPB1*0501, 5 DPB1*0601, DPB1*0801, DPB1*0901, DPB1*1001, DPB1*110101, DPB1*110102, DPB1*1301, DPB1*1401, DPB1*1501, DPB1*1601, DPB1*1701, DPB1*1801, DPB1*1901, DPB1*200101, DPB1*200102, DPB1*2101, DPB1*2201, DPB1*2301, DPB1*2401, DPB1*2501, DPB1*260101, DPB1*260102, DPB1*2701, DPB1*2801, DPB1*2901, DPB1*3001, DPB1*3101, DPB1*3201, DPB1*3301, DPB1*3401, 10 DPB1*3501, DPB1*3601, DPB1*3701, DPB1*3801, DPB1*3901, DPB1*4001, DPB1*4101, DPB1*4401, DPB1*4501, DPB1*4601, DPB1*4701, DPB1*4801, DPB1*4901, DPB1*5001, DPB1*5101, DPB1*5201, DPB1*5301, DPB1*5401, DPB1*5501, DPB1*5601, DPB1*5701, DPB1*5801, DPB1*5901, DPB1*6001, DPB1*6101N, DPB1*6201, DPB1*6301, DPB1*6401N, DPB1*6501, DPB1*6601, 15 DPB1*6701, DPB1*6801, DPB1*6901, DPB1*7001, DPB1*7101, DPB1*7201, DPB1*7301, DPB1*7401, DPB1*7501, DPB1*7601, DPB1*7701, DPB1*7801, DPB1*7901, DPB1*8001, DPB1*8101, DPB1*8201, DPB1*8301, DPB1*8401, DPB1*8501, DPB1*8601, DPB1*8701, DPB1*8801, DPB1*8901, DPB1*9001, DPB1*9101, DPB1*9201, DPB1*9301, DPB1*9401, DPB1*9501, DPB1*9601, 20 DPB1*9701, DPB1*9801, DPB*9901. HLA-DMA DMA*0101, DMA*0102, DMA*0103, DMA*0104. 25 HLA-DMB DMB*0101, DMB*0102, DMB*0103, DMB*0104, DMB*0105, DMB*0106. HLA-DOA DOA*010101, DOA*01010201, DOA*01010202, DOA*01010203, DOA*010103, 30 DOA*01010401, DOA*01010402, DOA*010105. 62 3745052_1 (GHMatters) P78534.AU.1 HLA-DOB DOB*01010101, DOB*01010102, DOB*010102, DOB*010201, DOB*010202, DOB*0103, DOB*01040101, DOB*01040102. 5 MHC Class I H-2Db, H-2Dd, H-2Dk, H-2Dq, H-2Kb, H-2Kd, H-2Kk, H-2Ld, H-2M3, H-2Ad, H-2Ag7, H-2Ak, H2-Ab, H-2Ed, H-2Ek, H-2Bxk, H-2F, H-21, H-2P, H-2R, H-2S, H-2Sxd, H-2T4, H 2U. 10 MHC Class 11 I-Ab, I-Ad, I-Ag7, I-Ak, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, I-Ea, I-Eb, I-Ed, I-Ek, I-Es, I-Eu, H-2Q, H-2Qa-2, H-2Qa-2a, Qa-la, Qa-lb. The invention is not limited to such MHC and HLA molecules, and can be adapted to newly 15 discovered such molecules, if desired, simply by establishing the reactivity of substances such as peptides with the molecules. This can be readily achieved using known techniques that are standard in the field. Particularly preferred HLA alleles for use with the present invention include the following: 63 3745052_1 (GHMatters) P78534.AU.1 HLA Class I HLA A HLA B HLA Cw A*6802 B*5801 Cw* 1701 A*6801 B*5701 Cw* 1601 5 A*66O1 B*5501 Cw*1502 A*3303 B*5201 Cw* 1402 A*3301 B*5101 Cw* 1203 A*3201 B*5001 Cw*0802 A*310102 B*4901 Cw*0801 10 A*3002 B*4501 Cw*0704 A*3001 B*4403 Cw*0703 A*2902 B*4402 Cw*0702 A*2608 B*4101 Cw*0701 A*2601 B*4002 Cw*0602 15 A'*25O1 B*4001 Cw*0501 A*2402 B*3901 Cw*0401 A*2301 B*3801 Cw*0304 A*11O1 B*3701 Cw*0303 A*0302 B*3503 Cw*0202 20 A*0301 B*3501 Cw*0102 A*0205 B*2705 A*0201 B*1801 A*O1O1 B*1501 B*1402 25 B*1401 B*1302 B *080 1 B*0705 B*0702 30 64 3745052_1 (GH Matters) P78534.AU.1 HLA Class II HLA DPB HLA DQA HLA DQB HLA DRB DPB1*1701 DQA1*0505 DQB1*0604 DRB1*1601 DPB1*1301 DQA1*0501 DQB1*0603 DRB1*1501 5 DPB1*1001 DQA1*0401 DQB1*0602 DRB1*1401 DPB1*0601 DQA1*0303 DQB1*0503 DRB1*1302 DPB1*0501 DQA1*0302 DQB1*0502 DRB1*1301 DPB1*0402 DQA1*0301 DQB1*0501 DRB1*1201 DPB1*0401 DQA1*0201 DQB1*0402 DRB1*1104 10 DPB1*0301 DQA1*0104 DQB1*0303 DRB1*1101 DPB1*0201 DQA1*0103 DQB1*0302 DRB1*0801 DPB1*0101 DQA1*0102 DQB1*0301 DRB1*0701 DQA1*0101 DQB1*0202 DRB1*0404 DQB1*0201 DRB1*0401 15 DRB1*0301 DRB1*0103 DRB1*0102 DRB1*0101 20 The most preferred alleles according to the invention are the following: HLA-A*0201, HLA-A*0206, HLA-A*0301, HLA-A*1101, HLA-A*2402, HLA-A*3401, HLA-B*0702, HLA-B*0801, HLA-B*1301, HLA-B*27, HLA-B*4002, HLA-B*5101, 25 HLA-Cw*03, HLA-cW*07 HLA-DRB1*0301, HLA-DRB1*0401, HLA-DRB1*0701, HLA-DRB1*1501, HLA DRB1*1104, HLA-DRB1*1101, HLA-DRB4*0101 30 HLA-DQA1*01, HLA-DQA1*02, HLA-DQA1*05 HLA-DQB1*03, HLA-DQB1*04, HLA-DQB1*05, HLA-DQB1*06 HLA-DPA 1*01, HLA-DPA 1*02 35 HLA-DPB1 *02, HLA-DPB1 *04 The invention will now be described by way of example only, with reference to the following specific embodiments. 40 In the claims which follow and in the description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify 65 3745052_1 (GHMatters) P78534.AU.1 the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. EXAMPLES 5 EXPERIMENT 1 - Reactivity ofpolypeptides against influenza antigens The purpose of the study was to demonstrate the reactivity of the above-described influenza polypeptides and their ability to induce a specific Thl-type cytokine response against 10 naturally processed and presented influenza proteins in the context of human HLA (HLA A*0201). As background to the experiments, it is useful to understand that Th1 and Th2 responses are defined by the pattern of cytokines produced by the T helper cells involved in them. That, 15 however, does not mean that the remaining lymphocytes (T and B cells) involved in those specific responses do not also produce cytokines that help drive the characteristic pattern of response in which they are involved. In this way, a Thl-like response is characterised by the production of IFN-y and IL-2, leading to the stimulation of a CD8+ CTL response and an associated (in mice) IgG2a antibody response. The IFN-y response can be produced both by 20 the CD4+ T helper 1 cells as well as by the CD8+ T cells that also form part of it. In this case the IFN-y component of the response produced by the CD8+ T cells was investigated. That was because the experiment was primarily investigating CD8+ T cell epitopes and it was desirable to prove that the response seen was caused by those cells. Since CD8+ T cells react to epitopes only on MHC class I molecules, human cells that share with the transgenic mouse 25 only one MHC class I molecule (i.e. HLA-A*0201) were used. A Th2-like response is characterised by the production of IL-4 and IL-10, leading to the stimulation of an IgGE, IgGI and (in mice) IgG2b antibody response. Both responses are antagonistic with IFN-y and IL-10 downregulating the production of each other. 30 All the experiments described below were carried out in duplicate. 66 3745052_1 (GHMatters) P78534.AU.1 Materials and methods Peptides and recombinant proteins All the polypeptides used in this study (i.e. P1: MIA amino acid (aa) 36 to 75 (SEQ ID 1); 5 P2: MiB aa 124 to 158 (SEQ ID 2); P3: NPA aa 255 to 275 (SEQ ID 3); P4: NPB aa 306 to 326 (SEQ ID 4); P5: PB1 aa 395 to 428 (SEQ ID 5); P6: M2 aa 32 to 55 (SEQ ID 6) and NRP: a control non-relevant polypeptide) were synthesised by Fmoc chemistry and resuspended in 10 % DMSO in PBS. 10 Cell lines and viruses The TI and JURKAT cell lines are human lymphoblastoid lines derived from HLA-A*0201 bearing and non-bearing individuals respectively. TI was maintained in IMDM medium (Invitrogen) whilst JURKAT was maintained in RPMI-1640 medium (Sigma) containing 10 mM HEPES and 1 mM sodium pyruvate. Both media were supplemented with 15 50 IU/50 mg/ml of penicillin/streptomycin (Sigma) and, as complete medium, 10 % FCS. Cell cultures were maintained at 37 0 C in a humidified atmosphere of 5 % Co 2 . Primary splenocytes were maintained in IMDM medium (Invitrogen) supplemented with 0.02 mM P -mercaptoethanol (Sigma), 50 IU/50 mg/ml of penicillin/streptomycin (Sigma) 20 and 10 % FCS (Sigma) at 37 0 C in a humidified atmosphere of 5 % CO 2 . Influenza A strains NewCaledonia/20/99, NYMC/X-147 and Influenza B strain Johannesburg/5/99 were obtained from NIBSC as lyophilised stocks and used for the infection of syngeneic (TI) and allogeneic (JURKAT) human cell lines. 25 Preparation of target cells for cytokine analysis Cell cultures in exponential phase were harvested by centrifugation (250 g, 5 min) and resuspended at a density of 106 cells/ml in serum-free medium. Aliquots of the cell suspensions were transfected with a range of polypeptide antigens at a concentration of 5 pg 30 per 106 cells using Lipofectin (Invitrogen) according to the manufacturer's instructions and incubated in complete medium for 8-10 hours before Mytomicin C (MMC) treatment. Alternatively, aliquots of the cell suspensions were infected with a range of live Influenza 67 3745052_1 (GHMatters) P78534.AU.1 virus (MOI of 5-10) for one hour, washed twice in serum free medium and incubated in complete medium for 24 hours before MMC treatment. For MMC treatment, cells were harvested by centrifugation (250 g, 5 min) and resuspended 5 in serum-free IMDM medium containing 50 pg/ml of Mitomycin C (Sigma). After 45 min incubation at 37C, the cell suspensions were washed four times in serum-free IMDM medium (250 g, 5 min) and finally resuspended in complete IMDM medium. Immunisations 10 Seven to ten week old C57BL/6-Tg(HLA-A2.1)lEnge/J mice (HLA-A*0201 transgenic on a C57/BL6 background, Jackson Labs) were immunised subcutaneously with a 200 Pl dose of the antigen preparation per mouse. In the test group, each dose of the antigen preparation contained 60 nmol of an equimolar mixture of all six peptides (10 nmol each) prepared in IFA (Sigma) according to the manufacturer's instructions (FLU-v preparation). In the control 15 group, each dose of the antigen preparation contained an equivalent dose of the non-relevant polypeptide prepared in IFA (Sigma) according to the manufacturer's instructions (NRP preparation). On day 14 post-immunisation, all animals received a booster immunisation using the same 20 doses and route of delivery as used originally. Finally, on day 21 or 22, all animals were culled and their spleens collected. 68 3745052_1 (GHMatters) P78534.AU.1 The immunisation protocol can be represented schematically as follows: Scheme 1 - innoculation FLU-v = combination of P1 P2 P3 P4 P5 & P6 Immunise mouse with FLU-v Harvest splenocytes after 21 or 22 days - any immune reaction will have caused amplification in mouse T cells reactive to correctly presented epitopes within P1-P6, which will become activated and/or proliferate. If peptides are correctly presented by both mouse MHC and human HLA, T cells reactive to epitopes presented in each of these contexts may be present (antigen presenting cells, APCs, in the transgenic mice will express both mouse MHC and human HLA). The harvested splenocytes may comprise significant quantities of activated/proliferated T cells, along with smaller quantities of other cells, such as antigen presenting cells (APCs) Obtain splenocytes containing: (a) HLA T cells in amplified quantities, reactive to APC(HLA)-P1 (or 1. mouse T-cells APC(HLA)-P2 etc.) (b) MHC T cells, non-reactive to APC(HLA)-P1 (or APC(HLA)-P2 etc.) (a) APC(HLA) 2. mouse antigen presenting cells (APCs) < (a) APC(H) (b) APC(MH C) 5 Statistical analysis Statistically significant differences in the IFN-y response to different antigens between FLU-v and NRP vaccinated animals were established through non-parametric Mann-Whitney analysis of the samples. Differences were considered statistically significant if the p value 10 was below 0.05. Cytokine ELISA Mouse spleens belonging to the same experimental group were pooled, gently pressed through cell strainers and red blood cells removed by treatment with red cell lysis buffer 15 (nine parts 0.16 M NH 4 C1 and one part of 0.17 M Tris, pH 7.2). Splenocyte suspensions from each experimental group were plated in 24-well plates at a density of 4 x 106 cells/well containing a range of polypeptide antigens (5 pg/ml) or, alternatively, MMC treated cell lines (splenocyte to cell (S:C) ratio 10:1) either transfected with polypeptide antigens or infected with different live Influenza virus as described above. 69 3745052_1 (GHMatters) P78534.AU.1 After 4 days incubation at 37 0 C, the supernatant was collected and analysed for IFN-y and IL-4 by a sandwich cytokine ELISA according to the manufacturer's protocol (Pharmingen). The lower detection limits for the assay were 9.77 pg/ml for IL-4 and 39.06 pg/ml for IFN-y. 5 Results Each individual polypeptide peptide described in this patent application (including P1, P2, P3, P4, P5 and P6 tested in this example) has been defined as containing T cell epitopes reactive in multiple human HLA molecules, amongst them HLA-A*0201. The aim of this 10 study is, therefore, to assess the ability of the above described polypeptides to induce a specific multi-antigen Thl-like immune (i.e. IFN-y mediated) response as well as the ability of this response to specifically react to naturally processed and presented Influenza antigens from several non-related strains pathogenic to humans in the context of infected human HLA A*0201 bearing cells. 15 Reactivity ofpeptide 1 Upon internal processing of the polypeptide by the antigen presenting cells (APCs) of the transgenic mice, the contained CD8+ T cell specific epitopes would be presented in the surface of the APC in association with the HLA-A*0201 molecules where they would 20 proceed to activate naive CD8+ T cells and induce a P1 specific Thl-like immune response. To confirm this, HLA-A*0201 bearing (TI) and non-bearing (JURKAT) human cell lines were intracellularly loaded with P1 by means of a lipid vehicle (Lipofectin, INVITROGEN). Splenocytes from animals immunised with the influenza polypeptide preparation (FLU-v) 25 were found to produce significantly increased levels of IFN-y compared to splenocytes from NRP immunised animals when co-cultured with MMC treated HLA-A*0201 bearing human cells (TI) transfected with P1, but not when co-cultured with non-HLA-A*0201 bearing human cells (JURKAT) treated in the same way (see Figure 1A, the data for which is presented in Table 1 below). 30 70 3745052_1 (GHMatters) P78534.AU.1 Table 1 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 ± 29.8 FLU Peptide 1 (sol) 119.3 ± 7.1 < 39 T1-FLUpep 1 (pro) 228.4± 16.6 55.8± 7 Ju-FLU pep 1 (pro) <39 51.2± 1.6 Note: "Lys" means the negative control background upon which all values are calculated. "Sol" means soluble peptide presented to the primary splenocyte population. "Pro" means that the 5 peptide is being presented complexed with the cell's HLA molecules following internal processing and loading of the resulting epitopes on to the MHC molecules. Values represent average ± standard error of the A IFN-y to Lys (pg/ml). The experiment can be represented schematically as follows: 10 Scheme 2 - control test for Ti and JURKA T TI transfected with P1 (or P2 etc.) or mouse antigen presenting cells allowed to present P1 naturally by adding P1 (or P2 etc.) to splenocytes APC(HLA)-P1 + 0- No reaction (no IFN-y) T cells reactive to APC(HLA)-NRP Control innoculation was with NRP JURKAT transfected with P1 (or P2 etc.) or mouse antigen presenting cells allowed to present P1 naturally by adding P1 (or P2 etc.) to splenocytes APC(non HLA)-P1 + 0 No reaction (no IFN-y) T cells reactive to APC(HLA)-NRP 15 Control innoculation was with NRP 71 3745052_1 (GHMatters) P78534.AU.1 Scheme 3 - FLU-v test results for Ti and JURKA T TI transfected with P1 (or P2 etc.) or mouse antigen presenting cells allowed to present P1 naturally by adding P1 (or P2 etc.) to splenocytes APC(HLA)-P1 + HLA T cells reactive to APC(HLA)-P1 (or P2 etc.) P1 Innoculation was with FLU-v 0 INF-y JURKAT transfected with P1 (or P2 etc.) or mouse antigen presenting cells allowed to present P1 naturally by adding P1 (or P2 etc.) to splenocytes APC(non-HLA)-P1 + T cells reactive to APC(HLA)-P1 No reaction (no IFN-y) (or P2 etc.) 5 Innoculation was with FLU-v As the transgenic mice used in these experiments do not bear any other human HLA and the ability of its CD8+ T cells to specifically recognise P1-derived epitopes in the context of other human HLAs which they have never encountered is low, these results clearly show that 10 the observed IFN-y response is specifically caused by primed CD8+ T cells recognising P1-derived epitopes in association with HLA-A*0201 molecules. It is also important to note that no IL-4 response was detected against the P1 transfected cells in either FLU-v or NRP immunised animals (data not shown). Since IL-4 production is 15 antagonistic to IFN-y production and hence to the creation of antigen specific CD8+ T cell responses, the lack of IL-4 production in both groups clearly shows that immunisation with FLU-v induces a specific Thl-like response to the P1 component of the preparation. 72 3745052_1 (GHMatters) P78534.AU.1 A significantly increased level in IFN-y production is also observed in the FLU-v compared to the NRP immunised groups when soluble P1 antigen is simply added to the splenocyte culture (in the absence of TI or JURKAT cells). However, the overall level of this IFN-y response is lower than that observed when the antigen was presented via the HLA-A*0201 5 bearing TI cells. The explanation for this observation is that P1 was defined on the basis of containing epitopes that are primarily reactive in the context of human and not mouse HLAs. The transgenic mice here used contain a full complement of mouse MHC molecules in addition to the HLA-A*0201 molecules, hence the soluble P1 captured by the APC population present in the primary splenocyte cultures can also be processed into the mouse 10 MHC Class I and II pathways (Peachman KK, Rao M, Alving CR, Palmer DR, Sun W, Rothwell SW. "Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens." Immunobiology. 2005;210(5):321-33), which mediate H-2D restricted CD8+ and CD4+ T cell responses respectively. As a result, if P1 contained multiple murine epitopes, it would be expected that 15 the IFN-y response to soluble P1 would be equal or greater to that observed for the case of human cell mediated presentation as a much larger pool of CD4+ and CD8+ T cells would be able to react to the stimulus. As this is not observed and the level of an immune response in vitro is primarily determined by the availability of antigen, it clearly follows that the P1-specific CD8+ T lymphocytes detected in the TI co-culture experiments would simply be 20 unable to respond at the same level due to the reduced amount of antigen being presented to them in the correct HLA-A*0201 context. Reactivity ofpeptide 2 Splenocytes from animals immunised with the FLU-v have been found to produce 25 significantly increased levels of IFN-y compared to splenocytes from NRP immunised animals when co-cultured with MMC treated HLA-A*0201 bearing human cells (TI) transfected with P2, but not when co-cultured with non-HLA-A*0201 bearing human cells (JURKAT) treated in the same way (see Figure iB, the data for which is set out in Table 2 below). As it was the case for P1, these results clearly show that the observed IFN-y response 30 is specifically caused by CD8+ T cells recognising P2-derived epitopes in association with HLA-A*0201 molecules. Similarly, as IL-4 production is antagonistic to IFN-y production and hence to the development of CD8+ T cells, the lack of an IL-4 response against P2 73 3745052_1 (GHMatters) P78534.AU.1 transfected cells in either FLU-v or NRP immunised animals (data not shown) clearly shows that FLU-v immunisation induces a P2-specific Thl-like response. Table 2 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 45.9 2257.5 ± 29.8 FLU Peptide 2 (sol) 976.9 24.1 468.4 ±14.7 T I-FLU pep 2 (pro) 372.9 6.4 154.5 ± 10.7 Ju-FLU pep 2 (pro) <39 <39 5 Note: "Lys" means the negative control background upon which all values are calculated. "Sol" means soluble peptide presented to the primary splenocyte population. "Pro" means that the peptide is being presented complexed with the cell's HLA molecules following internal processing and loading of the resulting epitopes on to the MHC molecules. Values represent 10 average ± standard error of the A IFN-y to Lys (pg/ml). A significantly increased IFN-y production was also observed in the FLU-v compared to NRP immunised groups when P2 was simply added to the splenocyte culture. In contrast to P1, however, the overall level of the IFN-y response was greater to the soluble antigen than to 15 that presented by the HLA-A*0201 bearing cells. This observation would indicate that P2 harbours not only strong HLA-A*0201 epitopes but also strong mouse (H-2D) epitopes. Reactivity ofpeptides 3, 4 and 5 As was the case for P2, significantly increased IFN-y production can be observed between 20 FLU-v and NRP immunised groups when P3, P4 and P5 are simply added to the culture as well as when they are presented via HLA-matched transfected human cells lines (TI), but not when they are presented via HLA-mismatched (JURKAT) human cell lines (see Figures IC, ID and 1E, the data for which is set out in Tables 3-5 below). In all three cases, the increment in IFN-y production is greater when splenocytes are co-cultured with transfected human cells 25 rather than when soluble antigen is simply added to the medium. These results, due to the same arguments developed for the case of P2, indicate that P3, P4 and P5 contain a number of strong mouse T cell epitopes in addition to the human ones. 74 3745052_1 (GHMatters) P78534.AU.1 Table 3 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 29.8 FLU Peptide 3 (sol) 1734.1 ± 57.2 268.0 11.0 T 1-FLU pep 3 (pro) 587.5 14.9 <39 Ju-FLU pep 3 (pro) 148.5 3.0 146.5 ± 17.6 Table 4 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 ± 29.8 FLU Peptide 4 (sol) 1170.5 ± 27.8 693.8 ± 5.6 T 1-FLU pep 4 (pro) 229.9± 35.2 84.6± 11.6 Ju-FLU pep 4 (pro) <39 <39 5 Table 5 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 ± 29.8 FLU Peptide 5 (sol) 1067.7 ± 7.3 220.5 ± 6.6 T I-FLU pep 5 (pro) 405.6 ± 11.8 <39 Ju-FLU pep 5 (pro) <39 <39 Note: "Lys" means the negative control background upon which all values are calculated. "Sol" 10 means soluble peptide presented to the primary splenocyte population. "Pro" means that the peptide is being presented complexed with the cell's HLA molecules following internal processing and loading of the resulting epitopes on to the MHC molecules. Values represent average ± standard error of the A IFN-y to Lys (pg/ml). 75 3745052_1 (GHMatters) P78534.AU.1 Finally, as all three peptides fail to induce the production of IL-4 (data not shown), it is clear that the immune response induced by vaccination with the FLU-v preparation induces a Thl-like response to each of these three polypeptides. 5 Reactivity ofpeptide 6 As was the case for P1, significantly increased IFN-y production can be observed between FLU-v and NRP immunised groups when P6 is simply added to the culture as well as when it is presented via HLA-matched transfected human cells lines (TI), but not when it is presented via HLA-mismatched (JURKAT) human cell lines (see Figure IF, the data for 10 which is set out in Table 6 below). Again as for P1, the greater response is observed to the soluble antigen, indicating that P6 does not contain strong H-2D epitopes. As the causes for these observations have already been explained for the case of PI they shall not be developed further here and one shall refer to that earlier section. 15 Table 6 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 ± 29.8 FLU Peptide 6 (sol) 496.2± 11.8 105.5 ± 7.0 T I-FLU pep 6 (pro) 1210.5 ± 11.5 817.6 ± 8.9 Ju-FLU pep 6 (pro) <39 <39 Note: "Lys" means the negative control background upon which all values are calculated. "Sol" means soluble peptide presented to the primary splenocyte population. "Pro" means that the peptide is being presented complexed with the cell's HLA molecules following internal 20 processing and loading of the resulting epitopes on to the MHC molecules. Values represent average ± standard error of the A IFN-y to Lys (pg/ml). The failure of stimulation with P6 to induce any IL-4 production (data not shown), clearly show that the immune response induced by FLU-v vaccination induces a Thl-like response 25 to P6. 76 3745052_1 (GHMatters) P78534.AU.1 Reactivity of FLU-v to non-related influenza strains The experiments described up to this point clearly show that immunisation with FLU-v induces a specific CD8+ T cell IFN-y response against each of the six constituent polypeptides. However, as these polypeptides were defined as containing reactive CD8+ T 5 cell epitopes subject to a low level of sequence variability within the influenza virus population analysed, it was also desirable to establish whether FLU-v vaccinated mice were capable of recognising, and hence inducing a specific Thl-like immune response, T cell epitopes naturally processed and presented following infection with different non-related strains of influenza. Such analysis provides a clear indication of the potential efficacy of the 10 FLU-v polypeptide mixture as an influenza vaccine which, by virtue of targeting T cell epitopes of low sequence variability across the human and animal influenza population, would provide protection against all current strains as well as those which may arise in the future from spontaneous recombination between highly pathogenic animal strains with current human strains. 15 For this analysis, primary splenocyte cultures of transgenic animals inmmunised with FLU-v or NRP were co-cultured with several influenza infected HLA-A*0201 bearing (TI) and non-bearing (JURKAT) human cells. The three influenza strains used for infection (A/NewCaledonia/20/99, AJNYMC/X-147 and B/Johannesburg/5/99) are all pathogenic to 20 humans and were obtained from the Influenza WHO repository, based at NIBSC (UK). As an antigen specific positive control an equimolar soluble preparation of the six polypeptides added to the primary splenocyte preparation was used. Splenocytes from FLU-v vaccinated animals produced a significantly higher level of IFN-y 25 compared to those of NRP vaccinated animals when co-cultured with MMC treated influenza infected HLA-A*0201 bearing human cells (TI) transfected, but not when co-cultured with non-HLA-A*0201 bearing human cells (JURKAT) treated in the same way (see Figure 2, the data for which is set out in Table 7 below). No IL-4 response was detected in any of the vaccinated mice against either the soluble polypeptide antigen or the Influenza infected cells 30 (data not shown). These results clearly show that the observed IFN-y response is specifically caused by primed CD8+ T cells recognising epitopes contained in the FLU-v preparation and which are also naturally processed and presented in association with HLA-A*0201 molecules in influenza infected human cells. 77 3745052_1 (GHMatters) P78534.AU.1 Table 7 A IFN-y to Lys (pg/ml) FLU-v NRP Con A 2395.6 ± 45.9 2257.5 ± 29.8 FLU peptide mix (sol) 1440.2 ± 44.9 678.3 ± 29.2 TI-Flu AJNC/20/99 2146.4 ± 23.7 1282.1 ± 4.8 Ju-Flu A/NC/20/99 1246.9 ±48.8 1206.4± 10.9 T1-Flu AJNYMC/X147 1949.4± 37.9 1101 ±5.9 Ju-Flu AJNYMC/X147 1342.3 ± 14.5 1248.6 ± 8.3 TI-Flu B/Johannesburg/5/99 1769.0 ± 33.6 1196.0 ± 16.2 Ju-Flu B/Johannesburg/5/99 257.6 ± 3.0 257.0 ± 8.3 Note: "Lys" means the negative control background upon which all values are calculated. "Sol" 5 means soluble peptide presented to the primary splenocyte population. "Pro" means that the peptide is being presented complexed with the cell's HLA molecules following internal processing and loading of the resulting epitopes on to the MHC molecules. TI is the HLA-A*020I-bearing human cell line. "Ju" refers to JURKAT which is the HLA-A*0201 non-bearing human cell line. AJNC/20/99 (i.e. A/NewCaledonia/20/99), AJNYMC/X-147 10 and B/Johannesburg/5/99 are, respectively, the two influenza A and one influenza B strains used for infection of the human cell lines. Values represent average ± standard error of the A IFN-y to Lys (pg/ml). Interestingly, the background production of IFN-y for all influenza infected groups was 15 greater than observed when similar analysis were carried out using purified polypeptide antigen. This observation, however, most likely reflects the inability of MMC treatment to fully inactivate the virus present in the cell preparation. This, in turn, would result in viable Influenza virus infecting susceptible mouse cells in the primary splenocyte cultures, thus leading to a primary response in vitro. This interpretation is sustained by the observation that 20 most influenza virus strains used induced the same level of background IFN-y response independently of the human cell line infected and the vaccinated group considered. The only exception to this rule is the much reduced background IFN-y production observed in 78 3745052_1 (GHMatters) P78534.AU.1 JURKAT cells infected with B/Johannesburg/5/99. However, as even in this case IFN-y production for both FLU-v and NRP vaccinated animals is equivalent, it would appear that the observed difference is caused more by the reduced susceptibility of JURKAT cells to infection by Influenza B/Johannesburg/5/99, than by any cause intrinsically associated to the 5 different vaccination regimes. Whatever the case, this observation, does not detract from the clear fact that vaccination with FLU-v leads to the specific recognition of naturally processed influenza epitopes presented in association with HLA-A*0201 molecules following infection of human cells with several non-related strains of infectious influenza virus. Therefore, FLU-v constitutes an effective candidate vaccine preparation for protection against multiple 10 influenza strains, thus obviating the need for the current yearly re-vaccination protocols. EXPERIMENT 2 - protective effect ofpolypeptides in mice The purpose of this study was to demonstrate that low dose immunisation with the identified 15 Influenza conserved T cell polyepitope peptides (FLU-v) induces protection, mediated by CD8+ T cells, against lethal challenge with the influenza virus. Materials and methods 20 Peptides, antisera and virus: The candidate vaccine preparation (FLU-v) tested in this study is composed of several peptides (i.e. P1: MIA amino acid (aa) 36 to 75 (SEQ ID 1); P2: MIB aa 124 to 158 (SEQ ID 2); P3: NPA aa 255 to 275 (SEQ ID 3); P4: NPB aa 306 to 326 (SEQ ID 4); P5: PB1 aa 395 to 428 (SEQ ID 5); P6: M2 aa 32 to 55 (SEQ ID 6)) which were all synthesised by Fmoc 25 chemistry and resuspended in DMSO in PBS (the concentration of DMSO in the final preparation was less than 5%). Lysozyme (Sigma) denatured by boiling was used as the control non relevant preparation (NRP-v). Purified rat anti-mouse CD8 IgG2a (clone YTS169.4) was obtained from AbD Serotec (UK) 30 whilst the infectious virus Influenza A/PR/8/34 were obtained from NIBSC as lyophilised standard stock. 79 3745052_1 (GHMatters) P78534.AU.1 Immunisations On day 1, seven to ten week old C57BL/6-Tg(HLA-A2.1)1Enge/J mice (HLA-A*0201 transgenic on a C57/BL6 background, Jackson Labs) were immunised subcutaneously at the base of the tail with a 200 pl dose of the antigen preparation emulsified in IFA (Sigma). In 5 the test group (n = 14), each dose of the antigen preparation contained 60 nmol of an equimolar mixture of all six peptides (10 nmol each) whilst in the control group (n = 14), each dose of the antigen preparation contained an equivalent dose of the non-relevant polypeptide. 10 On day 15 all animals received a booster immunisation using the same doses and route of delivery as used originally. On Day 16 both the test and control groups were split into two equal subgroups (n = 7 each; i.e. Ctrol-1, Ctrol-2, Test-i and Test-2). 15 On Day 19, all animals in the Ctrol-1 and Test-i groups received a 200 Pl intraperitoneal injection of rat anti-mouse-CD8 sera (100 pg) whilst all animals in the Ctrol-2 and Test-2 groups received an equivalent injection of unrelated sera. 20 The following day (Day 20), all groups were challenged intranasally under anaesthesia with a large lethal dose (approximately 1.5x107 pfu) of Influenza A/PR/8/34. On day 22, animals were again intraperitoneally injected with either rat anti-mouse-CD8 or unrelated sera as described above. 25 From day 20 all animals were monitored daily for symptoms of influenza (e.g. sneezing and pyrexia) as well as weight loss. All animals still alive on day 27 were culled and the study was terminated. 30 Results In order to assess the efficacy of the FLU-v preparation as a candidate Influenza vaccine it was desirable to set up a challenge study in NRP-v and FLU-v immunised animals using the 80 3745052_1 (GHMatters) P78534.AU.1 Influenza A/PR/8/34 strain. Typically, an intranasal dose of approximately 1.5x 10 pfu will kill non-immunised C57BL/6-Tg(HLA-A2.1)lEnge/J mice on day 4 or 5 after challenge (data not shown). 5 As shown in Fig. 3A, most animals immunised with either the FLU-v or NRP-v peptide preparations, but subject to CD8 depletion, had succumbed to infection by Influenza A/PR/8/34 by day 7 after intranasal challenge (71% vs 100% respectively). In contrast, as shown in Fig. 3B and in the absence of CD8 depletion, animals immunised with the FLU-v preparation showed a significant reduction (p < 0.05) in their mortality rate compared to 10 animals immunised with the NRP-v preparation (28% vs 100%). The results of this study clearly indicate that vaccination with the FLU-v peptide preparation, even at a low level dose of each of its constituent active peptides (10 nmol), induces a significant level of protection against lethal challenge with Influenza. These peptides, as 15 indicated earlier, where identified in silico primarily by their T cell reactivity within the context of Human HLA Class I. The results corroborate the fact that CD8+ T cells stimulated by vaccination with the FLU-v peptide preparation play a significant role in conferring protection against Influenza infection. 81 3745052_1 (GHMatters) P78534.AU.1

权利要求:
Claims (14)
[1] 1. A polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 85% homology with any of SEQ ID 1-6, or comprises 5 two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS 10 SEQ ID 3 DLIFLARSALILRGSVAHKSC SEQ ID 4 PGIADIEDLTLLARSMVVVRP SEQ ID 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID 6 IIGILHLILWILDRLFFKCIYRLF 15 wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete influenza virus protein.
[2] 2. A polypeptide according to claim 1, which polypeptide comprises one or more 20 sequences having at least 85% homology with SEQ ID 1, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of SEQ ID 1 that has the same length as the epitope.
[3] 3. A polypeptide according to claim 2, further comprising one or more sequences having 25 at least 85% homology with any of SEQ ID 2-6, or further comprising two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 2-6 that has the same length as the epitope.
[4] 4. A polypeptide according to claim 1, which polypeptide comprises one or more 30 sequences having at least 85% homology with SEQ ID 3, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of SEQ ID 3 that has the same length as the epitope. 82 3745052_1 (GHMatters) P78534.AU.1
[5] 5. A polypeptide according to claim 4, further comprising one or more sequences having at least 85% homology with any of SEQ ID 1, 2 and 4-6, or further comprising two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 1, 2 and 4-6 that has the same length as the epitope. 5
[6] 6. A polypeptide according to claim 1, which polypeptide comprises one or more sequences having at least 85% homology with SEQ ID 4, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of SEQ ID 4 that has the same length as the epitope. 10
[7] 7. A polypeptide according to claim 6, further comprising one or more sequences having at least 85% homology with any of SEQ ID 1-3, 5 and 6, or further comprising two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 1-3, 5 and 6 that has the same length as the epitope. 15
[8] 8. A polypeptide according to claim 1, which polypeptide comprises one or more sequences having at least 85% homology with SEQ ID 6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of SEQ ID 6 that has the same length as the epitope. 20
[9] 9. A polypeptide according to claim 6, further comprising one or more sequences having at least 85% homology with any of SEQ ID 1-5, or further comprising two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 1-5 that has the same length as the epitope. 25
[10] 10. A polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences defined by the following amino acid residues of an influenza virus protein, or comprises two or more epitopes having 7 amino acids or more from a sequence defined by the following amino acid residues of an influenza virus protein: 30 83 3745052_1 (GHMatters) P78534.AU.1 residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein residues 306-326 of an NP protein 5 residues 395-428 of an PB1 protein residues 32-55 of an M2 protein wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete 10 influenza virus protein.
[11] 11. A polypeptide according to claim 10, which polypeptide comprises the sequence defined by the amino acid residues 36-75 of an M1 protein, or comprises two or more epitopes having 7 amino acids or more from a sequence defined by the amino acid residues 15 36-75 of an M1 protein.
[12] 12. A polypeptide according to claim 11, further comprising one or more sequences defined by the following amino acid residues of an influenza virus protein, or further comprising two or more epitopes having 7 amino acids or more from a sequence defined by 20 any of the following amino acid residues of an influenza virus protein: residues 124-158 of an M1 protein residues 255-275 of an NP protein residues 306-326 of an NP protein 25 residues 395-428 of an PB1 protein residues 32-55 of an M2 protein
[13] 13. A polypeptide according to claim 10, which polypeptide comprises the sequence defined by the amino acid residues 255-275 of an NP protein, or comprises two or more 30 epitopes having 7 amino acids or more from a sequence defined by the amino acid residues
[14] 255-275 of an NP protein. 84 3745052_1 (GHMatters) P78534.AU.1 14. A polypeptide according to claim 13, further comprising one or more sequences defined by the following amino acid residues of an influenza virus protein, or further comprising two or more epitopes having 7 amino acids or more from a sequence defined by any of the following amino acid residues of an influenza virus protein: 5 residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 306-326 of an NP protein residues 395-428 of an PB1 protein 10 residues 32-55 of an M2 protein 15. A polypeptide according to claim 10, which polypeptide comprises the sequence defined by the amino acid residues residues residues 306-326 of an NP protein, or comprises two or more epitopes having 7 amino acids or more from a sequence defined by the amino 15 acid residues 306-326 of an NP protein. 16. A polypeptide according to claim 15, further comprising one or more sequences defined by the following amino acid residues of an influenza virus protein, or further comprising two or more epitopes having 7 amino acids or more from a sequence defined by 20 any of the following amino acid residues of an influenza virus protein: residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein 25 residues 395-428 of an PB1 protein residues 32-55 of an M2 protein 17. A polypeptide according to claim 10, which polypeptide comprises the sequence defined by the amino acid residues residues residues residues 32-55 of an M2 protein, or 30 comprises two or more epitopes having 7 amino acids or more from a sequence defined by the amino acid residues residues 32-55 of an M2 protein. 85 3745052_1 (GHMatters) P78534.AU.1 18. A polypeptide according to claim 17, further comprising one or more sequences defined by the following amino acid residues of an influenza virus protein, or further comprising two or more epitopes having 7 amino acids or more from a sequence defined by any of the following amino acid residues of an influenza virus protein: 5 residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein residues 306-326 of an NP protein 10 residues 395-428 of an PB1 protein 19. A polypeptide according to any of claims 1-18, which polypeptide comprises a cytotoxic T lymphocyte (CTL) epitope. 15 20. A polypeptide according to any preceding claim, comprising 2, 3, 4, 5 or more epitopes. 21. A polypeptide according to any preceding claim, which is immunogenic to an epitope within any of the sequences of SEQ ID 1-6. 20 22. A polypeptide according to any preceding claim, which is immunogenic to an influenza virus strain. 23. A polypeptide according to claim 22, which is immunogenic to a plurality of 25 influenza virus strains. 24. A polypeptide according to any preceding claim, further comprising one or more further sequences from an influenza virus protein. 30 25. A polypeptide according to claim 23, wherein when the polypeptide is at least 85% homologous to SEQ ID 1, the protein is an influenza M1 protein, when the polypeptide is at least 85% homologous to SEQ ID 2, the protein is an influenza M1 protein, when the polypeptide is at least 85% homologous to SEQ ID 3, the protein is an influenza NP protein, 86 3745052_1 (GHMatters) P78534.AU.1 when the polypeptide is at least 85% homologous to SEQ ID 4, the protein is an influenza NP protein, when the polypeptide is at least 85% homologous to SEQ ID 5, the protein is an influenza PB1 protein, and when the polypeptide is at least 85% homologous to SEQ ID 6, the protein is an influenza M2 protein. 5 26. A polypeptide according to any preceding claim, wherein said homology is substantially 100%. 27. A polypeptide according to any preceding claim, wherein the epitope comprises 8, 9 10 10 or 11 amino acids or more. 28. A polypeptide according to any preceding claim, having no more than 50 amino acid residues. 15 29. A polypeptide according to any preceding claim comprising from 15-35 amino acid residues. 30. An immunogenic multi-epitope polypeptide, which multi-epitope polypeptide comprises two or more polypeptides wherein the polypeptides comprise one or more 20 sequences having at least 85% homology with any of SEQ ID 1-6, or which multi-epitope polypeptide comprises two or more epitopes having 7 amino acids or more, each epitope having at least 85% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: 25 SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID 3 DLIFLARSALILRGSVAHKSC SEQ ID 4 PGIADIEDLTLLARSMVVVRP SEQ ID 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ 30 SEQ ID 6 IIGILHLILWILDRLFFKCIYRLF wherein, the multi-epitope polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele. 87 3745052_1 (GHMatters) P78534.AU.1 31. An immunogenic multi-epitope polypeptide according to claim 30, which comprises all of the polypeptides of SEQ ID 1, 3, 4, and 6, or comprises a polypeptide for each of SEQ ID 1, 3, 4, and 6 having at least 85% homology for that sequence. 5 32. An immunogenic multi-epitope polypeptide according to claim 31, which comprises all of the polypeptides of SEQ ID 1-6, or comprises a polypeptide for each of SEQ ID 1-6, having at least 85% homology for that sequence. 10 33. An immunogenic multi-epitope polypeptide, which multi epitope polypeptide comprises two or more polypeptides wherein each polypeptide comprise one or more sequences defined by the following amino acid residues of an influenza virus protein, or which multi-epitiope polypeptide comprises two or more epitopes having 7 amino acids or more from a sequence defined by the following amino acid residues of an influenza virus 15 protein: residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein 20 residues 306-326 of an NP protein residues 395-428 of an PB1 protein residues 32-55 of an M2 protein wherein, the polypeptide is immunogenic in a vertebrate expressing a major 25 histocompatibility complex (MHC) allele. 34. An immunogenic multi-epitope polypeptide according to claim 33, which comprises all of the sequences defined by the following amino acid residues of an influenza virus protein: 30 88 3745052_1 (GHMatters) P78534.AU.1 residues 36-75 of an M1 protein residues 255-275 of an NP protein residues 306-326 of an NP protein residues 32-55 of an M2 protein 5 35. An immunogenic multi-epitope polypeptide according to claim 34, which comprises all of the sequences defined by the following amino acid residues of an influenza virus protein: 10 residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein residues 306-326 of an NP protein residues 395-428 of an PB1 protein 15 residues 32-55 of an M2 protein 36. A polypeptide composition comprising two or more polypeptides as defined in any preceding claim. 20 37. A polypeptide composition according to claim 36, in which polypeptides having sequences of SEQ ID 1, 3, 4, and 6 are all present. 38. A polypeptide composition according to claim 37, in which polypeptides having sequences of SEQ ID 1-6 are all present, or in which all of the sequences defined by the 25 following amino acid residues of an influenza virus protein are present: residues 36-75 of an M1 protein residues 124-158 of an M1 protein residues 255-275 of an NP protein 30 residues 306-326 of an NP protein residues 395-428 of an PB1 protein residues 32-55 of an M2 protein 89 3745052_1 (GHMatters) P78534.AU.1 39. A polypeptide, or polypeptide composition, as defined in any preceding claim for use in medicine. 40. A method of producing a polypeptide as defined in any preceding claim, which 5 method comprises combining two or more epitopes to form the polypeptide. 41. A polypeptide construct, which construct comprises a polypeptide as defined in any preceding claim and a carrier. 10 42. A method of producing a polypeptide construct as defined in claim 41, which method comprises combining two or more epitopes and/or a polypeptide with the carrier. 43. A polypeptide construct or a method according to claim 41 or claim 42, wherein the carrier is a molecule. 15 44. A polypeptide construct or a method according to any of claims 41-43, wherein the carrier comprises an adjuvant and/or an excipient. 45. A medicament or vaccine composition against influenza, comprising a polypeptide, or 20 polypeptide composition, as defined in any of claims 1-39, and an appropriate excipient and/or adjuvant. 46. A medicament or vaccine composition against influenza, comprising a polypeptide construct as defined in claim 41, claim 43 or claim 44 and optionally an appropriate excipient 25 and/or adjuvant. 47. A method of producing a medicament or vaccine composition as defined in claim 45, which method comprises mixing a polypeptide, or a polypeptide composition, as defined in any of claims 1-39 with an appropriate excipient and/or adjuvant. 30 48. Use of a polypeptide, a polypeptide composition, a polypeptide construct or a medicament or vaccine composition as defined in any of claims 1-39, 41 and 43-46 in the 90 3745052_1 (GHMatters) P78534.AU.1 manufacture of a medicament or vaccine, effective in the treatment or prevention of influenza. 49. A method of treating or preventing influenza, which method comprises administering 5 a polypeptide, a polypeptide composition, a polypeptide construct, a medicament or vaccine composition, as defined in any of claims 1-39, 41 and 43-46 to a vertebrate. 50. A method according to claim 49, wherein the vertebrate is selected from a mammal, a bird, a reptile and a fish. 10 51. A method according to claim 50, wherein the vertebrate is a human, a domestic animal, or a farm animal, a bovine animal, or is fowl. 52. A method according to claim 51, wherein the vertebrate is selected from a chicken, a 15 duck, a goose, a pig, a horse, a cow, a dog, or a cat. 53. A polypeptide, polypeptide construct, method, medicament, vaccine or use according to any preceding claim, wherein the influenza is an influenza A strain. 20 54. A polypeptide, polypeptide construct, method, medicament, vaccine or use according to any of claims 1-52, wherein the influenza is an influenza B strain. 91 3745052_1 (GHMatters) P78534.AU.1

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10765734B2|2020-09-08|Influenza peptides and compositions

---

AU2013201008C1|2016-02-11|Peptide sequences and compositions

---

AU2007226430B2|2013-08-29|Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof

同族专利:

---

公开号 | 公开日

---

AU2013201008C1|2016-02-11|

---

AU2013201008B2|2015-06-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US20050013826A1|2002-12-20|2005-01-20|Shneider Alexander M.|Vaccine compositions and methods|

---

法律状态:
2015-10-08| FGA| Letters patent sealed or granted (standard patent)|

---

2015-11-05| DA2| Applications for amendment section 104|Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2015 . |

---

2016-02-11| DA3| Amendments made section 104|Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 SEP 2015 |

优先权:

---

申请号 | 申请日 | 专利标题

---

GB0602416.0||2006-02-07||

---

GB0613977.8||2006-07-13||

---

AU2007213562A|AU2007213562A1|2006-02-07|2007-02-05|Peptide sequences and compositions|

---

AU2013201008A|AU2013201008C1|2006-02-07|2013-02-22|Peptide sequences and compositions|AU2013201008A| AU2013201008C1|2006-02-07|2013-02-22|Peptide sequences and compositions|